Editorial Board


Diabetes Research - Open Journal

Shaw Watanabe, MD, PhD

President
Life Science Promotion Foundation
25-3-1004, Daikyo-cho, Shinjuku-ku
Tokyo 160-0005, Japan

BiographyResearch InterestScientific ActivitiesPublications

Dr. Watanabe had graduated from Keio University, School of Medicine in 1965, and got his Doctors degree in 1970. He had worked as a Assistant Professor, Department of Pathology, Keio University School of Medicine during 1973 and 1977, Visiting Scientist of National Cancer Institute, USA (1975-1976), Section Head of Pathology Division and Director of Epidemiology Division, National Cancer Center (1985-1996). He had also worked as a Professor and Chairman, Department of Nutrition and Epidemiology, Tokyo University of Agriculture (1995-2005), and Director General, National Institute of Health and Nutrition (2005-2009). At Present, he is the President of Life Science Promoting Association since 2009. He is also the President of the Society of National Integrated Medicine (2011-Present). He was the President of APCCN 2014 in Tokyo in 2013 and the Chairman of the East Asia Conference on Standardization of Rice Function in Kyoto in 2014. He is the chief editor of the Clinical and Functional Nutriology and the Life Science in Japan. 
He was an emeritus member of the Japan Pathological Society, Japan Epidemiology Society, Japan Cancer Society, Society of Functional Food Factors, etc. He had done more than 2000 autopsy as pathologist, had built population based prospective cohort study (JPHC study), contributed to expand shoku-iku (eating education) as a chairman.
He was also one of the scientific board members in the Ministry of Health, Labour and Welfare, Ministry of Agriculture, Forest and Fishery, Cabinet Office and Environmental Agency.

His research interests include: Dietary treatment, Physical activity to control the diabetes, Ethical Issues.

Certification

• (1970) Medical Doctor Liscence No.‚ P‚ W‚ X‚ W‚ O‚ X
• (1973) Licensed Anatomical Pathologist Liscence No.‚ Q‚ Q‚ U‚ V
• (1979) Leader, Surgical Pathologist Liscence No. 429
• Leader, Society of Pathological Nutrition


Professional Activities

• WHO consultant on Tobacco or Health
• (1990-1995) IARC Fellowship Selection Committee Member
• Workshop member of dioxin toxicity, IARC
• Chairman, Shokuiku Promotion, Cabinet Office, Japan
• (2006-2007) Chairman, Chemical Substance Regulation Law
• Board member of Health and Science Council, Ministry of Health, Labour and Welfare (2005- present)
• Board member, Japan Anti-Aging Medicine
• Board member, Japanese Society of Clinical Nutrition
• Board member, Japan Anti Oxidant Unit Study Group
• Editor, Clinical and Functional Nutriology
• Council, Asia Pacific J Clinical Nutrition


Awards

• (1993) WHO TOH Medal
• (1993) Award of Japan Medical Association
• (2000) Award from Japan Epidemiological Association
• (2014) Award of Contribution to Society from the Keio University Medical School

1. Watanabe S. Dietary therapy for the elderly. Nihon Ronen Igakkai Zasshi. 2014; 51(2): 138-140.
2. Tatsumi Y, Morimoto A, Deura K, Mizuno S, Ohno Y, Watanabe S. Effects of soybean product intake on fasting and postload hyperglycemia and type 2 diabetes in Japanese men with high body mass index: The Saku Study. J Diabetes Investig. 2013; 4(6): 626-633. doi: 10.1111/jdi.12100
3. Morimoto A, Tatsumi Y, Deura K, Mizuno S, Ohno Y, Watanabe S. Impact of cigarette smoking on impaired insulin secretion and insulin resistance in Japanese men: The Saku Study. J Diabetes Investig. 2013; 4(3): 274-280. doi: 10.1111/jdi.12019
4. Tatsumi Y, Ohno Y, Morimoto A, Nishigaki Y, Mizuno S, Watanabe S. Age differences in the risk of diabetes incidence according to body mass index level in Japanese women. Obes Res Clin Pract. 2013; 7(6): e455-e463. doi: 10.1016/j.orcp.2012.05.001
5. Tatsumi Y, Ohno Y, Morimoto A, Nishigaki Y, Mizuno S, Watanabe S. BMI percentile curves for Japanese men and women aged 20-79 years who underwent a health check-up in 1980 and 2005. Obes Res Clin Pract. 2013; 7(5): e401-e406. doi: 10.1016/j.orcp.2012.05.004
6. Morimoto A, Tatsumi Y, Deura K, Miyamatsu N, Noda M, Watanabe S. Impact of impaired insulin secretion and insulin resistance on the incidence of diabetes in a Japanese cohort. Diabetologia. 2013; 56(11): 2546-2547. doi: 10.1007/s00125-013-3068-9
7. Park J, Ishikawa-Takata K, Tanaka S, et al. The relationship of body composition to daily physical activity in free-living Japanese adult men. Br J Nutr. 2014; 111(1): 182-188. doi: 10.1017/S0007114513001918
8. Goto M, Goto A, Morita A, et al. Low-molecular-weight adiponectin and high-molecular-weight adiponectin levels in relation to diabetes. Obesity (Silver Spring). 2014; 22(2): 401-407. doi: 10.1002/oby.20553
9. Goto A, Morita A, Goto M, et al. Validity of diabetes self-reports in the Saku diabetes study. J Epidemiol. 2013; 23(4): 295-300. doi: 10.2188/jea.JE20120221
10. Morimoto A, Tatsumi Y, Deura K, et al. Impact of impaired insulin secretion and insulin resistance on the incidence of type 2 diabetes mellitus in a Japanese population: the Saku study. Diabetologia. 2013; 56(8): 1671-1679. doi: 10.1007/s00125-013-2932-y
11. Goto M, Morita A, Goto A, et al. Reduction in adiposity, β-cell function, insulin sensitivity, and cardiovascular risk factors: a prospective study among Japanese with obesity. PLoS One. 2013; 8(3): e57964. doi: 10.1371/journal.pone.0057964
12. Takezawa J, Yamada K, Miyachi M, et al. Preproghrelin gene polymorphisms in obese Japanese women. Minor homozygotes are light eaters, do not prefer protein or fat, and apparently have a poor appetite. Appetite. 2013; 63: 105-111. doi: 10.1016/j.appet.2012.12.006
13. Goto A, Morita A, Goto M, et al. Associations of sex hormone-binding globulin and testosterone with diabetes among men and women (the Saku Diabetes study): a case control study. Cardiovasc Diabetol. 2012; 11: 130. doi: 10.1186/1475-2840-11-130
14. Morimoto A, Ohno Y, Tatsumi Y, Mizuno S, Watanabe S. Effects of healthy dietary pattern and other lifestyle factors on incidence of diabetes in a rural Japanese population. Asia Pac J Clin Nutr. 2012; 21(4): 601-608.
15. Goto M, Morita A, Goto A, et al. Dietary glycemic index and glycemic load in relation to HbA1c in Japanese obese adults: a cross-sectional analysis of the Saku Control Obesity Program. Nutr Metab (Lond). 2012; 9(1): 79. doi: 10.1186/1743-7075-9-79
16. Tatsumi Y, Ohno Y, Morimoto A, Nishigaki Y, Mizuno S, Watanabe S. Lifestyle and the risk of diabetes mellitus in a Japanese population. J Behav Med. 2013; 36(3): 225-233. doi: doi: 10.1007/s10865-012-9427-z
17. Hirai T, Fujimine Y, Watanabe S, Nakano T. Distribution of polybrominated diphenyl ethers in Japanese autopsy tissue and body fluid samples. Environ Sci Pollut Res Int. 2012; 19(8): 3538-3546. doi: 10.1007/s11356-012-0915-z
18. Nakade M, Aiba N, Morita A, Miyachi M, Sasaki S, Watanabe S. What behaviors are important for successful weight maintenance? J Obes. 2012; 2012: 202037. doi: 10.1155/2012/202037
19. Morimoto A, Ohno Y, Tatsumi Y, Nishigaki Y, Maejima F, Mizuno S, Watanabe S. Impact of smoking cessation on incidence of diabetes mellitus among overweight or normal-weight Japanese men. Diabetes Res Clin Pract. 2012; 96(3): 407-413. doi: 10.1016/j.diabres.2012.03.007
20. Morimoto A, Ohno Y, Tatsumi Y, Nishigaki Y, Maejima F, Mizuno S, Watanabe S. Risk of smoking and body mass index for incidence of diabetes mellitus in a rural Japanese population. Prev Med. 2012; 54(5): 341-344. doi: 10.1016/j.ypmed.2012.02.016
21. Nakade M, Aiba N, Suda N, et al. Behavioral change during weight loss program and one-year follow-up: Saku Control Obesity Program (SCOP) in Japan. Asia Pac J Clin Nutr. 2012; 21(1): 22-34.
22. Miyake R, Ohkawara K, Ishikawa-Takata K, Morita A, Watanabe S, Tanaka S. Obese Japanese adults with type 2 diabetes have higher basal metabolic rates than non-diabetic adults. J Nutr Sci Vitaminol (Tokyo). 2011; 57(5): 348-354.
23. Park J, Ishikawa-Takata K, Tanaka S, et al. Relation of body composition to daily physical activity in free-living Japanese adult women. Br J Nutr. 2011; 106(7): 1117-1127. doi: 10.1017/S0007114511001358
24. Fujino Y, Tanabe N, Honjo K, et al. A prospective cohort study of neighborhood stress and ischemic heart disease in Japan: a multilevel analysis using the JACC study data. BMC Public Health. 2011; 11: 398. doi: 10.1186/1471-2458-11-398
25. Tanaka T, Morita A, Kato M, Congener-specific polychlorinated biphenyls and the prevalence of diabetes in the Saku Control Obesity Program (SCOP). Endocr J. 2011; 58(7): 589-596.
26. Fujino Y, Tanabe N, Honjo K, et al. Interest in health screening as a predictor of long-term overall mortality: multilevel analysis of a Japanese national cohort study. Prev Med. 2011; 52(1): 78-83. doi: 10.1016/j.ypmed.2010.10.012
27. Taku K, Lin N, Cai D, et al. Effects of soy isoflavone extract supplements on blood pressure in adult humans: systematic review and meta-analysis of randomized placebo-controlled trials. J Hypertens. 2010; 28(10): 1971-1982. doi: 10.1097/HJH.0b013e32833c6edb
28. Taku K, Melby MK, Kurzer MS, Mizuno S, Watanabe S, Ishimi Y. Effects of soy isoflavone supplements on bone turnover markers in menopausal women: systematic review and meta-analysis of randomized controlled trials. Bone. 2010; 47(2): 413-423. doi: 10.1016/j.bone.2010.05.001
29. Taku K, Melby MK, Takebayashi J, et al. Effect of soy isoflavone extract supplements on bone mineral density in menopausal women: meta-analysis of randomized controlled trials. Asia Pac J Clin Nutr. 2010; 19(1): 33-42.
30. Wahlqvist ML, Keatinge JD, Butler CD, et al. A Food in Health Security (FIHS) platform in the Asia-Pacific Region: the way forward. Asia Pac J Clin Nutr. 2009; 18(4): 688-702.
31. Watanabe S, Melby M, Aiba N. Food safety and food labeling from the viewpoint of the consumers. Asia Pac J Clin Nutr. 2009; 18(4): 532-537.
32. Takezawa J, Yamada K, Morita A, Aiba N, Watanabe S. Preproghrelin gene polymorphisms in obese Japanese: Association with diabetes mellitus in men and with metabolic syndrome parameters in women. Obes Res Clin Pract. 2009; 3(4): 179-191. doi: 10.1016/j.orcp.2009.04.003
33. Lee JK, Murakami A, Watanabe S, Ohigashi H. Suppressive properties of extracts from Japanese edible plants regarding nitric oxide generation. Asian Pac J Cancer Prev. 2009 10(2): 263-272.
34. Otaki N, Kimira M, Katsumata S, Uehara M, Watanabe S, Suzuki K. Distribution and major sources of flavonoid intakes in the middle-aged Japanese women. J Clin Biochem Nutr. 2009; 44(3): 231-238. doi: 10.3164/jcbn.08-231
35. Messina M, Watanabe S, Setchell KD. Report on the 8th International Symposium on the Role of Soy in Health Promotion and Chronic Disease Prevention and Treatment. J Nutr. 2009; 139(4): 796S-802S. doi: 10.3945/jn.108.104182
36. Taku K, Umegaki K, Ishimi Y, Watanabe S. Effects of extracted soy isoflavones alone on blood total and LDL cholesterol: Meta-analysis of randomized controlled trials. Ther Clin Risk Manag. 2008; 4(5): 1097-1103.
37. Ishiwata N, Melby MK, Mizuno S, Watanabe S. New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese women. Menopause. 2009; 16(1): 141-148. doi: 10.1097/gme.0b013e31818379fa
38. Melby MK, Utsugi M, Miyoshi M, Watanabe S. Overview of nutrition reference and dietary recommendations in Japan: application to nutrition policy in Asian countries. Asia Pac J Clin Nutr. 2008; 17(Suppl 2): 394-398.
39. Fujino Y, Mori M, Tamakoshi A, et al. A prospective study of educational background and breast cancer among Japanese women. Cancer Causes Control. 2008; 19(9): 931-937. doi: 10.1007/s10552-008-9154-5
40. Peñalvo JL, Adlercreutz H, Uehara M, Ristimaki A, Watanabe S. Lignan content of selected foods from Japan. J Agric Food Chem. 2008; 56(2): 401-409. doi: 10.1021/jf072695u
41. Taku K, Umegaki K, Sato Y, Taki Y, Endoh K, Watanabe S. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr. 2007; 85(4): 1148-1156. Erratum in: Am J Clin Nutr. 2007; 86(3): 809.
42. Iida T, Todaka T, Hirakawa H, et al. Concentration and distribution of dioxins and related compounds in human tissues. Chemosphere. 2007; 67(9): S263-S271.
43. Melby MK, Watanabe S, Whitten PL, Worthman CM. Sensitive high-performance liquid chromatographic method using coulometric electrode array detection for measurement of phytoestrogens in dried blood spots. J Chromatogr B Analyt Technol Biomed Life Sci. 2005; 826(1-2): 81-90.
44. Hosoi S, Honma K, Daimatsu T, Kiyokawa M, Aikawa T, Watanabe S. Lower energy content of human milk than calculated using conversion factors. Pediatr Int. 2005; 47(1): 7-9.
45. Ouchi K, Gamache P, Acworth I, Watanabe S. Measurement of isoflavones using liquid chromatography with multi-channel coulometric electrochemical detection. Biofactors. 2004; 22(1-4): 353-356.
46. Zhuo XG, Watanabe S. The construction of web database server-client system for functional food factors. Biofactors. 2004; 22(1-4): 329-332.
47. Murashima M, Watanabe S, Zhuo XG, Uehara M, Kurashige A. Phase 1 study of multiple biomarkers for metabolism and oxidative stress after one-week intake of broccoli sprouts. Biofactors. 2004; 22(1-4): 271-275.
48. Melby MK, Murashima M, Watanabe S. Phytochemical intake and relationship to past health history in Japanese women. Biofactors. 2004; 22(1-4): 265-269.
49. Kita J, Tada J, Ito M, et al. Intake of phytochemicals among Japanese, calculated by the new FFF database. Biofactors. 2004; 22(1-4): 259-263.
50. Uesugi S, Watanabe S, Ishiwata N, Uehara M, Ouchi K. Effects of isoflavone supplements on bone metabolic markers and climacteric symptoms in Japanese women. Biofactors. 2004; 22(1-4): 221-228.
51. Watanabe S, Zhuo XG, Kimira M. Food safety and epidemiology: New database of functional food factors. Biofactors. 2004; 22(1-4): 213-219.
52. Takachi R, Kimira M, Uesugi S, Kudo Y, Ouchi K, Watanabe S. The effect of dietary and plasma fatty acids on platelet aggregation in senior generation of Japanese women. Biofactors. 2004; 22(1-4): 205-210.
53. Haba R, Watanabe S, Wada M, Udaka S. Effects of lactoferrin, soya germ and polyamine on 2-amino-1-methyl-6- phenylimidazo[4,5-b]-pyridine(PhIP)- induced breast carcinogenesis in rats. Biofactors. 2004; 22(1-4): 127-131.
54. Ono M, Munakata N, Watanabe S. UV exposure of elementary school children in five Japanese cities. Photochem Photobiol. 2005; 81(2): 437-445.
55. Zhuo XG, Melby MK, Watanabe S. Soy isoflavone intake lowers serum LDL cholesterol: a meta-analysis of 8 randomized controlled trials in humans. J Nutr. 2004; 134(9): 2395-2400.
56. Murashima M, Kikuchi Y, Nomiyama T, et al. [Intake and excretion of cadmium and iron balance and influence of dietary habits among young women]. Nihon Eiseigaku Zasshi. 2004; 59(1): 31-37.
57. Kimira M, Kudo Y, Takachi R, Haba R, Watanabe S. [Associations between dietary intake and urinary excretion of sodium, potassium, phosphorus, magnesium, and calcium]. Nihon Eiseigaku Zasshi. 2004; 59(1): 23-30.
58. Kikuchi Y, Nomiyama T, Kumagai N, et al. Uptake of cadmium in meals from the digestive tract of young non-smoking Japanese female volunteers. J Occup Health. 2003; 45(1): 43-52.
59. Watanabe S, Uesugi S, Zhuo X, Kimira M. [Phytoestrogen and cancer prevention]. Gan To Kagaku Ryoho. 2003; 30(7): 902-908.
60. Toide K, Yamazaki H, Nagashima R, et al. Aryl hydrocarbon hydroxylase represents CYP1B1, and not CYP1A1, in human freshly isolated white cells: trimodal distribution of Japanese population according to induction of CYP1B1 mRNA by environmental dioxins. Cancer Epidemiol Biomarkers Prev. 2003; 12(3): 219-222.
61. Ouchi K, Watanabe S. Measurement of bisphenol A in human urine using liquid chromatography with multi-channel coulometric electrochemical detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2002; 780(2): 365-370.
62. Watanabe S, Uesugi S, Kikuchi Y. Isoflavones for prevention of cancer, cardiovascular diseases, gynecological problems and possible immune potentiation. Biomed Pharmacother. 2002; 56(6): 302-312.
63. Haba R, Watanabe S, Arai Y, Chiba H, Miura T. Suppression of lipid-hydroperoxide and DNA-adduct formation by isoflavone-containing soy hypocotyl tea in rats. Environ Health Prev Med. 2002; 7(2): 64-73. doi: 10.1007/BF02897332
64. Watanabe S. Current controversies around carbohydrate restriction and the risk of high-protein diets. Diabetes Res Open J. 2015; 1(5): e7-e10. doi: 10.17140/DROJ-1-e003
65. Kawashima N, Watanabe S, Morita A, Aiba N, Miyachi M, Sakai T. Changes of fat volume and adipocytokines by the randomized intervention program for obesity control program (SCOP). Diabetes Res Open J. 2015; 1(5): 136-146. doi: 10.17140/ DROJ-1-122

Sho-ichi Yamagishi, MD, PhD

Professor and Chairman
Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications
Kurume University School of Medicine
830-0011 Fukuoka Prefecture
Kurume, Asahimachi 67, Japan

BiographyResearch InterestScientific ActivitiesPublications

Dr. Yamagishi is a Professor and Chairman of Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Japan. He has received a PhD from Kanazawa University, Japan in 1993. He received Angiogenesis Stem Cell Award from AHA in 2003, Distinguished Investigator Award from Japan Diabetes Society in 2005, and Research Award from Japanese Society of Anti-Aging Medicine in 2012.

His research interests include: Diabetes, Cardiology, Glycation and Oxidative Stress.

Awards

• (2003) American Heart Association (AHA) Basic Science Award (Angiogenesis and Stem Cell Award)
• (2005) Japan Diabetes Society Lilly Award
• (2012) Research Award from Japanese Society of Anti-Aging Medicine

Dr. Yamagishi has published more than 500 research papers including Nature, JCI, JACC, JASN, Diabetes, Diabetes Care, and FASEB J.

Takashi Nomiyama, MD, PhD

Associate Professor
Department of Endocrinology and Diabetes Mellitus
School of Medicine
Fukuoka University
7-45-1 Nanakuma, Jonan-Ku, Fukuoka 814-0180, Japan

BiographyResearch InterestScientific ActivitiesPublications
Education

• (1995) MD (Medicine), Juntendo University Tokyo, Japan
• (2002) PhD (Diabetology), Juntendo University Graduate School/Tokyo, Japan


Employment History

• (2012-Present) Associate Professor, Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University, Fukuoka
• (2010-2012) Senior Assistant Professor, Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University, Fukuoka
• (2009-2010) Assistant, Department of Medicine, Metabolism and Endocrinology, Juntendo University, School of Medicine, Tokyo
• (2008-2009) Assistant, Department of Internal Medicine, Division of Diabetes and Endocrinology, Juntendo Tokyo Kotoh Geriatric Medical Center
• (2005-2008) Post-Doctoral Fellow, Department of Internal Medicine, Division of Endocrinology and Molecular Medicine, University of Kentucky College of Medicine
• (2004-2005) Assistant, Department of Medicine, Metabolism and Endocrinology, Juntendo University, School of Medicine, Tokyo
• (2002-2004) Post-Doctoral Fellow, Department of Medicine, Metabolism and Endocrinology, Juntendo University, School of Medicine, Tokyo
• (1995-1998) General Internal Medicine Residency, Juntendo University Hospital, Tokyo

His research interests include: Diabetes and vascular biology, Incretin biology.

Awards

• (2004) Young Investigator Award of Japan Endocrinology Society
• (2006) Young Investigator Travel Award of 7th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology
• (2012) Outstanding research award of the Japanese Society of Constitutional Medicine


Grants

• (2005-2007) Suzuki Manpei foundation Post Doctoral Grant
• (2007-2008) American Heart Association Post Doctoral Grant
• (2009) Grant from Ministry of Education, Sports and Culture of Japan (21790883)
• (2009) Grant from Suzuken Memorial Foundation

1. Zhao Y, Nomiyama T, Findeisen HM, et al. Epigenetic regulation of the NR4A orphan nuclear receptor NOR1 by histone acetylation. FEBS Lett. 2014; 588(24): 4825-4830. doi: 10.1016/j.febslet.2014.11.017
2. Terawaki Y, Nomiyama T, Kawanami T, et al. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury. Cardiovasc Diabetol. 2014; 13: 154. doi: 10.1186/s12933-014-0154-3
3. Tanabe M, Akehi Y, Nomiyama T, Murakami J, Yanase T. Total testosterone is the most valuable indicator of metabolic syndrome among various testosterone values in middle-aged Japanese men. Endocrin J. 2014. doi: 10.1507/endocrj.EJ14-0313
4. Nomiyama T, Kawanami T, Irie S, et al. Exendin-4, a glicagon-like peptide-1 receptor agonist, attenuates prostate cancer growth. Diabetes. 2014; 63(11): 3891-3905. doi: 10.2337/db13-1169
5. Masuzaki H, Takemoto N, Kawamoto E, Nomiyama T, Tanaka H, Morita M. Discussion meeting on the clinical update and topics in variety of diseases closely related with diabetes mellitus. Nihon Naika Gakkai Zasshi. 2013; 102(4): 938-954. doi: 10.2169/naika.102.938
6. Terawaki Y, Nomiyama T, Ohta C, et al. The efficacy of sitagliptin in basal supported oral therapy. Prog Med. 2013; 33: 2217-2221.
7. Murase K, Nagaishi R, Takenoshita H, Nomiyama T, Akehi Y, Yanase T. Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension. Endocr J. 2013; 60(8): 967-976. doi: 10.1507/endocrj.EJ13-0060
8. Akehi Y, Kawate H, Murase K, et al. Proposed diagnostic criteria for subclinical Cushing’s syndrome associated with adorenal incidentaloma. Endocr J. 2013; 60(7): 903-912. doi: 10.1507/endocrj.EJ12-0458
9. Terawaki Y, Nomiyama T, Akehi Y, et al. The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis. Diabetology and Metab Synd. 2013; 5(1): 10. doi: 10.1186/1758-5996-5-10
10. Ervinna N, Mita T, Yasunari E, et al. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology. 2013; 154(3): 1260-1270. doi: 10.1210/en.2012-1855
11. Nagaishi R, Nomiyama T, Okamura A, et al. Efficacy and Safety of DPP-4 Inhibitor Linagliptin in Japanese Patients with Type 2 Diabetes. Prog Med. 2012; 32: 2225-2230.
12. Nomiyama T, Akehi Y, Yanase T. Diabetes in other diseases and conditions. Nihon Rinsho. 2012; 70(Suppl 3): 414-417. doi: 22768556
13. Noda K, Zhang B, Iwata A, et al. Lifestyle changes through the use of delivered meals and dietary counseling in a single-blind study: the STYLIST study. Circ J. 2012; 76(6): 1335-1344. doi: 10.1253/circj.CJ-12-0164
14. Mita T, Azuma K, Goto H, et al. IRS-2 deficiency in macrophages promotes their accumulation in the vascular wall. Biochem Biophys Res Commun. 2011; 415(4): 545-550. doi: 10.1016/j.bbrc.2011.10.086
15. Nomiyama T, Akehi Y, Takenoshita H, et al. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2012; 95(2): e27-e28. doi: 10.1016/j.diabres.2011.08.016
16. Gizard F, Zhao Y, Findeisen HM, et al. Transcriptional regulation of the S-Phase kinase-associated protein 2 by the NR4A orphan nuclear receptor NOR1 in vascular smooth muscle cells. J Biol Chem. 2011; 286(41): 38485-38493. doi: 10.1074/jbc.M111.295840
17. Goto H, Nomiyama T, Mita T, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun. 2011; 405(1): 71-84. doi: 10.1016/j.bbrc.2010.12.131
18. Zhao Y, Howatt DA, Gizard F, et al. Deficiency of the NR4A orphan nuclear receptor NOR1 decreases monocyte adhesion and atherosclerosis. Circ Res. 2010; 107(4): 501-511. doi: 10.1161/CIRCRESAHA.110.222083
19. Mita T, Goto H, Azuma K, et al. Impact of insulin resistance on enhanced monocyte adhesion to endothelial cells and atherosclerosis independeny of LDL cholesterol level. Biochem Biophys Res Commun. 2010; 395(4): 477-483. doi: 10.1016/j.bbrc.2010.04.031
20. Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010; 59(4): 1030-1037. doi: 10.2337/db09-1694
21. Nomiyama T, Watada H. ARB as a drug for diabetic microangiopathy. Nihon Rinsho. 2009; 67(4): 777-782.
22. Tamura Y, Watada H, Tanaka Y, et al. Preliminary report: mitochondrial DNA 5178 polymorphism in male elite Japanese endurance runners. Matabolism. 2009; 59(1): 62-63. doi: 10.1016/j.metabol.2009.07.005
23. Nomiyama T, Zhao Y, Gizard F, et al. Deficiency of the NR4A Neuron-Derived Orphan Receptor-1 Attenuates Neointima Formation After Vascular Injury. Circulation. 2009; 119(4): 577-586. doi: 10.1161/CIRCULATIONAHA.108.822056
24. Gizard F, Nomiyama T, Zhao Y, et al. The PPAR (alpha)/p16INK4a Pathway Inhibits Vascular Smooth Muscle Cell Proliferation by Repressing Cell Cycle-Dependent Telomerase Activation. Circ Res. 2008; 103(10): 1155-1163. doi: 10.1161/CIRCRESAHA.108.186205
25. Nomiyama T, Bruemmer D. Liver X receptor as therapeutic targets in metabolism and atherosclerosis. Curr Atheroscler Rep. 2008; 10(1): 88-95. doi: 10.1007/s11883-008-0013-3
26. Nomiyama T, Perez-Tilve D, et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest. 2007; 117(10): 2877-2888. doi: 10.1172/JCI31986
27. Nakamachi T, Nomiyama T, Gizard F, et al. PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes. Diabetes. 2007; 56(6): 1662-1667. doi: 10.2337/db06-1177
28. Tamura Y, Ogihara T, Uchida T, et al. Amelioration of glucose tolerance by hepatic inhibition of nuclear factor kappaB in db/db mice. Diabetologia. 2007; 50(1): 131-141. doi: 10.1007/s00125-006-0467-1
29. Kapoor M, Nomiyama T, Bruemmer D, Kojima F, Crofford LJ. Growth factors and cytokines: Emphasis on their role in wound healing and atherosclerosis. Current Anesthesia & Critical Care. 2006; 17: 13-20. doi: 10.1016/j.cacc.2006.02.002
30. Nomiyama T, Nakamachi T, Gizard F, et al. The NR4A orphan nuclear receptor NOR1 is induced by platelet-derived growth factor and mediates vascular smooth muscle cell proliferation. J Biol Chem. 2006; 281(44): 33467-33476. doi: 10.1074/jbc.M603436200
31. Mita T, Watada H, Ogihara T, et al. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis. 2007; 191(1): 162-167. doi: 10.1016/j.atherosclerosis.2006.03.005
32. Ogawa D, Nomiyama T, Nakamachi T, et al. Activation of Peroxisome Proliferator-Activated Receptor {gamma} Suppresses Telomerase Activity in Vascular Smooth Muscle Cells. Circ Res. 2006; 98(7): e50-e59. doi: 10.1161/01.RES.0000218271.93076.c3
33. Nishiyama K, Tanaka Y, Nakajima K, et al. Polymorphism of the solute carrier family 12 (sodium/chloride transporters) member 3, SLC12A3, gene at exon 23 (+78G/A: Arg913Gln) is associated with elevation of urinary albumin excretion in Japanese patients with type 2 diabetes: a 10-year longitudinal study. Diabetologia. 2005; 48(7): 1335-1338. doi: 10.1007/s00125-005-1785-4
34. Watada H, Nomiyama T, Kawamori R. Mechanism of progression of atherosclerosis in patients with impaired glucose tolerance (IGT). Nihon Rinsho. 2005; 63 Suppl 2: 101-106.
35. Takayanagi N, Onuma T, Kato S, Nishiyama K, Nomiyama T, Kawamori R. Association between LDL particle size and postprandial increase of remnant-like particles in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2004; 66(3): 245-252. doi: 10.1016/j.diabres.2004.04.002
36. Nomiyama T, Igarashi Y, Taka H, et al. Deterioration of Insulin Stimulated Glucose Uptake by Peroxynitrite is Associated with Tyrosine-nitration of Insulin Receptor Substrate-1. Biochem Biophys Res Commun. 2004; 320(3): 320: 639-647.
37. Shimo-Nakanishi Y, Hasebe T, Suzuki A, et al. Functional effects of NAD(P)H oxidase p22phox C242T mutation in human leukocytes and association with thrombotic cerebral infarction. Atherosclerosis. 2004; 175: 109-115. doi: 10.1016/j.atherosclerosis.2004.01.043
38. Nomiyama T, Tanaka Y, Piao L, et al. Accumulation of Somatic Mutation in mitochondrial DNA and Atherosclerosis in Diabetic Patients. Ann NY Acad Sci. 2004; 1011: 193-204. doi: 10.1007/s00125-002-0893-7
39. Ogihara T, Watada H, Kanno R, et al. p38 mitogen-activated protein kinase is involved in activin A- and HGF-mediated expression of pro-endocrine gene neurogenin 3 in AR42J-B13 cells. J Biol Chem. 2003; 278(24); 21693-21700. doi: 10.1074/jbc.M302684200
40. Takagi M, Tanaka Y, Yamasaki Y, et al. Responsiveness of insulin-induced cardiac sympathetic nerve activation associates with blood pressure regulation in diabetics. Am J Physiol Endocrinol Metab. 2003; 284(5): E1022-E1026. doi: 10.1152/ajpendo.00169.2002
41. Nakajima K, Tanaka Y, Nomiyama T, et al. RANTES Promoter Genotype Is Associated With Diabetic Nephropathy in Type 2 Diabetic Subjects. Diabetes Care. 2003; 26(3): 892-898. doi: 10.2337/diacare.26.3.892
42. Nomiyama T, Tanaka Y, Piao L, et al. The polymorphism of manganese superoxide dismutase is associated with diabetic nephropathy in Japanese type 2 diabetic patients. J Hum Genet. 2003; 48(3): 138-141.
43. Piao L, Tanaka Y, Nomiyama T, et al. Combined Genotypes of ACE and NADPH Oxidase p22phox Associated with Somatic Mutation of mtDNA and Carotid Intima-Media Thickness in Japanese Patients with Type 2 Diabetes Mellitus. Curr Ther Res. 2002; 63(12): 842-852. doi: 10.1016/S0011-393X(02)80089-3
44. Nomiyama T, Tanaka Y, Hattori N, et al. Accumulation of somatic mutation in mitochondrial DNA extracted from peripheral blood cells in diabetic patients. Diabetologia. 2002; 45(11): 1577-1583. doi: 10.1007/s00125-002-0893-7
45. Nomiyama T, Kawamori R, Hattori N. Pathogenesis and contribution of mitochondria to diabetes or deafness. Nihon Rinsho. 2002; 60 Suppl 4: 273-277.
46. Nakajima K, Tanaka Y, Nomiyama T, et al. Chemokine receptor genotype is associated with diabetic nephropathy in Japanese with type 2 diabetes. Diabetes. 2002; 51(1): 238-242. doi: 10.2337/diabetes.51.1.238
47. Matsunaga H, Tanaka Y, Tanaka M, et al. Antiatherogenic mitochondrial genotype in patients with type 2 diabetes. Diabetes Care. 2001; 24(3): 500-503. doi: 10.2337/diacare.24.3.500

Guray Guven, PhD

Research Scientist
New Product Research & Development
Conductive Technologies Inc.
935 Borom Road, York, PA 17404, USA

BiographyResearch InterestScientific ActivitiesPublications

Presently Dr. Guven is working as a Research Scientist at Conductive Technologies, Inc. (York, PA), which offers extensive product development to enable the next generation of medical and diagnostic electrochemical biosensor product designs. His specialties are in the broad areas of medical devices, biosensors, clinical diagnostics, microfluidics and electrochemistry. He was a Postdoctoral Research Associate at Clarkson University (Potsdam, NY). He earned a Ph.D. in Biochemical Engineering at Jacobs University Bremen in Germany. He has published/presented more than 24 peer-reviewed papers/proceedings. He is editorial board member of Biosensors Journal and Ad Hoc reviewer of several prestigious journals such as Electrochemistry Communications, Journal of Diabetes Science and Technology, Analyst and Analytical Methods.

His research interests include: Electrochemical Sensors, Amperometric Sensors, Continuous Glucose Monitoring Systems, Microfluidics, Lab-on-a-Chip, Point-of-Care Diagnostics & Medical Diagnostic Instrumentation, Reagent Formulation and Manufacture.

Professional Memberships

• American Chemical Society
• Sigma Xi Scientific Society
• International Society of Electrochemistry and Electrochemical Society

1. Guven G, Lozano-Sanchez P, Guven A. Power generation from human leukocytes/lymphocytes in mammalian biofuel cell. International Journal of Electrochemistry. 2013; 2013: 1-11. doi: 10.1155/2013/706792
2. Guven A, Fioroni M, Guven G. Functionalized nanocontainers operated as controlled release systems and bioactuators. Biosensors Journal. 2013; 2: 106. doi: 10.4172/2090-4967.1000106 doi: 10.4172/2090-4967.1000106
3. Guven G, Perendeci A, Tanyolac A. Reaction kinetics on treatment of food industry wastewaters by electrochemical oxidation. Desalination and Water Treatment. 2014; 52: 7092-7100. doi: 10.1080/19443994.2013.827780
4. Jin Z, Guven G, Bocharova V, et al. Electrochemically controlled drug-mimicking protein release from iron-alginate thin-films associated with an electrode. ACS Applied Materials & Interfaces. 2012; 4(1): 466-475. doi: 10.1021/am201578m
5. Guven G, Perendeci A, Ozdemir K, Tanyolac A. Specific energy consumption in electrochemical treatment of food industry wastewaters. Journal of Chemical Technology and Biotechnology. 2012; 87(4): 513-522. doi: 10.1002/jctb.2739
6. Guven G. Process optimization for the electroenzymatic hydroxylation of 3-phenoxtoluene catalyzed by P450 BM-3. ECS Transactions. 2011; 35(26): 9-23. doi: 10.1149/1.3646484
7. Zhao L, Guven G, Li Y, Schwaneberg U. First steps towards a Zn/Co(III)sep driven P450 BM-3 reactor. Applied Microbiology and Biotechnology. 2011; 91(4): 989-999. doi: 10.1007/s00253-011-3290-7
8. Yu EH, Prodanovic R, Guven G, Ostafe R, Schwaneberg U. Electrochemical oxidation of glucose using mutant glucose oxidase from directed protein evolution for biosensor and biofuel cell applications. Applied Biochemistry and Biotechnology. 2011; 165(7-8): 1448-1457. doi: 10.1007/s12010-011-9366-0
9. Guven G, Prodanovic R, Schwaneberg U. Protein engineering - An option for enzymatic biofuel cell design. Electroanalysis. 2010; 22(7-8): 765-775. doi: 10.1002/elan.200980017
10. Cekic SZ, Holtmann D, Guven G, Mangold K-M, Schwaneberg U, Schrader J. Mediated electron transfer with P450cin. Electrochemistry Communications. 2010; 12(11): 1547-1550. doi: 10.1016/j.elecom.2010.08.030
11. Guven G, Perendeci A, Tanyolac A. Electrochemical treatment of simulated beet sugar factory wastewater. Chemical Engineering Journal. 2009; 151(1): 149-159. doi: 10.1016/j.cej.2009.02.008
12. Guven G, Perendeci A, Tanyolac A. Electrochemical treatment of deproteinated whey wastewater and optimization of treatment conditions with response surface methodology. Journal of Hazardous Materials. 2008; 157(1): 69-78. doi: 10.1016/j.jhazmat.2007.12.082

Stephen I-Hong Hsu, MD, PhD

Chief Executive Officer
Chief Scientific Officer
Prometheon Pharma, LLC
Sid Martin Biotechnology Incubator
University of Florida
10285 Research Drive
Alachua, FL 32615, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Hsu is the Founder, CEO and Chief Scientific Officer of Prometheon Pharma, LLC, a resident company of the Sid Martin Biotechnology Incubator (named #1 incubator in the world, 2013) of the University of Florida. Dr. Hsus international academic career as a clinician-scientist and administrator of multiple clinical and graduate training programs spans more than three decades. He received a combined MD-PhD degree in Molecular Pharmacology as a Scholar of the NIH Medical Scientist Training Program at the Albert Einstein College of Medicine. His studies on the molecular genetics of the mdr (P-glycoprotein) genes were done in the laboratory of Susan Horwitz, whose group identified the mechanism of action of bleomycin and taxol. He completed his Internal Medicine Residency and Nephrology Fellowship Training at the Massachusetts General Hospital, during which he co-edited the first textbook of evidence-based medicine. He held his first academic appointments at the Yong Loo Lin School of Medicine (National University of Singapore) and the Genome Institute of Singapore (Biopolis), where he developed research programs in the molecular genetics of kidney diseases and prostate cancer. As the Director of Research for the National Kidney Foundation of Singapore, he developed a disease prevention program and expanded his expertise to population-based and genetic epidemiology through the development of a nationwide screening program for the detection of early disease. He also continued to practice clinical nephrology during the SARS epidemic in Singapore at the National University Hospital where he held the distinction of being the youngest member in the history of the hospitals Medical Board. In 2005 he was recruited to the Renal Unit of the Brigham and Womens Hospital (Harvard Medical School). In 2007, he was recruited to be the first occupant of the R. Glenn Davis (DCI) Endowed Chair in Clinical and Translational Medicine, and the Director of the MD-PhD Training Program at the University of Florida College of Medicine where he held joint appointments in the Departments of Medicine and Molecular Genetics and Microbiology. He is the first recipient of an inaugural award for Innovations in Research Training and Education by the American Association of Medical Colleges. He was named a Scholar of the Clinical Translational Science Institute at the University of Florida in 2009.

Dr. Hsu is the Chief Scientific Officer for Prometheon Pharma, LLC, setting the direction for their research and development efforts in a proprietary transdermal patch platform technology for peptide/protein drug delivery. He also leads a research team in further determining the basis for resistance to diet-induced obesity in a TRIP-Br2 knockout mouse model he developed (Nature Medicine, January 2013). This effort is the basis for a drug discovery and development program aimed at identifying lead compounds for novel classes of anti-obesity and anti-cachexia drugs.

AWARDS


• (1992) Alpha Omega Alpha Medical Honor Society
• (1992) Up John Achievement Award for outstanding achievement in molecular pharmacology research
• (1992) Award for distinguished performance in research (1st Prize), The Associated Medical Schools of New York
• (1999) Best Basic Science Poster Award, 3rd NUH Faculty of Medicine Annual Scientific Meeting
• (2000) The Pharos Editors Prize for the essay On Being a Scientist
• (2001) Royal Society of Medicine Library Prize (2001) for textbook Evidence-Based On Call: Acute Medicine. Editors S. Straus, S.I.-H. Hsu,C.M. Ball, R.S. Phillips, Harcourt-Brace, UK
• (2002) Singapore Biomedical Research Council Young Investigator Award
• (2003) Merit Award, Basic Science Poster Contest, 4th Combined Scientific Meeting (Life Sciences in Singapore: Integrating Multidimensional Perspectives)
• (2003) Blue Ribbon Poster Award, World Congress of Nephrology, Germany
• (2004) Best Clinical Science Poster Award Finalist, NUS-NUH annual scientific meeting, Singapore
• (2004) Doctor Award Finalist, National Healthcare Group Annual Scientific Congress, Singapore
• (2005) National Kidney Foundation Clinician-Scientist Award, USA
• (2005) American Society of Nephrology Gottschalk Award, USA
• (2009) Clinical Translational Science Institute Scholar Award, University of Florida, Gainesville, FL
• (2010) Excellence in Teaching Award, Department of Medicine, University of Florida, Gainesville, FL
• (2010) Donald Etzweiler Visiting Scholar, International Diabetes Center, Minneapolis, MN
• (2011) Semi-Finalist (Sweet Sixteen), 2nd Annual Cade Museum Prize for Innovation Award (USA)
• (2012) Finalist (Final Four), 3rd Annual Cade Museum Prize for Innovation Award (USA)
• (2012) Inaugural Award for Innovations in Research Training and Education (American Association of Medical Colleges, USA)
• (2014) Grand Prize, MIT-CHIEF Business Plan Competition from among 200+ applicants worldwide (Massachusetts Institute of Technology, Boston, MA)


PROFESSIONAL SOCIETY MEMBERSHIPS


• (1990-Present) American Medical Association
• (1995-Present) American Society of Nephrology
• (1995-Present) International Society of Nephrology
• (2000-Present) American Heart Association High Blood Pressure Research Council
• (2000-Present) American Heart Association Council on Kidney in Cardiovascular Disease
• (2000-Present) American Heart Association Kidney Council, Member
• (2002-Present) American Association for the Advancement of Science, Invited Member
• (2005-Present) American College of Physicians
• (2008-Present) Florida Medical Association
• (2008-Present) Florida Society of Nephrology
• (2009-Present) American Association for Cancer Research
• (2009-Present) International Human Papillomavirus Society
• (2009-Present) Society of Clinical and Translational Science
• (2010-Present) Kidney & Urology Foundation of America
• (2010-Present) United Mitochondrial Disease Foundation
• (2010-Present) American Society for Biochemistry and Molecular Biology
• (2011-Present) American Physician Scientist Association
• (2012-Present) American Diabetes Association
• (2014-present) European Society for Paediatric Endocrinology

PUBLICATIONS (PEER REVIEWED PAPERS)


1. Hsu, SIH, Lothstein L, Horwitz SB. Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. J Biol Chem. 1989; 264: 12053-12062.
2. Lothstein L, Hsu SIH, Horwitz SB, Greenberger LM. Alternate overexpression of two P-glycoprotein genes is associated with changes in multidrug resistance in a J774.2 cell line. J Biol Chem. 1989; 264: 16054-16058.
3. Hsu, SIH, Cohen D, Kirschner L, Lothstein L, Hartstein M. Horwitz SB. Structural analysis of the mouse mdr1a(P-glycoprotein) promoter reveals the basis for differential transcript heterogeneity in multli drug-resistant J774. 2 cells. Mol Cell Biol. 1990; 10: 3596-3606. doi: 10.1128/MCB.10.7.3596
4. Yang CPH, Cohen D, Greenberger LM, Hsu SIH, Horwitz SB. Differential transport properties of two mdr gene products are distinguished by progesterone. J Biol Chem. 1990; 265: 10282-10288.
5. Cohen D, Piekarz RL, Hsu SIH, DePinho RA, Carrasco N, Horwitz SB. Structural and functional analysis of the mouse mdr1b gene promoter. J Biol Chem. 1991; 266: 2239-2244.
6. Cohen D, Higman SM, Hsu SIH, Horwitz SB. The involvement of a LINE-1 element in a DNA arrangement upstream of the mdr1a gene in a taxol multi-drug resistant murine cell line. J Biol Chem. 1992; 267: 20248-20254.
7. Kirschner LS, Greenberger LM, Hsu SIH, et al. Biochemical and genetic characterization of the multidrug resistance phenotype in murine macrophage-like J774.2 cells. Biochem Pharmacol. 1992; 43: 77-87. doi: 10.1016/0006-2952(92)90664-5
8. Hsu SIH, Thadhani RI, Daniels GH. Acute compartment syndrome in a hypothyroid patient. Thyroid. 1995; 5: 305-308. doi: 10.1089/thy.1995.5.305
9. Hsu SIH. Somatization among Asian immigrants and refugees as a culturally-shaped illness behavior. Annals Acad Med Singapore. 1999; 28: 841-845.
10. Hsu SIH. On being a scientist. Pharos Alpha Omega Alpha Honor Med Soc. 2000; 63: 11-13.
11. Hsu SIH, Ramirez SB, Winn MP, Bonventre JV, Owen WF. Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney Int. 2000; 57: 1818-1835. doi: 10.1046/j.1523-1755.2000.00032.x
12. Lim YK, Jenner A, Bin Ali A, et al. Haptoglobin reduces renal oxidative DNA and tissue damage during phenyl hydrazine-induced hemolysis. Kidney Int. 2000; 58: 1033-1044. doi: 10.1046/j.1523-1755.2000.00261.x
13. Hsu SIH. The molecular pathogenesis and experimental therapy of IgA nephropathy: recent advances and future prospects. Curr Mol Med. 2001; 1: 183-196.
14. Hsu SIH, Yang CM, Sim KG, Hentschel DM, O Leary E, Bonventre JV. TRIP-Br: a novel family of PHD zinc finger and bromodomain interacting proteins that regulate the transcriptional activity of E2F-1/DP-1. EMBO J. 2001; 20: 2273-2285. doi: 10.1093/emboj/20.9.2273
15. Ramirez SPB, Hsu SIH, Nandakumar M, Friedman EA, Durai TT, Owen WF. Funding ESRD care through charity: the paradigm of the National Kidney Foundation of Singapore. Semin Nephrol. 2001; 21: 411-418.
16. Mazze RS, Simonson G, Strock E, et al. Staged diabetes management: a systematic evidence-based approach to the prevention and treatment of diabetes and its co-morbidities. Pract Diab Int. 2001; 18: S1-S16. doi: 10.1002/pdi.240
17. Hsu SIH. Biopsy-proven acute tubulointerstitial nephritis and toxic epidermal necrolysis associated with vancomycin therapy. Pharmacotherapy. 2001; 21: 1233-1239. doi: 10.1592/phco.21.15.1233.33901
18. Ramirez SPB, Hsu SIH, McClellan W. Low body weight is a risk factor for proteinuria in a multi-ethnic Southeast Asian pediatric population. Am J Kid Dis. 2001; 38: 1045-1054.
19. Ramirez SPB, McClellan W, Port FK, Hsu SIH. Risk factors for proteinuria among a large, multiracial, Southeast Asian population. J Am Soc Nephrol. 2002; 13: 1907-1917. doi: 10.1097/01.ASN.0000018406.20282.C8
20. Ramirez SPB, Hsu SIH, McClellan W. Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore Program. Kidney Int Suppl. 83: S61-S65.
21. Ramirez SPB, Durai TT, Hsu SIH. Paradigms of public-private partnerships in end-stage renal disease care: The National Kidney Foundation Singapore. Kidney Int. 2003; Suppl(83): S101-S107.
22. Hsu, SIH, Couser WG. Chronic Progression of Tubulointerstitial Damage in Proteinuric Renal Disease is Mediated by Complement Activation: A Therapeutic Role for Complement Inhibitors? J Am Soc Nephrol. 2003; Suppl(2): S186-S191. doi: 10.1097/01.ASN.0000070032.58017.20
23. Gupta S, Takhar SPP, Degenkolbe R, et al. The Human Papillomavirus Type 11 and 16 E6 proteins modulate the cell-cycle regulator and transcription cofactor TRIP-Br1. Virology. 2003; 317: 155-164. doi: 10.1016/j.virol.2003.08.008
24. Thio SSC, Bonventre JV, Hsu SIH. The CtBP2 co-repressor is regulated by NADH-dependent dimerization and possesses a novel N-terminal repression domain. Nucleic Acids Res. 2004; 32: 1836-1847. doi: 10.1093/nar/gkh344
25. Qiu LQ, Sinniah R, Hsu SIH. Down-regulation of Bcl-2 by podocytes is associated with progressive glomerular injuries and clinical indices of poor renal outcome in human IgA nephritis. J Am Soc Nephrol. 2004; 15: 79-90. doi: 10.1097/01.ASN.0000104573.54132.2E
26. Qiu LQ, Sinniah R, Hsu SIH. Role of differential and cell type-specific expression of cell cycle regulatory proteins in mediating progressive glomerular injury in human IgA nephropathy. Lab Invest. 2004; 84: 1112-1125. doi: 10.1038/labinvest.3700144
27. Qiu LQ, Sinniah, R, Hsu SIH. Coupled induction of iNOS and p53 up-regulation in renal resident cells may be linked with apoptotic activity in the pathogenesis of progressive IgAN. J Am Soc Nephrol. 2004; 15: 2066-2078. doi: 10.1097/01.ASN.0000133532.99109.3D
28. Sim KG, Zang Z, Yang MC, Bonventre JV, Hsu SIH. TRIP-Br links E2F to novel functions in the regulation of cyclin E expression during cell cycle progression and in the maintenance of genomic stability. Cell Cycle. 2004; 3: 1296-1303. doi: 10.4161/cc.3.10.1157
29. Hsu SIH. Diseases of the kidney: Molecular mechanisms and current therapy. Curr Mol Med. 2005; 5: 454.
30. Vidal BC Jr, Bonventre JV, Hsu, SIH. Towards the application of proteomics in renal disease diagnosis. Clin Science. 2005; 109: 421-430. doi: 10.1042/CS20050085
31. Zheng L, Sinniah R, Hsu SIH. In situ glomerular expression of activated NF-B in human lupus nephritis and other proteinuric glomerulonephritides. Virch Arch. 2005; 448: 172-183. doi: 10.1007/s00428-005-0061-9
32. Zheng L, Sinniah, R, Hsu SIH. The role of NF-kB activation in tubulointerstitial lesions in lupus nephritis. Hum Pathol. 2006; 7: 637-647.
33. Sim KG, Cheong JK, Hsu SIH. The TRIP-Br family of transcriptional regulators is essential for the execution of cyclin E-mediated cell cycle progression. Cell Cycle. 2006; 5: 1111-1115. doi: 10.4161/cc.5.10.2797
34. Soo RA, Wu J, Aggarwal A, et al. Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. Annals Oncol. 2006; 17: 1625-1630.
35. Zang ZZ, Sim KG, Cheong JK, Yang CM, Yap CS, Hsu SIH. Exploiting the TRIP-Br family of cell cycle regulatory proteins as chemotherapeutic drug targets in human cancer. Cancer Biol Ther. 2007; 6: 712-718. doi: 10.4161/cbt.6.5.3964
36. Zheng L, Sinniah R, Hsu SIH. Pathogenic role of NF-kB activation in tubulointerstitial inflammatory lesions in human lupus nephritis. J Histochem Cytochem. 2008; 56: 517-529. doi: 10.1369/jhc.7A7368.2008
37. Cheong JK, Gunaratnam L, Hsu SIH. CRM1-mediated nuclear export is required for 26 S proteasome-dependent degradation of the TRIP-Br2 proto-oncoprotein. J. Biol Chem. 2008; 283: 1161-11676. doi: 10.1074/jbc.M708365200
38. Zang ZZ, Gunaratnam L, Cheong JK, et al. Identification of PP2A as a novel interactor and regulator of TRIP-Br1. Cell Signal. 2009; 21: 34-42. doi: 10.1016/j.cellsig.2008.09.018
39. Cheong JK, Gunaratnam L, Zang ZZ, et al. TRIP-Br2 promotes oncogenesis in nude mice and is frequently overexpressed in multiple human tumors. J Transl Med. 2009; 7(8): 15. doi: 10.1186/1479-5876-7-8
40. Chan CB, Liu X, Jang SW, et al. NGF inhibits human leukemia proliferation by downregulating cyclin A1 expression through promoting acinus/CtBP2 association. Oncogene. 2009; 28: 3825-3836. doi: 10.1038/onc.2009.236
41. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinic opathological correlations, and classification. Kidney Int. 2009; 76: 534-545. doi: 10.1038/ki.2009.243
42. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. Roberts IS, Cook HT, Troyanov S, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009; 76: 546-556. doi: 10.1038/ki.2009.168.
43. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. Coppo R, Troyanov S, Camilla R, et al. The Oxford IgA nephropathy clinic opathological classification is valid for children as well as adults. Kidney Int. 2010; 77: 921-927. doi: 10.1038/ki.2010.43
44. Penney KL, Schumacher FR, Peter Kraft P, et al. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. Carcinogenesis. 2011; 32: 853-859. doi: 10.1093/carcin/bgr050
45. Lewis NP, Treise D, Hsu SIH, Allen WL, Kang H. DTC genetic testing companies fail transparency prescriptions. New Gen and Soc. 2011; 30: 291-307. doi: 10.1080/14636778.2011.600434
46. Liew CW, Boucher J, Cheong JK, et al. Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance. Nat Med. 2013; 19: 217-226. doi: 10.1038/nm.3056
47. Cheong JK, Hsu SIH. Derailing UPS of protein turnover in cancer and other human diseases. J Cancer Res. 2013; 11. doi: 10.1155/2013/167576
48. O Mara RJ, Hsu SIH, Wilson DR. Should MD-PhD scholars pursue graduate training in disciplines beyond conventional biomedical or clinical sciences?. Acad Med. 2014.

Sophia Chew Tsong Huey, MBBS, MMed (Anaes.), FANZCA

Senior Consultant
Department of Anaesthesiology
Singapore General Hospital
Outram Rd, 169608, Singapore

BiographyResearch InterestScientific ActivitiesPublications

Dr. Chew is a Senior Consultant at the Singapore General Hospital, Department of Anaesthesia and Surgical Intensive Care. She is also an Adjunct Assistant Professor at the Yong Loo Lin School of Medicine and the Duke-NUS Graduate Medical School.
Her subspecialty interest is in the field of cardiothoracic anaesthesia and she leads the department efforts in research. She was awarded the Wong Hock Boon –Singapore Medical Association Outstanding Mentor Award in 2013.
Dr Chew is the Principal Investigator of the Perioperative and Genomic Outcome Study of Cardiac Patients in Singapore. She is currently examining the impact of cardiopulmonary bypass and acute kidney injury and the impact of diabetes mellitus on the outcome of patients undergoing cardiac surgery.

Her research interests include: Diabetes mellitus and outcome in cardiac surgical patients, The association of genetics and diabetes mellitus on acute kidney injury after cardiac surgery, Ethnicity and acute kidney injury in cardiac surgery , Impact of miniCPB and conventional CPB in determining safety outcomes after cardiac surgery, Development of continuous glucose monitoring devices, Improvement of diabetic control in surgical patients, Acute kidney injury and development of end-stage renal disease in cardiac surgical patients, Blood conservation in cardiac surgical patients.

AWARDS AND HONORS

• (1997-1998) Awarded the FY 96 HMDP fellowship in cardiac anaesthesia for 12 months, U.S.A. Completed cardiac fellowship program at Duke University Medical Center, Division of Cardiothoracic Anesthesiology, Durham, North Carolina
• (1998) Awarded the runner-up prize on poster presentation “Preliminary report on the association of Apolipoprotein E genotype and renal impairment after CABG surgery” at Dukes Department of Anesthesiology Academic Evening
• SGH QI Project of the year 2009 ( To achieve blood glucose level of between 4 to 8 mmol/l in patients undergoing cardiac surgery )
• (2009) MOH Appreciation Excel Award nominee
• (2009) PS21 Excel Award Nominee
• (2013) Wong Hock Boon Society-Singapore Medical Association Outstanding Mentor Award


PROFESSIONAL SOCIETY MEMBERSHIP

• Singapore Society of Anaesthesiologists
• Medical Protection Society


SOCIAL

• (1995) Member of social subcommitee for 9th Asean Congress of Anaesthesiologists meeting

1. Chew STH, Tan SS, Ip C, Tan T. A survey of patients knowledge of anaesthesia and perioperative care. Singapore Medical Journal. 1998; 39(9): 399-402.
2. Chew STH, Low TC. Preoperative versus postoperative pethidine for extraction of impacted third molars. Annals, Academy of Medicine. 1997; 26: 426-429.
3. Garduno C, Chew S, Forbess J, Smith PK, Grocott HP. Persistent left superior vena cava and partial anomalous pulmonary venous connection: incidental diagnosis by transeophageal echocardiography during coronary bypass surgery. J Am Soc Echocardiogr. 1999; 12: 682-685.
4. Chew S. Renal transplant- An Anaesthetic Perspective. Proceedings. 1997; 6(3): 52-55.
5. Chew STH, Conlon PJ, White WD, et al. Preliminary report on the association of apolipoprotein E genotype with renal impairment after coronary bypass surgery. Anesthesiology. 2000; 93: 325-331.
6. Koh LKD, Ip-Yam C, Kong CF, Chew S. Evaluation of a modified grading system for direct laryngoscopy. our preliminary experience in Singapore. SGH Proceedings. 2000. 9(2): 79-82.
7. Kong CF, Chew STH, Ip-Yam PC. Intravenous opioids reduce airway irritation during induction of anaesthesia with desflurane in adults. Br J Anaesth. 2000; 84: 364–367.
8. McCreath BJ, Swaminathan M, Booth VJ, Chew STH et al. Mitral valve surgery and renal injury . Port access versus median sternotomy. Annals Thorac Surg. 2003; 75: 812-819
9. Chew STH. Recovery following tonsillectomy. A comparison between tramadol and morphine for analgesia . Singapore Medical Journal. 2003; 44(6): 296- 298
10. Soh CR, Pietrobon R, Freiberger J, et al. Hyperbaric oxygen therapy in necrotising soft-tissue infections - A study of patients in the United States Nationwide Inpatient Sample. Intensive Care Med. 2012; 38(7): 1143-1151. doi: 10.1007/s00134-012-2558-4.
11. Chew STH, Mar WMT, Lian T. Association of ethnicity and acute kidney injury after cardiac surgery in a South East Asian Population. British Journal of Anaesthesia. 2013; 110(3): 397-401. doi: 10.1093/bja/aes415.
12. Ng R, Chew STH, Weiling L, Kah TL. Identification of Modifiable Risk Factors for Acute Kidney Injury After Coronary Artery Bypass Graft Surgery in an Asian Population. JTCVS. 2013; 13: 833R1. doi: 10.1016/j.jtcvs.2013.09.040.
13. Chew STH, Kah TL. Reply to the editor on association of ethnicity and acute kidney injury after cardiac surgery in a South east Asian population. British journal of Anaesthesia. 2013. doi: 10.1093/bja/aes415.
14. Ng R, Chew STH, Weiling L, Kah TL. Reply to Identification of Modifiable Risk Factors for Acute Kidney Injury After Coronary Artery Bypass Graft Surgery in an Asian Population. JTCVS.2014. doi: 10.1016/j.jtcvs.2013.09.040.
15. Ng R, Chew STH, Weiling L, Kah TL. Persistent Kidney Injury at Hospital discharge after cardiac surgery with cardiopulmonary bypass in patients with normal preoperative serum creatinine and normal estimated glomerular filtration rate. JCVA.2014. doi: 10.1053/j.jvca.2014.05.007.
16. Ng R, Oo AM, Weiling L, Tan TE, Kah TL, Chew STH. Changing Glucose Control target and Risk of Surgical Site Infection in a South East Asian population. JTCVS. 2014.

Oscar Lorenzo, PhD

Principal Investigator
Cardiovascular Research Laboratory
IIS-FJD Hospital
Autonoma University
University City Cantoblanco
28049 Madrid, Spain

BiographyResearch InterestScientific ActivitiesPublications

Dr. Lorenzo received his PhD in 2001 at the Autonoma University (Madrid). Currently, he is working as Principal Investigator in the Cardiovascular Research Laboratory at the IIS-FJD Hospital in the Autonoma University. His research has included studies in hypertension and diabetes effects on the cardiovascular system. Based on this research and fellowship training he has received several awards and honours, such as: BIAL European Awards in 2000. He is serving as expert reviewer for journals like International J Cardiology, J Mol Cell Cardiol, Cardiovasc Diabetol, J hypertension, Am J Physiol Heart.

His research interests include: Hypertension and diabetes effects on the cardiovascular system.

MEMBERSHIPS


• Member of national societies and networks of Diabetes and Cardiology


HONORS


• (2000) BIAL European Awards
• (2011) Professor of Research

He has authored more than fifty research articles/books.

Massimo Collino, PhD

Associate Professor of Pharmacology and Toxicology
Department of Drug Science and Technology
University of Turin
Corso Raffaello 33
10125 Torino, Italy

BiographyResearch InterestScientific ActivitiesPublications
EDUCATION


• (1998) Bachelor Degree in Pharmaceutical Chemistry and Technology at the University of Turin, Faculty of Pharmacy summa cum laude
• (31/12/2003) PhD in Pharmacology and Toxicology
• (2003-2004) Visiting Scientist at The William Harvey Research Institute, Centre for Experimental Medicine, Nephrology & Critical Care, Barts and The London, Queen Marys School of Medicine and Dentistry, London (UK)
• (2002-2014) Assistant Professor of Pharmacology and Toxicology, Dept. Drug Science and Technology, University of Turin (Italy)

His research interests include: Pathophysiology and the pharmacological therapy of diet-induced insulin resistance and the related cardiovascular risk factors, mainly organ-related ischemic events. Specifically, investigation of the pharmacological potential of selective ligands of the enzyme GSK-3beta, nuclear receptors PPAR and erythropoietin derivatives in in vivo models of ischemic diseases (myocardial infarction, stroke, acute kidney injury), Shock (hemorrhagic and endotoxic shock) and diet-induced (mainly sugar-induced) dysmetabolism. Most recent research activity has been focused on the validation of the NLRP3 inflammasome, a multiprotein complex leading to the processing and secretion of the proinflammatory cytokines interleukin-(IL-)1beta and IL-18, as pharmacological target for cardiometabolic diseases.

MEMBERSHIPS


• World Journal of Diabetes (ISSN 1948-9358; DOI: 10.4239)
• World Journal of Pharmacology (ISSN 2220-3192; DOI: 10.5497)
• Journal of Diabetes & Metabolism (ISSN:2155-6156)

PUBLICATIONS IN INTERNATIONAL JOURNALS


1. Dianzani C, Lombardi G, Collino M, Ferrara C, Cassone MC, Fantozzi R. Priming effects of substance P on calcium changes evoked by interleukin-8 in human neutrophils. J Leukoc Biol. 2001; 69: 1013-1018.
2. Dianzani C, Collino M, Lombardi G, Garbarino G, Fantozzi R. Substance P increases neutrophil adhesion to human umbilical vein endothelial cells. Br J Pharmacol. 2003; 139: 1103-1110.
3. Collin M, Rossi A, Cuzzocrea S, et al. Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. J. Leukoc. Biol. 2004; 76: 961-970.
4. Collino M, Patel NS, Lawrence KM, et al. The selective PPARγ antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney Int. 2005; 68: 529-536.
5. Collino M, Aragno M, Mastrocola R, et al. Modulation of the oxidative stress and inflammatory response by peroxisome proliferator-activated receptor-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur. J. Pharmacol. 2006; 530: 70-80.
6. Gallicchio M, Rosa AC, Benetti E, Collino M, Dianzani C, Fantozzi R. Substance P-induced cyclooxygenase-2 expression in human umbilical vein endothelial cells. Brit. J. Pharmacol. 2006; 147: 681-689.
7. Dianzani C, Collino M, Gallicchio M, et al. Evaluation of in vitro anti-inflammatory activity of some 2-alkyl-4,6-dimethoxy-1,3,5- triazines. J. Pharm. Pharmacol. 2006; 58: 219-226.
8. Dianzani C, Collino M, Gallicchio M, Di Braccio M, Roma G, Fantozzi R. Effects of antiinflammatory [1,2,4]triazolo[4,3-a] [1,8]naphthyridine derivatives on human stimulated PMN and endothelial cells: an in vitro study. J. Inflamm. 2006; 3: 4-15.
9. Collino M, Aragno M, Mastrocola R, et al. Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radic Biol Med. 2006; 41: 579-589.
10. Patel NS, Cuzzocrea S, Collino M, et al. The role of cycloxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo. Eur J Pharmacol. 2007; 562: 148-154.
11. Gallicchio M, Rosa AC, Dianzani C, et al. Celecoxib decreases expression of the adhesion molecules ICAM-1 and VCAM-1 in a colon cancer cell line (HT29). Br J Pharmacol. 2008; 153(5): 870-878.
12. Dianzani C, Brucato L, Gallicchio M, Rosa AC, Collino M, Fantozzi R. Celecoxib modulates adhesion of HT29 colon cancer cells to vascular endothelial cells by inhibiting ICAM-1 and VCAM- 1 expression. Br J Pharmacol. 2008; 153: 1153-1161.
13. Murch O, Abdelrahman M, Collino M, et al. Sphingosylphosphorylcholine reduces the organ injury/dysfunction and inflammation caused by endotoxemia in the rat. Crit Care Med. 2008; 36: 550-559. doi: 10.1097/01.CCM.0B013E3181620D2F.
14. Collino M, Thiemermann C, Mastrocola R, et al. Treatment with the glycogen synthase kinase-3β inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus. Shock. 2008; 30: 299-307. doi: 10.1097/SHK.0b013e318164e762.
15. Collino M, Patel NS, Thiemermann C. PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. Therapeutic Advances in Cardiovascular Disease. 2008; 2: 179- 197. doi: 10.1177/1753944708090924.
16. Tripatara P, Patel NS, Collino M, et al. Generation of Endogenous Hydrogen Sulfide by Cystathionine Gamma-Lyase limits the Renal Injury and Dysfunction caused by Ischemia/Reperfusion. Lab Invest. 2008; 88: 1038-1048. doi: 10.1038/labinvest.2008.73.
17. Sivarajah A, Collino M, Yasin M, et al. Anti-apoptotic and anti-inflammatory effects of hydrogen sulphide in a rat model of regional myocardial ischaemia and reperfusion. Shock. 2009; 31: 267-274. doi: 10.1097/SHK.0b013e318180ff89.
18. Collino M, Aragno M, Castiglia S, et al. Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3beta. Diabetes. 2009; 58: 235-242. doi: 10.2337/db08-0691.
19. Miglio G, Rosa AC, Rattazzi L, Collino M, Lombardi G, Fantozzi R. PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem Int. 2009; 55: 496-504. doi: 10.1016/j.neuint.2009.05.001.
20. Aragno M, Tomasinelli CE, , Vercellinatto I, et al. SREBP-1c in nonalcoholic fatty liver disease induced by Western-type high-fat diet plus fructose in rats. Free Radic Biol Med. 2009; 47: 1067-1074. doi: 10.1016/j.freeradbiomed.2009.07.016.
21. Collino M, Castiglia S, Manoni M, et al. Effects of a semisynthetic N-,O-sulfated glycosaminoglycan K5 polysaccharide derivative in a rat model of cerebral ischemia/reperfusion injury. Thromb Haemost. 2009; 102: 837-845. doi: 10.1160/TH09-01-0012.
22. Kapoor A, Collino M, Castiglia S, Fantozzi R, Thiemermann C. Shock. 2010; 34: 117-124. doi: 10.1097/SHK.0b013e3181cd86d6.
23. Collino M, Aragno M, Castiglia S, et al. Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. Br J Pharmacol. 2010; 160: 1892-1902. doi: 10.1111/j.1476-5381.2010.00671.x.
24. Kapoor A, Shintani Y, Collino M, et al. Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock. American Journal of Respiratory and Critical Care Medicine. 2010; 182:1506-1515. doi: 10.1164/rccm.201002-0240OC.
25. Lovell MJ, Yasin M, Lee KL, et al. Bone marrow mononuclear cells reduce myocardial reperfusion injury by activating the PI3K/Akt survival pathway. Atherosclerosis. 2010; 213: 67-76 doi: 10.1016/j.atherosclerosis.2010.07.045.
26. Miglio G, Rosa AC, Rattazzi L, et al. The subtypes of peroxisome proliferator-activated receptors expressed by human podocytes and their role in decreasing podocyte injury. Br J Pharmacol. 2011;162: 111-125. doi: 10.1111/j.1476-5381.2010.01032.x.
27. Collino M, Benetti E, Miglio G, et al. Peroxisome proliferator-activated receptor β/δ agonism protects the kidney against ischemia/reperfusion injury in diabetic rats. Free Radic Biol Med. 2011; 50: 345-353. doi: 10.1016/j.freeradbiomed.2010.10.710.
28. Patel NS, Nandra KK, Brines M, et al. A non-erythropoietic peptide that mimicks the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock. Mol Med. 2011. doi: 10.2119/molmed.2011.00053.
29. Benetti E, Patel NS, Collino M. The Role of PPARβ/δ in the Management of Metabolic Syndrome and its Associated Cardiovascular Complications. Endocr Metab Immune Disord Drug Targets. 2011; 11: 273-284.
30. Collino M. High dietary fructose intake: Sweet or bitter life? . World J Diabetes. 2011; 2:77-81. doi: 10.4239/wjd.v2.i6.77.
31. Patel NS, Collino M, Yaqoob MM, Thiemermann C. Erythropoietin in the intensive care unit: beyond treatment of anemia. Ann Intensive Care. 2011; 1: 40. doi: 10.1186/2110-5820-1-40.
32. Rosa AC, Rattazzi L, Miglio G, Collino M, Fantozzi R. Angiotensin II induces tumor necrosis factor-α expression and release from cultured human podocytes. Inflamm Res. 2012; 61: 311-317. doi: 10.1007/s00011-011-0412-8.
33. Nandra KK, Takahashi K, Collino M, et al. Acute treatment with bone marrow-derived mononuclear cells attenuates the organ injury/dysfunction induced by hemorrhagic shock in the rat. Shock. 2012; 37: 592-598. doi: 10.1097/SHK.0b013e31824e4c0d.
34. Patel NS, Kerr-Peterson HL, Brines M, et al. Delayed Administration of Pyroglutamate Helix B Surface Peptide (pHBSP), a Novel Nonerythropoietic Analog of Erythropoietin, Attenuates Acute Kidney Injury. Mol Med. 2012; 18: 719-727. doi: 10.2119/molmed.2012.00093.
35. Collino M, Pini A, Mastroianni R, et al. The non-anticoagulant heparin-like K5 polysaccharide derivative K5-N,OSepi attenuates myocardial ischaemia/reperfusion injury. J Cell Mol Med. 2012; 16: 2196-2207. doi: 10.1111/j.1582-4934.2012.01530.x.
36. Bertinaria M, Rolando B, Giorgis M, et al. Carnosine analogues containing NO-donor substructures: synthesis, physicochemical characterization and preliminary pharmacological profile. Eur J Med Chem. 2012; 54: 103-112. doi: 10.1016/j.ejmech.2012.04.032.
37. Rosa AC, Grange C, Pini A, et al. Overexpression of histamine H4 receptors in the kidney of diabetic rats. Inflamm Res. 2013; 62: 357-365. doi: 10.1007/s00011-012-0587-7.
38. Collino M, Benetti E, Rogazzo M, et al. (2012). Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPARagonism correlates with impaired NLRP3 inflammasome activation. Biochem Pharmacol. 2013; 85: 257-264. doi: 10.1016/j.bcp.2012.10.014.
39. Nandra KK, Collino M, Rogazzo M, Fantozzi R, Patel NS, Thiemermann C. Pharmacological preconditioning with erythropoietin attenuates the organ injury and dysfunction induced in a rat model of hemorrhagic shock. Dis Model Mech. 2013; 6: 701-709. doi: 10.1242/dmm.011353.
40. Bangash MN, Patel NS, Benetti E, et al. Dopexamine can attenuate the inflammatory response and protect against organ injury in the absence of significant effects on hemodynamics or regional microvascular flow. Crit Care. 2013; 17(2): R57. doi: 10.1186/cc12585.
41. Khan AI, Coldewey SM, Patel NS, et al. Erythropoietin attenuates cardiac dysfunction in experimental sepsis in mice via activation of the β-common receptor. Dis Model Mech. 2013; 6(4): 1021-1030. doi: 10.1242/dmm.011908.
42. Coldewey SM, Rogazzo M, Collino M, Patel NS, Thiemermann C. Inhibition of IκB kinase reduces the multiple organ dysfunction caused by sepsis in the mouse. Dis Model Mech. 2013; 6(4): 1031-1042. doi: 10.1242/dmm.012435.
43. Collino M, Pini A, Mugelli N, et al. Beneficial effect of prolonged heme oxygenase 1 activation in a rat model of chronic heart failure. Dis Model Mech. 2013; 6(4): 1012-1020. doi: 10.1242/dmm.011528.
44. Coldewey SM, Khan AI, Kapoor A, et al. Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptor. Kidney Int. 2013; 84(3): 482-490. doi: 10.1038/ki.2013.118.
45. Benetti E, Chiazza F, Patel NS, Collino M. The NLRP3 Inflammasome as a Novel Player of the Intercellular Crosstalk in Metabolic Disorders. Mediators Inflamm. 2013; 2013: 678627. doi: 10.1155/2013/678627.
46. Benetti E, Mastrocola R, Rogazzo M, et al. High Sugar Intake and Development of Skeletal Muscle Insulin Resistance and Inflammation in Mice: A Protective Role for PPAR- δ Agonism. Mediators Inflamm. 2013; 2013: 509502. doi: 10.1155/2013/509502.
47. Collino M, Rogazzo M, Pini A, et al. Acute treatment with relaxin protects the kidney against ischaemia/reperfusion injury. J Cell Mol Med. 2013; 17: 1494-1505. doi: 10.1111/jcmm.12120.
48. Mastrocola R, Collino M, Rogazzo M, et al. Advanced glycation end products promote hepatosteatosis by interfering with SCAP-SREBP pathway in fructose-drinking mice. Am J Physiol Gastrointest Liver Physiol. 2013; 305: G398-G407. doi: 10.1152/ajpgi.00450.2012.
49. Collino M, Rudich A, Konrad D. Mediators of interorgan crosstalk in metabolic inflammation. Mediators Inflamm. 2013; 2013: 609096. doi: 10.1155/2013/646271.

Omorogieva Ojo, PhD

Senior Lecturer in Primary Care
Faculty of Education and Health
University of Greenwich
Room G308
Avery Hill Campus, Avery Hill Road
London. SE9 2UG, UK

BiographyResearch InterestScientific ActivitiesPublications

Dr. Ojo is a Senior Lecturer in primary care at the University of Greenwich, London. He is the coordinator of the Diabetes Care and Management course for post registration nurses and Patient Pathways of Care for pre-registration participants.
He teaches diabetes and nutrition related topics in different courses across the School of Health and Social care and conducts study days in collaboration with partner organisations outside the University. He is a link lecturer for students attending clinical placement in various community settings and also the Professional Tutorial Group Leader for students, providing academic and pastoral support to these students.
Dr. Ojo supervises undergraduate, Masters and PhD research students. His research interests are in diabetes and clinical nutrition. These are reflected in his publications and conference presentations. Dr. Ojos work is recognised both nationally and internationally and he has been a keynote speaker at the NNNG conference, a reviewer for Journals, Editor of Journals and sits on the Editorial Board on a number of International Journals.
He has previously held the post of Lead Nutrition Specialist, rising to the position of Acting Service Lead of the Home Enteral Nutrition Team in Lewisham Healthcare NHS Trust. His duties and responsibilities included:
• Providing nutritional support to enteral tube fed patients in the community
• Management, Teaching, Training and Mentoring of community nurses, students, carers and patients on home enteral nutrition.
• Conducting risk assessment, research and clinical audits.
• Developing home enteral nutrition team policy for the Primary Care Trust.
Dr. Ojo has also worked as a post-doctoral research fellow in the School of Science, University of Greenwich. His duties and responsibilities included:
• Conducting research on the effect of diet and exercise on overweight and obese subjects in the community.
• Providing support to undergraduate and post graduate research students including PhD students undertaking research.

His research interests include: Diabetes, Structured Education in Diabetes for Ethnic Minorities, Evaluation of the Glycaemic index of some carbohydrate rich ethnic minority foods in the UK, Clinical Nutrition, Enteral tube feeding in the community.

SCIENTIFIC SOCIETIES


• (1970-Present) Colegio Médico de Chile
• (1971-Present) Sociedad de Biología de Chile
• (1971-Present) Sociedad Médica de Santiago
• (1982-Present) Fellow of the American College of Physicians
• (1986-Present) Member American Gastroenterological Association
• (1988-1990) Member of International liaison committee of the AGA
• (1989-Present) Albo di Medicina e Chirurgia di Roma, Italy
• (1992-2000) Member of the International Advisory Board on Gallstones

1. Brooke J, Ojo O. Cognitive screening in patients with diabetes in primary care. British Journal of Community Nursing. 2014; 19(8): 401-406. doi: 10.12968/bjcn.2014.19.8.401
2. Ojo O. Problems with use of a Foley catheter in home enteral tube feeding. British Journal of Nursing. 2014; 23(7): 360-364.
3. Hickman S, Ojo O. Implementing Early Supported Discharge in patients with acute exacerbation of Chronic Obstructive Pulmonary Disease. Journal of Nursing and Health Care. 2013; 1(1): 148-159.
4. Ojo O. Diabetes in Ethnic Minorities in UK: The role of diet in glucose dysregulation and prevalence of diabetes. Journal of Food & Nutritional Disorders. 2013; 2(2): 1-7.
5. Ojo O. The Impact of Changes in Health and Social Care on Enteral Feeding in the Community. Nutrients. 2012; 4(11): 1709-1722. doi: 10.3390/nu4111709.
6. Ojo O, Bowden J. Infection control in enteral feed and feeding systems in the community. British Journal of Nursing. 2012; 21(18): 1070-1075.
7. Ojo O. Managing Diabetes in people on home enteral tube feeding. Diabetes and Primary Care. 2012; 14(2): 113-119.
8. Ojo O, Patel I. Home enteral nutrition and team working. Journal of Community Nursing. 2012; 26(2): 15-18.
9. Ojo O. Balloon gastrostomy tubes for long-term feeding in the community. British Journal of Nursing. 2011; 20(1): 34-38.
10. Ojo O. Diaspora Nigerians: Good People, Fat Nation. The Nation. 2011.
11. Wright K, Ojo O. Foot care for residents with type 2 diabetes. Nursing & Residential Care. 2010; 12(12): 585-589.
12. Ojo O. Managing patients on enteral feeding tubes in the community. British Journal of Community Nursing. 2010; 15(11): S6-S13.
13. Ojo O. Evaluating Care: home enteral nutrition. Journal of Community Nursing. 2010; 24(3): 18-25.
14. Ojo O. Home Enteral Nutrition NICE Guidelines and Nutrition Support in primary care. British Journal of Community Nursing. 2010; 15(3): 116-120.
15. Ojo O, Deane R. Effects of cassava processing methods on antinutritional components and health status of children. Journal of Science of Food and Agriculture. 2002; 82: 252-257.
16. Todlana FS, Ojo O, Grant G. The functional effects of lupinseed and its fractions on lipid metabolism in hooded lister rats. In Biologically- active phytochemicals in food. Pfsnnhauser W, Fenwick GR, Khokhar S. The Royal Society of Chemistry. 2001; 107-109.
17. Ojo O, Deane R, Amuna P. The use of anthropometric and clinical parameters for early identification and categorisation of nutritional risk in pre-school children in Benin-City, Nigeria. The Journal of the Royal Society for the Promotion of Health. 2000; 120(4): 230-235.
18. Ojo O, Deane R, Prashad D, Ikhatua UJ. Body Composition of Children in a Depressed Economy. Annals of the New York Academy of Sciences. 2000; 904: 424-428.

Emily Piven, OTD, MHE, OTR

Retired Associate Professor of Occupational Therapy
University of Texas at El Paso Occupational Therapy Program
College of Nursing and Health Sciences
USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Piven (Formerly Dr. Emily Piven Haltiwanger) worked at the University of Texas at El Paso in the Rehabilitation Sciences Department at the College of Health Sciences for 10 years. She received her Clinical Doctorate of Occupational Therapy from Creighton University in 2004, Master’s Degree of Health Education from the Medical College of Georgia, and baccalaureate degree in Occupational Therapy from Virginia Commonwealth University in 1974. She is currently active in the World Federation of Occupational Therapists task force for development of an international education course on Disaster Preparedness and Response to train disaster volunteers from the rehabilitation profession. Dr. Piven has published numerous research articles in psychosocial adaptation to diabetes and chronic illness. She serves as Associate Editor of Occupational Therapy International, and Associate Editor of TANG: International Journal of Genuine Traditional Medicine, and is on the editorial boards of the Open Journal of Depression, the Journal of Clinical Trials, and the open access Internet Journal of Allied Health Sciences and Practice. In 2011, she was awarded the first Lifetime Achievement Award by the El Paso Diabetes Association and Academic Educator of the Year Award by the Texas Occupational Therapy Association. As a clinician, Dr. Piven worked in 23 rehabilitation settings expanding occupational therapy positions in Maryland, Missouri, South Carolina and Georgia. She was also in private practice for 18 years. She has been a pioneer in her profession developing individual and group interventions for management of diabetes for adolescents and elders for prevention of tertiary complications of the disease. She has presented her research in diabetes for the last 13 years at regional, national and international occupational therapy and health education conferences.

Her research interests include: secondary prevention; cultural diversity; psychosocial adaptation to diabetes and other chronic illnesses, the effect of glucose levels on frequency-domain measures of heart rate variability signals; and complementary and alternative medicine treatment of acute and chronic pain through acupuncture point activation.

$500.00 Health and Wellness Initiative for Women Attending Minority Institutions Grant: Funding the PASS Program for Peer Assisted Student Support 2010-2012 cooperating with Student Health.
$75,000 January 4, 2007- June 30, 2008 Center for Border Health Research “Development of a Predictive Screening Tool for Potential Non-adherence to Diabetes Regimen Among Elderly Mexican Americans with Type 2 Diabetes Mellitus” Leticia Lantican, BSN, MS, MA, PhD Principal Investigator, and Emily Haltiwanger, OTD, MHE, OTR
$75,000 October 1, 2007- September 30, 2008 “A pilot study to investigate the improvement in adherence behaviors of type 2 Mexican-American elderly Spanish-Speaking diabetics, through participation in a culturally appropriate support group mentoring system” Principal Investigator, Emily Haltiwanger, OTD, MHE, OTR Theresa Byrd, Dr PH
$33,000 October 1, 2005-September 30, 2006 “A pilot study to investigate the improvement in adherence behaviors of type 2 Mexican-American elderly diabetics, through participation in a culturally appropriate support group mentoring system” Principal Investigator, Emily Haltiwanger, OTD, MHE, OTR, Theresa Byrd, Dr PH

1. Piven EF. Editorial: Culturally-Tailored Education Programs to Address Health Literacy Deficits and Pervasive Health Disparities among Hispanics in Rural Shelbyville, Kentucky: From an Occupational Therapy Perspective. Journal of Community Medicine and Health Education. 2014; 4 (1): e123-124.
2. Piven EF, Duran R. Reduction of non-adherent behavior in a Mexican-American adolescent with type 2 diabetes. Occupational Therapy International. 2014; doi: 10.1002/oti.1363.
3. Derakhshanrad S, Rassafiani M, Haghgoo H, Piven EF, Nazeran H. Neuro-occupation: A nonlinear dynamical system perspective to the brains neural mechanism. Journal of Research in Rehabilitation Sciences, North America. 2013; 9: 754-766.
4. Piven EF and Nazeran H. The experience of Mexican-Americans transitioning to insulin pump technology. Journal of Community Medicine and Health Education. 2013; 3(4): 222-227.
5. Haltiwanger EP. Preventing falls. Diabetes Self-management. 2013; 30 (2): 10-14.
6. Haltiwanger EP, Galindo DM. Reduction of depressive symptoms in an elderly Mexican-American female with type 2 diabetes mellitus: A single-subject study. Occupational Therapy International. 2013; 20: 35-44. doi: 10.1002/oti.1338.
7. Piven E, Dharia R, Jones K, Davis C, Nazeran H. Effect of energetic acupuncture point activation using IceWave pain patches on reduction of pain. International Journal of Genuine Traditional Medicine. 2013; 3(1): e5-10.
8. Piven EF. Services to the homeless with serious mental illness: From an occupational therapy perspective. Journal of Clinical Trials. 2012; 2 (4): e112.
9. Haltiwanger EP. Experience of Mexican-American elders with diabetes: A phenomenological study. Occupational Therapy in Health Care. 2012; 26(2-3): 150-162. doi: 10.3109/07380577.2012.694585.
10. Haltiwanger EP. Effect of a group adherence intervention for Mexican-American older adults with type 2 diabetes. American Journal of Occupational Therapy. 2012; 66: 447-454. doi: 10.5014/ajot.2012.004457.
11. Haltiwanger EP and Brutus H. A culturally sensitive diabetes peer support for older Mexican-Americans. Occupational Therapy International. 2012; 19 (2): 67-75. doi: 10.1002/oti.320.
12. Nazeran H, Blake-Greenberg S, Haltiwanger E. Mild stimulation of stomach 36 acupuncture point by organic nanoscale SP6 patch improves cellular physiologic functional status of different organs. International Journal of Genuine Traditional Medicine (TANG) e-journal. 2012; 2 (1): 1-6.
13. Medina DV, Haltiwanger EP, Funk KP. The experience of chronically ill elderly Mexican-American men with spouses as caregivers. Physical and Occupational Therapy in Geriatrics. 2011; 29 (3): 189-201
14. Haltiwanger EP and Underwood NS. Life after driving: A community-dwelling seniors experience. Physical and Occupational Therapy in Geriatrics. 2011; 29 (2): 156-167.
15. Haltiwanger E, Rojo R, Funk K. Living with cancer and the impact of participating in an expressive arts support group: A case study. Occupational Therapy in Mental Health. 2011; 27(2): 65-86.
16. Haltiwanger E. Client empowerment through cultural sensitivity. OT Practice. 2010; 15(15): 7-11.
17. Haltiwanger E, Stein F. Editorial: Occupational therapy and complementary and alternative medicine. Special Edition Occupational Therapy International. 2009; 16(1): 1-5. doi: 10.1002/oti.268.
18. Piven EF. Editorial: Culturally-Tailored Education Programs to Address Health Literacy Deficits and Pervasive Health Disparities among Hispanics in Rural Shelbyville, Kentucky: From an Occupational Therapy Perspective. Journal of Community Medicine and Health Education. 2014; 4 (1): e123-124. doi:
19. Piven EF, Duran R. Reduction of non-adherent behavior in a Mexican-American adolescent with type 2 diabetes. Occupational Therapy International. 2014; doi: 10.1002/oti.1363.
20. Derakhshanrad S, Rassafiani M, Haghgoo H, Piven EF, Nazeran H. Neuro-occupation: A nonlinear dynamical system perspective to the brains neural mechanism. Journal of Research in Rehabilitation Sciences, North America. 2013; 9: 754-766. doi:
21. Piven EF, Nazeran H. The experience of Mexican-Americans transitioning to insulin pump technology. Journal of Community Medicine and Health Education. 2013; 3(4): 222-227.
22. Haltiwanger EP. Preventing falls. Diabetes Self-management. 2013; 30 (2): 10-14.
23. Haltiwanger EP, Galindo DM. Reduction of depressive symptoms in an elderly Mexican-American female with type 2 diabetes mellitus: A single-subject study. Occupational Therapy International. 2013; 20: 35-44. doi: 10.1002/oti.1338.
24. Piven E, Dharia R, Jones K, Davis C, Nazeran H. Effect of energetic acupuncture point activation using IceWave pain patches on reduction of pain. International Journal of Genuine Traditional Medicine. 2013; 3(1): e5-10.
25. Piven EF. Services to the homeless with serious mental illness: From an occupational therapy perspective. Journal of Clinical Trials. 2012; 2 (4): e112.
26. Haltiwanger EP. Experience of Mexican-American elders with diabetes: A phenomenological study. Occupational Therapy in Health Care. 2012; 26(2-3): 150-162. doi: 10.3109/07380577.2012.694585.
27. Haltiwanger EP. Effect of a group adherence intervention for Mexican-American older adults with type 2 diabetes. American Journal of Occupational Therapy. 2012; 66: 447-454. doi: 10.5014/ajot.2012.004457.
28. Haltiwanger EP, Brutus H. A culturally sensitive diabetes peer support for older Mexican-Americans. Occupational Therapy International. 2012; 19(2): 67-75. doi: 10.1002/oti.320.
29. Nazeran H, Blake-Greenberg S, Haltiwanger E. Mild stimulation of stomach 36 acupuncture point by organic nanoscale SP6 patch improves cellular physiologic functional status of different organs. International Journal of Genuine Traditional Medicine (TANG) e-journal. 2012; 2 (1): 1-6.
30. Medina DV, Haltiwanger EP, Funk KP. The experience of chronically ill elderly Mexican-American men with spouses as caregivers. Physical and Occupational Therapy in Geriatrics. 2011; 29 (3): 189-201
31. Haltiwanger EP and Underwood NS. Life after driving: A community-dwelling seniors experience. Physical and Occupational Therapy in Geriatrics. 2011; 29 (2): 156-167.
32. Haltiwanger E, Rojo R, Funk K. Living with cancer and the impact of participating in an expressive arts support group: A case study. Occupational Therapy in Mental Health. 2011; 27(2): 65-86.
33. Haltiwanger E. Client empowerment through cultural sensitivity. OT Practice. 2010; 15(15): 7-11.
34. Haltiwanger E, Stein F. Editorial: Occupational therapy and complementary and alternative medicine. Special Edition Occupational Therapy International. 2009; 16(1): 1-5. doi: 10.1002/oti.268.
35. Piven EF. Increasing Adherence to the Diabetes Regimen: An Occupational Therapy Perspective. Diabetes Res Open J. 2014; 1(1): e001.

Jian-Xiong Chen, MD, FAHA

Associate Professor
Department of Pharmacology and Toxicology
University of Mississippi Medical Center
Room G325, Jackson, MS, 39216, USA

BiographyResearch InterestScientific ActivitiesPublications

After receiving the M.D. and a master’s degree in pharmacology from Central South University of China, Dr. Chen completed his postdoctoral training in pathology at Vanderbilt University Medical Center. Dr. Chen served as an assistant professor in Pathology, and became associate professor of Pediatrics at Vanderbilt University from 2002-2010.Hejoined the University of Mississippi Medical Center as an associate professor at Department of Pharmacology and Toxicology in 2011-present. Dr. Chen is Fellow of American Heart Association (AHA) and member of American Physiology Society. Dr. Chen has served as a grant reviewer committee of NIH, AHA and British Medical Research Council. During the past 12 years, Dr. Chen has been a part of a very successful research team that have been well-funded by NIH and AHA. He is the author of 40peer-reviewed publications and is currently funded by National Heart, Lung and Blood Institute. The long-term goals of his laboratory research are to understand the pathogenesis and identify the intracellular molecular basis that may contribute to abnormal angiogenesis and regeneration, exacerbation of cardiac dysfunction and heart failure, then, to develop novel therapies that can prevent or reverse these devastating diabetic cardiovascular diseases.

His research interests include: Oxidants and angiogenesis, angiogenic factors gene therapy on diabetic impaired angiogenesis, myocardial regeneration and bone marrow/stem cell differentiation.


CURRENT RESEARCH:

The long-term goals of my laboratory research are to identify the intracellular molecular basis that may contribute to diabetes-associated impairment of angiogenesis and regeneration, exacerbation of cardiac dysfunction and heart failure, then, to develop novel therapies that can prevent or reverse these devastating diabetic cardiovascular diseases. Specifically, my laboratory research interesting is focused on: The receptor tyrosine kinase (RTK) angiopoietins/Tie-2 system,prolyl hydroxylases-2 (PHD2), apelin/APJ and Notch signaling interactions in the regulation of vascular smooth muscle maturation, capillary growth and regression, cardiac hypertrophy and heart failure. By using genetic modified Notch3 knockout, conditional knockout of PHD2 diabetic mice model, myocardial ischemia-induced angiogenesis in vivo and in vitro angiogenesis models, we will define: (1) the molecular mechanisms by which hyperglycemia or diabetes disrupt angiopoietins/Tie-2 system and cause vessel immaturation and regression; (2) their interactive effects with PHD2/HIF-1a signaling and apelin/APJ on myocardial neovessel maturation and angiogenesis; (3) the mechanisms by which hyperglycemia interferes with pro-inflammatory programme of endothelial cell with a focus on the role of elevated Ang-2; and (4) whether disruption of Jagged1/Notch3 contributes to diabetes-induced abnormal vascular smooth muscle maturation, vascular progenitor differentiation and facilitate adverse cardiac remodeling and heart failure in diabetes. Identify novel molecular basis as a potential therapeutic target in diabetic cardiac hypertrophy and fibrosis will provide novel approaches to prevent and/or reverse diabetic myocardial ischemia disease.

PROFESSIONAL ORGANIZATIONS:

• Member of American Heart Association
• Member of American Physiological Society


INVITED TALKS:

2008: July 23; invited talk, Beijing University Medical Center, Beijing, PR China, Title: NADPH oxidase and diabetic angiogenesis.
2010: May 4, invited talk, University of Missouri, Department of Pharmacology and Physiology, Columbia, MO. Title Angiopoietins/Tie-2 system and diabetic abnormal angiogenesis.
2010: July 12, invited talk, University of Mississippi Health Center, Department of Pharmacology, Jackson, MS. Title “Angiopoietins/Tie-2 system in diabetic vascular complications”.
2011 March 16, invited talk, University of Mississippi Health Center, Department of Physiology& Biophysics, Jackson, MS. Title “Angiopoietins/Tie-2 in diabetic infarcted heart”.
2011 November 4, invited talk, University of Southern Mississippi, Department of Biological Science, Hattiesburg, MS. Title “Angiopoietins/Tie-2 system in diabetic complications”.
2012 December 11, invited talk, University of Mississippi Medical Center, Department of Biochemical Science, Jackson, MS. Title “Mechanisms of impairment of myocardial angiogenesis in type II diabetes”.

PEER-REVIEWED MANUSCRIPTS

1. Liao DF, Yu L, Chen JX. A new method to study correlation between endothelium dmage and free rardicals-morphology change of endothelium under scanning electron microscopy. Journal of Hengyang Medical College. 1992; 20(4): 341-343.
2. Chen JX, Yu L, Liao DF, Cao JG, Zhu BY. The effect of oxygen free radicals on airway of guinea pig and its mechanism. Journal of Hengyang Medical College. 1993; 21(4): 360-362.
3. Chen JX, Yu L, Liao DF, et al. Protective effect of gypenosides on free radical injury in isolated guinea pig heart. Journal of Hengyang Medical College. 1993; 21(3): 243-245.
4. Wan Y, Weng SA, Chen JX, Wu HX, Cao YS. Effects of estradiol on asthma of guinea pigs and its relationship to beta-adrenergic receptors. Chinese Pharmacological Bulletin. 1993, 9(4): 295-297.
5. Chen JX, Wu HX, You W. The role of endotoxin in the bronchial hyper-reactivity formation. National Medical Journal of China. 1994; 74(1): 38-40.
6. Chen JX, Cao YS. Protection ammonium glycyrrhizanate against endotoxin-induced bronchial hyperreactivity. Chinese Journal of Pharmacology and Toxicology. 1994; 8(3): 235-236.
7. Chen JX, Cao YS. Effect ammonium glycyrrhizanate against endotoxin-induced bronchial hyperreactivity-in relation to beta-cAMP system. Chinese Traditional and Herbal Drugs. 1994; 1(1): 17-18.
8. Xiao GL, Liao DF, Chen JX, Yu L. Protective effect of gypenosides on OFR-induced damage of relaxing capacity of rabbit thoracic aortae in vitro. Chinese Pharmacological Bulletin. 1994; 10(2): 136-138.
9. Chen JX, Tang XQ, Zhu BY, Liao DF. The mechanism of exogenous oxygen free radicals induced vasospasm of isolated basilar artery. Chinese Journal Arteriosclerosis. 1994; 2(2): 88-91.
10. Liao DF, Chen JX, Huang HL, Tang XQ, Cao JG, Yu L. Correlation bwteen the protection of probucol on injury of endothelial cells by free radicals and the activity of nitric oxide. Chinese Journal Arteriosclerosis. 1994; 2(2): 67-71.
11. Chen JX, Liao DF, Yu L, Xiao GL, Zhu BY, Tang XQ. Protective effect of captopril on electrolyzed perfusion solution induced vasospasm of isolated basilar artery. Chinese Journal of Pharmacology and Toxicology. 1995; 9(1): 44-46.
12. Li LX, Yu L, Chen JX, et al. Oxidized low density lipoprotein promotion of adhesion of monocytes to endothelial cells in vitro. Chinese Journal Arteriosclerosis. 1996; 4(4): 272-275.
13. Chen JX, Liao DF, Tang XQ, Yu L, Zeng H, Cao JG. Protection of Gypenosides against oxygen free radical induced vasospasm of isolated rabbit basilar artery. Chinese Traditional and Herbal Drugs. 1997, 28(4): 219-221.
14. Huang HL, Chen JX, Zeng H et al. Oxygen free radicals stimulates epithelial-leukocyte adhesion. Journal of Hengyang Medical College. 1996; 24(4): 255-257.
15. Chen JX, Zeng H, Zhu BY. Effect of endotoxin on Endothelin-1, Thromboxane A2 and prostaglandin E2 secretion and role of oxygen free radicals. Journal of Hengyang Medical College. 1998; 26(8): 121-123. 16. 16. Liao DF, Lu N, Lei LS, Yu L, Chen JX. Effects of gypenosides on mouse splenic lymphocyte transformation and DNA polymerase II activity in vitro. Acta Pharmacological Sin. 1995; 16(4): 322-4.
17. Chen JX, Chen WZ, Hung HL, Chen LX, Xie ZZ, Zhu PY. Protective effects of Ginkgo biloba extract against lysophosphatidylcholine induced endothelium cell damage. Acta Pharmacological Sin. 1998; 19(4): 359-363.
18. Li LX, Chen JX, Liao DF, Yu L. Probucol inhibits oxidized-low density lipoprotein induced adhesion of monocytes to endothelial cells by reducing P-selectin synthesis in vitro. Endothelium. 1998; 6: 1-8.
19. Su CY, Chong KY, Chen JX, Ryter SW, Lai CC. A physiological relevant hyperthermia selectively activates constitutive Hsp70 in H9c2 cardiac myoblasts and confers oxidative protection. J Mol Cell Cardiol. 1999; 31: 845-855.
20. Chen JX, Zeng H, Chen X, Su CY, Lai CC. Induction of heme oxygenase-1 by Ginkgo biloba extract but not its tepernoids constituents partially mediated its protective effect against lysophosphatidylcholine-induced damage. Pharmacological Research. 2001; 43(1): 63-69.
21. Chen JX, Berry LC, Christman BW, Tanner M, Myers PR, Meyrick BO. NO regulates LPS-stimulated cyclooxygenase gene expression and activity in pulmonary artery endothelium. Am J Physiology. 2001; 280: L450-457.
22. Chen JX, Berry LC, Tanner M, Myers PR, Meyrick BO. Nitric oxide donors regulate nitric oxide synthase in bovine pulmonary artery endothelium. J Cellular Physiology. 2001; 186: 116-123.
23. Chen JX, Berry LC, Meyrick BO. Glutathione mediates LPS-stimulated COX-2 expression via early transient P42/44 activation. J Cellular Physiology. 2003; 197: 86-93.
24. Chen JX, Lawrence ML, Cunningham G, Christman BW, Meyrick B. Hsp90 and Akt Modulate Ang-1 Induced Angiogenesis via NO in Coronary Artery Endothelium. J Appl Physiol. 2004; 96: 612-620.
25. Chen JX, Meyrick BO. Hypoxia Increases Hsp90 Binding to eNOS via a PI3Kinase-Akt Pathway in Porcine Coronary Artery Endothelium. Lab Invest. 2004; 84(2): 182-190.
26. Chen JX, Chen Y, DeBusk L, Lin W, Lin PC. Dual functional roles of Tie-2/angiopoietin in TNF-alpha-mediated angiogenesis. Am J Physiol Heart Circ Physiol. 2004; 287(1): H187-95.
27. Pei J, Yan PK, Chen JX, Zhu BY, Lei XY, Yin WD, Liao DF. High-density lipoprotein 3 inhibits oxidized low- density lipoprotein-induced apoptosis via promoting cheolesterol efflux in RAW264.7 cells. Acta Pharmacological Sin. 2006; 27(2): 151-7.
28. Chen JX, Zeng H, Lawrence ML, Sadikot RT, Blackwell TS, Meyrick B. Role of NADPH oxidase-derived reactive oxygen species (ROS) in angiopoietin-1-induced angiogenesis. Am J Physiol Heart Circ Physiol. 2006; 291: 1563-1572.
29. Chen JX, Zeng H, Qin-Hui Tuo, Heidi Yu, Meyrick B, Judy Aschner. NADPH oxidase mediates myocardial Akt, ERK1/2 activation and angiogenesis after hypoxia/reperfusion. Am J Physiol Heart Circ Physiol. 2007; 292: H1664-1674.
30. Tuo QH, Zeng H, Stinnett A, Yu HD, Aschner JL, Chen JX. Critical role of angiopoietins/Tie-2 in hyperglycemic exacerbation of myocardial infarction and impaired angiogenesis. Am J Physiol Heart Circ Physiol. 2008; 294(6): H2547-57
31. Chen JX, Stinnett A. Disruption of Ang-1/Tie-2 signaling contributes to the impaired myocardial vascular maturation and angiogenesis in type II diabetic mice. Arterioscler Thromb Vasc Biol. 2008; 28: 1606-1613. doi: 10.1161/ATVBAHA.108.169235.
32. Chen JX, Stinnett A. Critical role of the NADPH oxidase subunit p47phox on vascular TLR expression and neointimal lesion formation in high fat diet-induced obesity. Lab Invest. 2008; 88: 1316-1328. doi: 10.1038/labinvest.2008.92.
33. Chen JX, Stinnett A. Ang-1 gene therapy inhibits hypoxia-inducible factor-1alpha (HIF-1alpha)-prolyl-4-hydroxylase-2, stabilizes HIF-1alpha expression, and normalizes immature vasculature in db/db mice. Diabetes. 2008; 57(12): 3335-43. doi: 10.2337/db08-0503.
34. Tuo QH, Xiong GZ, Zeng H, et al. Angiopoietin-1 protects myocardial endothelial cell function blunted by angiopoietin-2 and high glucose condition. Acta Pharmacol Sin. 2011; 32(1): 45-51. doi: 10.1038/aps.2010.183.
35. Chen JX, Tuo QH, Liao DF, Zeng H. Inhibition of protein tyrosine phosphatase improves impaired angiogenesis via enhancing Ang-1/Tie-2 signaling in diabetes. Experimental Diabetes Research. 2012; 2012: 836759 doi: 10.1155/2012/836759.
36. Chen JX, Zeng H, Reese J, Aschner JL, Barbara Meyrick. Overexpression of angiopoietin-2 impairs myocardial angiogenesis and exacerbates cardiac fibrosis in the diabetic db/db mouse model. Am J Physiol Heart Circ Physiol . 2012; 302(4): H1003-12. doi: 10.1152/ajpheart.00866.2011
37. Zeng H, Li L, Chen JX. Overexpression of Angiopoietin-1 increases CD133+/c-kit+ cells and reduces myocardial apoptosis in db/db mouse infarcted hearts. PLoS One. 2012; 7(4): e35905. doi: 10.1371/journal.pone.0035905.
38. Chen JX, OMara PW, Poole SD, et al. Isoprostanes as physiological mediators of transition to newborn life: Novel mechanisms regulating patency of the term and preterm ductus arteriosus. Pediatric Research. 2012; 72: 122-128.
39. Li L, Zeng H, Chen JX. Apelin-13 increases myocardial progenitor cells and improves repair of post-myocardial infarction. Am J Physiol Heart Circ Physiol. 2012: 303 (5): H605-18. doi: 10.1152/ajpheart.00366.2012.
40. Li L, Zeng H, Hou X, He X, Chen JX. Myocardial Injection of Apelin-Overexpressing Bone Marrow Cells Improves Cardiac Repair via Upregulation of Sirt3 after Myocardial Infarction. PLoS ONE. 2013; 8(9): e71041. doi: 10.1371/journal.pone.0071041.
41. Zeng H, He X, Hou X, Li L, Chen JX. Apelin gene therapy increases myocardial vascular density and ameliorates diabetic cardiomyopathy via upregulation of Sirtuin 3. Am J Physiol Heart Circ Physiol. 2014; 306: H585-H597. doi: 10.1152/ajpheart.00821.2013.
42. Hou X, Zeng H, Tuo Q-H, Liao D-F, Chen J-X. Apelin gene therapy increases autophagy via activation of sirtuin 3 in diabetic heart. Diabetes Res Open J. 2015; 1(4): 84-91. doi: 10.17140/DROJ-1-115

Terry D. Hinds, Jr., PhD

Assistant Professor
Department of Physiology and Pharmacology
University of Toledo College of Medicine
2801 W. Bancroft, Toledo, OH, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Hinds is an Assistant Professor in the Department of Physiology and Pharmacology at the University of Toledo. The focus of his research is on heme oxygenase (HO) reduction of obesity induced fatty liver, which can prevent diabetes and cardiovascular disease. Diet induced obesity results in elevated levels of glucose and fatty acids in liver, resulting in enhanced production of reactive oxygen species (ROS). The heme oxygenase enzyme is functionally important for reducing ROS by increasing production of the antioxidant, bilirubin. His studies show that increasing HO activity attenuates the development of NAFLD in obese mice by significantly increasing expression of the nuclear receptor, peroxisome proliferator-activated receptor alpha (PPARalpha), resulting in the reversal of hepatic steatosis, increased energy expenditure, and decreased body weight. Dr. Hinds has recently elucidated the HO-1-PPARalpha-FGF21 axis as a new signaling paradigm that can manage obesity induced NAFLD, preventing diabetes and cardiovascular disease.

His research interest include: Heme Oxygenase (HO) reduction of obesity induced fatty liver, which can prevent diabetes and cardiovascular disease.

TELEVISION INTERVIEW

• Plugged-In, WGTE PBS Channel 30, Toledo, Ohio, December 16, 2009.
• A monthly series that explores the latest innovations in technology and research
• Interview on genetic factors controlling obesity with special emphasis on childhood obesity

PEER-REVIEWED PUBLICATIONS

1. Marino JS, Hinds TD, Hoover R, et al. Suppression of Protein Kinase C Theta Contributes to Enhanced Myogenesis in vitro via IRS1 and ERK1/2 phosphorylation. BMC Cell Biology. 2013; 14: 39 doi: 10.1186/1471-2121-14-39.
2. Hinds TD, Meadows C,Sodhi K, et al. Increased HO-1 Levels Ameliorate the Development of Fatty Liver Via Reduction of Heme. Obesity. 2013.
3. Sodhi K, Puri N, Kim DH, et al. PPAR-delta Binding to Heme Oxygenase 1 Promoter Prevents Angiotensin II Induced Adipocyte Dysfunction in Goldblatt Hypertensive Rats. International Journal of Obesity. 2013; 38(3):456-465. doi: 10.1038/ijo.2013.116.
4. Fedorova LV, Sodhi K, Weis CG, et al. Peroxisome proliferator-activated receptor-delta agonist, HPP593, prevents renal necrosis under chronic ischemia. PLoS ONE. 2013; 8(5):e64436. doi: 10.1371/journal.pone.0064436.
5. Vanella L, Sodhi K, Kim DH, et al. Increased Heme-Oxygenase 1 Expression Diminished Adipocyte Differentiation and Lipid Accumulation by Upregulation of the Canonical Wnt Signaling Cascade. Stem Cell Research and Therapy. 2013; 4(2):28. doi: 10.1186/scrt176.
6. Hinds TD, Stechschulte J, Cash LA, et al. Protein phosphatase 5 mediates lipid metabolism through reciprocal control of glucocorticoid and PPAR{gamma} receptors. J Biol Chem. 2011; 286(50):42911-22. doi: 10.1074/jbc.M111.311662.
7. Wuescher L, Angevine K, Hinds T, Ramakrishnan S, Najjar S, Mensah-Osman E. Insulin regulates Menin expression, cytoplasmic localization and interaction with FOXO1. Am J Phys Endo and Met. 2011; 301(3):E474-E483. doi: 10.1152/ajpendo.00066.2011.
8. Chen H, Yong W, Hinds TD, et al. Fkbp52 regulates androgen receptor transactivation activity and male urethra morphogenesis. J Biol Chem. 2010; 285: 27776-27784. doi: 10.1074/jbc.M110.156091.
9. Hinds TD, Ramakrishnan J, Cash S, et al. Discovery of glucocorticoid receptor-beta in mice with a role in metabolism. Mol Endocrinol. 2010; 24: 1715-1727. doi: 10.1210/me.2009-0411.
10. Periyasamy S, Hinds TD, Shemshedini L, Shou W, Sanchez ER. FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A. Oncogene. 2010; 29: 1691-1701. doi: 10.1038/onc.2009.458.
11. Warrier M, Hinds TD, Ledford K J, et al. Susceptibility to diet-induced hepatic steatosis and glucocorticoid resistance in FK506-binding protein 52-deficient mice. Endocrinology. 2010; 151: 3225-3236. doi: 10.1210/en.2009-1158.
12. Wolf IM, Periyasamy S, Hinds TD, Yong W, Shou W, Sanchez ER. Targeted ablation reveals a novel role of FKBP52 in gene-specific regulation of glucocorticoid receptor transcriptional activity. J Steroid Biochem Mol Biol. 2009; 113: 36-45. doi: 10.1016/j.jsbmb.2008.11.006.
13. Banerjee A, Periyasamy S, Wolf IM, et al. Control of glucocorticoid and progesterone receptor subcellular localization by the ligand-binding domain is mediated by distinct interactions with tetratricopeptide repeat proteins. Biochemistry. 2008; 47: 10471-10480. doi: 10.1021/bi8011862.
14. Hinds TD, Sanchez ER. Protein phosphatase 5. Int J Biochem Cell Biol. 2008; 40(11): 2358-2362.

Mehmet Akif Buyukbese, MD

Professor of Internal Medicine
Medical Director at Diabetes Care & Education
Dunyadiyabet Center
Dunyagoz Hospitals Group
Dunyagoz Hastanesi, Dünyadiyabet Merkezi
Zeytinlik M. Sahilyolu C., 34140 Atakoy, Istanbul
Turkey

BiographyResearch InterestScientific ActivitiesPublications

Dr. Buyukbese perused both MD and Internal Medicine residency degrees from Istanbul University where he’d started focusing on diabetes. Founded internal medicine department at KSU School of Medicine in Kahramanmaras and served as a head for 6 years. Board certified in internal medicine.
Several diabetes management and research experiences in the USA: Albert Einstein College of Medicine, Bronx, NY (2001), MD Anderson Cancer Center&Univ TX Houston Diabetes and Endocrinology (2007) Indian Medical Health Center, Diabetes Outpatient Clinic, NIH, (Phoenix) (2008-2009).
Worked as a postdoctoral research fellow in UK (2003) (Univ. of Leicester, Clinical Diabetes Research Centre) and Kronos Longevity Research Institute, Phoenix, Arizona, USA.
Holds an ECFMG certificate (2008).Gave diabetes lectures in GoettingenUniv-Germany through ERASMUS Programme (2012).Members of International Diabetes Foundation (IDF), Board of Trustees of Turkish Diabetes Foundation, European Society of Cardiology, Turkish Society of Metabolic Syndrome, Internal Medicine Society of Turkey. Served for Southeastearn Anatolia Diabetes Project for 6 years (2000-2006) andKahramanmaras City Coordinator of ‘Presidency of Turkey Diabetes-Peer’ Project for 2 years (2011-2013).Carried on his diabetes patient and family medicine physician (gp) education programs as well as phase 3 and phase 4 diabetes drug clinical studies.Currently, working as the medical director of dunyadiabetes centers at Dunyagoz Hospital in Istanbul since from Jan 2014.
Have more than a 100 publications both in Turkish and English in internal medicine area mostly in diabetes. In the editorial board ofJournal of Clinical Medicine and Research, and reviewer of Science Alert, European Journal of General Medicine, Balkan Medical Journal (SCI-Exp), Diabetes Forum (Turkish), Diabetes Science and Endocrinology (Turkish), Glance at Diabetes (Turkish), Turkey Clinics Medical Science, Turkey Clinics Endocrinology, Dialogue in Endocrinology (Turkish), ..etc

His research interests include: Diabetes education for public, patient, family, primary care practitioners and internal medicine physicians, Internal Medicine, hypertension and Lipid management.

ADVISORY BOARD OF SCIENTIFIC MEETINGS

• National Obesity Congress, Antalya. April 24-27, 2002
• National Obesity Congress, Bodrum. November 16-19, 2006


INVITED SPEAKER – LECTURER (INTERNATIONAL)

“• Southeastern Anatolian Diabetes Project (GAPDIAB Project)” FEND (Federation of European Nurses in Diabetes) 9th Annual Conference, Munich-Germany, September 3, 2004.
• “Turkish Diabetes Epidemiology Study (TURDEP), Southeastern Anatolia Diabetes Project (GAPDIAB) and related audit studies and Diabetes in South London’’ Diabetes Centre, Royal Infirmary Hospital University Hospitals of Leicester-UK, March 2003.


MEMBERSHIPS

• 2008-2009, Present American Gerotologic Society of America (GSA)
• 2005-Present, Turkish Society of Metabolic Syndrome
• 2004-Present, Turkish Association of Diabetes, Obesity and Nutrition
• 2004-Present, Hypertension Study Group of Turkish Society of Cardiology
• 2004-Present, Lipid Study Group of Turkish Society of Cardiology
• 2004-Present, Heart Faliure Study Group of Turkish Society of Cardiology
• 2004-Present, Coronary Heart Disease Study Group of Turkish Society of Cardiology
• 2003-Present International Diabetes Federation (IDF)
• 2000-Present, Turkish Diabetes Foundation
• 2000-Present, Turkish Society of Internal Medicine •
• 1998-Present, Turkish Medical Association
• 1997-Present, Turkish Society of Cardiology

INTERNATIONAL PUBLICATIONS (SCI-SCI EXPANDED JOURNALS)

1. Buyukbese MA, Pamuk OM, Yurekli OA, Yesil N. Effect of fibromiyalgia on bone mineral density in patients with fibromiyalgia and rheumatoid artritis patients. Journal of Postgraduate Medicine. 2013; 59(2): 106-109.
2. Aslan D, Yilmazturk GC, Akalin N, Buyukbese MA, Sermez Y, Fenkci S. Klinik Laboratuvar Test SonuClarının Uluslararası ve Ulusal Harmonizasyonu, Standardizasyonu ve HbA1c Ornegi. Turkish Journal of Biochemistry. 2011; 36(4): 374-383.
3. Salbe AD, Johnston CS, Buyukbese MA, Tsitouras PD, Harman SM. Vinegar lacks antiglycemic action on enteral carbohydrate absorption in human subjects. Nutr Res. 2009; 29(12): 846-849.
4. Kurtoglu S, Atabek ME, Dizdarer C, Pirgon O, Isguven P, Emek S. PREDICTIVE Turkey Study Group. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study. Pediatr Diabetes. 2009; 10(6): 401-407.
5. Kantarceken B, Cetinkaya A, Inanc Tolun F, Yerhan H, Citirik C, Buyukbese MA. Metabolic conditions of fatty liver in non-diabetic obese women. J Endocrinol Invest. 2007; 30(8): 672-676.
6. Guven A, Cetinkaya A, Aral M, et al. High sensitivity C-reactive protein in patients with metabolic syndrome Angiology. 2006; 57: 295-302.
7. Kokoglu OF, Hosoglu S, Geyik MF, et al. Clinical and laboratory features of brucellosis in two university hospitals in southeast Turkey. Tropical Doctor. 2006; 36: 49-51.
8. Cetinkaya A, Bulbuloglu E, Kantarceken B, et al. Effects of L-carnitine on oxidant/antioxidant status in acetic acid-induced colitis. Digestive Diseases and Sciences. 2006; 51: 488-494.
9. Kokoglu OF, Ucmak H, Hosoglu S, et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic C hepatitis. Journal of Gastroenterology and Hepatology. 2006; 21: 575-580.
10. Buyukbese MA, Cetinus A, Cetinkaya A, Aras S. Ferritin level in postmenopausal women does not seem to play a significant role on osteoporosis. Southern Medical Journal. 2005; 98: 845.
11. Cetinus E, Buyukbese MA, Uzel M, Ekerbicer H, Karaoguz A. Hand Grip Strength in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice. 2005; 70: 278-286.
12. Dogan E, Erkoc R, Sayarlioglu H, Buyukbese A. Nonketotic hyperosmolar coma in a patient with type 1 diabetes-related nephropathy: case report. Advances in Therapy. 2005; 22: 429-432.
13. Cetinkaya A, Belge Kurutas E, Buyukbese MA, Kantarceken B, Bulbuloglu E. Levels of malondialdehyde and superoxide dismutase in subclinical hyperthyroidism. Mediators of Inflammation. 2005; 1: 57-59.
14. Bakaris S, Ozdemir M, Isik IO, Buyukbese MA, Ozdemir G. Impression cytology changes and corneoconjunctival calcification in patients with chronic renal failure. Acta Cytologica (The Journal of Clinical Cytology and Cytopathology). 2005; 49: 1-6.
15. Cetinkaya A, Bulbuloglu E, Belge Kurutas E, Ciralik H, Kantarceken B, Buyukbese MA. Beneficial effects of N-acetylcysteine on acetic acid-induced colitis in rats. The Tohoku Journal of Experimental Medicine. 2005; 206: 131-139.
16. Gul M, Kurutas E, Ciragil P, et al. Urinary t5ract infection aggravates oxidative stres in diabetic patients. The Tohoku Journal of Experimental Medicine. 2005; 206: 1-6.
17. Buyukbese MA, Cetinkaya A, Kocabas R, Guven A, Tarakcioglu M. Leptin levels in obese women with and without type 2 diabetes mellitus. Mediators of Inflammmation. 2004; 13: 321-325.
18. Ozdemir M, Bakaris S, Ozdemir G, Buyukbese MA, Cetinkaya A. Ocular surface disorders and tear function changes in patients with chronic renal failure. Canadian Journal of Ophthalmology. 2004; 39: 526-532.
19. Buyukbese MA, Koksal N, Guven A, Cetinkaya A. The effects of Maras powder use on respiratory functions. The Tohoku Journal of Experimental Medicine. 2004; 204: 173-178.
20. Celik M, Bulbuloglu E, Buyukbese MA, Cetinkaya A. Abdominal wall endometrioma: Localizing at rectus abdominus sheath. Turkish Journal of Medical Sciences (Tubitak). 2004; 34: 341-343.
21. Guven A, Koksal N, Buyukbese MA, et al. Farklı bir dumansız tutun kullanımının kardiyak parametreler uzerine etkisi Maras Otu (The effects of a different smokeless tobacco Maras Powder use over cardiac parameters). The Anatolian Journal of Cardiology. 2003; 3: 230-235.
22. Ozdemir M, Buyukbese MA, Cetinkaya A, Ozdemir G. The risk factors for the ocular surface disorders and tear dysfunction in non-insulin dependent diabetes mellitus. Diabetes Research and Clinical Practice. 2003; 59: 195-199.
23. Koksal N, Buyukbese MA, Guven A, Cetinkaya A, Hasanoglu HC. Organophosphate intoxication as a consequence of mouth to mouth breathing from an affected case. Chest. 2002; 122: 740-741.
24. KılınC M, Yuregir G, Ezberci F, EkerbiCer H, Buyukbese MA. Evaluations of thyroid hormons and goitre in a rural community in a region of Anatolia. Turkish Journal of Medical Science. (Tubitak) 2001; 31: 547-551.


INTERNATIONAL PUBLICATIONS INDEXED OTHER THAN SCI and SCI-EXPANDED JOURNALS

1. Buyukbese T, Buyukbese MA. Medicine and Violance. European Journal of General Medicine. 2014; 11(2): EJGM 00645.
2. Ozyurt AMK, Baykan H, Ozkose M, Silay E, Kalender AM, Buyukbese MA. A rare minor trauma causing diabetic hand ulcer. Arch Clin Exp Surg. 2014; 3(2).
3. Ucmak H, Buyukbese Sarsu S, Buyukbese MA, Kus S. Laparoscopic splenectomy and infection. Journal of Microbiology and Infectious Disease. 2013; 3(1): 1-2.
4. Ucmak H, Sucakli MH, Buyukbese MA, Toprak R, Kus S. Infections of gastrointestinal laporoscopic surgery: systemic review. Journal of Medical Research and Science. 2012; 2(1): 69-77.
5. Altinoluk B, Kankilic N, Nacar AB, et al. Relationship between the use of diuretics and overactive bladder in patients with heart failure. Journal of Clinical and Analytical Medicine. 2012; 1-3
6. Buyukbese MA, Bakar B. Diabetes where continents meet. Turkey European Journal of General Medicine. 2012; 9(3): 214-215.
7. Buyukbese MA, Basmaci C, Konuk N. Two endocrinological disorders with one psychatric agent. European Journal of General Medicine. 2007; 4(1): 54.
8. Cetinkaya A, Kantarceken B, Buyukbese MA, Celik M, Tolun FI. Serum homocysteine levels in patients with non-alcoholic fatty liver disease. European Journal of General Medicine. 2007; 4: 19-24.
9. Sasmaz Sezai, Buyukbese MA, Cetinkaya A, Celik M, Arican O. The prevalance of skin disorders in type 2 diabetic patients. The Internet Journal of Dermatology. 2005; 3 (1): 1-7.
10. Buyukbese MA, Cetinkaya A, Dogan E. Geriatric patient with repetetive hypoglycaemic episodes. European Journal of General Medicine. 2005; 2: 169-172.
11. Ozdemir S, Buyukbese MA, Kadioglu P, Soysal T, Senturk H, Akin P. Plasmapheresis: An effective therapy for refractory hyperthyroidism in the elderly. Indian Journal of Medical Sciences. 2002; 56: 65-68.
12. Altinli E, Pekmezci S, Balkan T, et al. Castlemans disease masquerading as sigmoid colon tumor and Hodgkin lymphoma; a report of two cases. Swiss Surgery. 2002; 8: 7-10.

Bernard C. Szirth, PhD

Director, Tele-Ocular Program
Institute of Ophthalmology and Visual Science
Doctors Office Center, Suite 6100
Rutgers, the State University of New Jersey
New Jersey Medical School
90 Bergen Street, Newark, NJ 07103, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Szirth is the Director of the TeleHealth Program at the New Jersey Medical School. He is responsible for the Vision Threatening Diseases screening community base program at the Institute of Ophthalmology and Visual Science in Newark, New Jersey. He has lectured extensively over the past 30 years in 22 Countries around the World and has published over 60 papers in English, Japanese and Spanish. He holds 4 International Patents in the field of eye care including a super wide angle retinal camera; RetCam. Ben Szirth is also a consultant to Canon Medical Systems (USA) and Canon Inc (Japan).

His research interests include: TeleHealth (Age Related Macular Degeneration, Diabetes, Glaucoma), Advanced Optical Systems, AI Medical VTD (Vision Threatening Diseases) detection, Tele-Robotics in Ophthalmic Care, Retinal Imaging

PROFESSIONAL ACTIVITIES

British Journal of Ophthalmology

(2013-present)
Position: Invited Reviewer


Juvenile Diabetes Research Foundation International Children with Diabetes

(2011-present)
Position: Friends for Life Faculty


Association for Research in Vision and Ophthalmology (ARVO)

(2005-Present)
Position: Member

ARTICLES:

1. Murphree AL, Doiron DR, Gomer CJ, Szirth BC. Clinical application on hematoporphyrin photoradiation therapy in recurrent retinoblastoma. Invest Ophthalmol Vis Sci. 1982; 22: 7.
2. Szirth BC, Gomer CJ, Doiron DR, Lingua RW, McNamara WL, Murphree AL. Photographic documentation of hematoporphyrin derivative (HpD) and fluorescein angiography in experimental ocular tumors. J Ophthal Photography. 1983; 6: 26-31.
3. Gomer CJ, Szirth BC, Doiron DR, et al. Preclinical evaluation of hematoporphyrin derivative for the treatment of intraocular tumors: A preliminary report. Adv Exp Med Biol. 1983; 160: 109-14.
4. Gomer CJ, Doiron DR, Jester JV, Szirth BC, Murphree AL. Hematoporphyrin derivative photoradiation therapy for the treatment of intraocular tumors: Examination of acute normal ocular tissue toxicity. Cancer Res. 1983; 43(2): 721-7.
5. Szirth BC, White L, Benedict W. Photographic documentation of human retinoblastoma transplanted into the anterior chamber of the athymic nude mouse eye. J Ophthal Photography. 1983; 6(2): 76-8.
6. Lingua R, Azen S, Szirth BC, Edelman P, Walonker F. Succinycholine as a predictor in strabismus surgery. J Pediatr Ophthalmol Strabismus. 1983; 20(4): 145-8.
7. White L, Szirth BC, Moore T. Chemotherapeutic response in the nude mouse retinoblastoma model. (Clayton Ocular Oncology Center, Childrens Hospital of Los Angeles, California 90027). Med & Pediatr Oncology. 1983; 11(3).
8. White L, Szirth BC, Benedict WF. Evaluation of response to therapy in retinoblastoma heterotransplanted to athymic mouse eyes. Med & Pediatr Oncology. 1983; 11(3).
9. Gomer C, Doiron DR, White L, et al. Hematoporphyrin derivative photoradiation induced damage to normal and tumor tissue of the pigmented rabbit eye. Curr Eye Res. 1984; 3(1): 229-37.
10. Gomer C, Jester J, Razum N, Szirth BC, Murphree AL. Photodynamic therapy of intraocular tumors: Examination of hematoporphyrin derivative distribution and long-term damage in rabbit ocular tissue. Cancer Res. 1985; 45(8): 3718-3725.
11. Szirth BC, Murphree AL, McNamara WL. Infant fundus photography. J Ophthal Photography. 1985; 8(1): 30-3.
12. Szirth BC, Edelman P, Rains III V, Wong GD, McNamara WL, Murphree AL. The Photo-Deviometer. J Ophthal Photography. 1986; 9(1): 55-9.
13. Szirth BC, Kimm L, Glennelle E, Murphree AL. Flash selection in strabismus photography. J Ophthal Photography. 1986; 9(1): 60-3.
14. Kimm L, Glennelle E, Szirth BC. Color reversal film selection using the ring flash for nine gaze photography. J Ophthal Photography. 1986; 9(1): 64-6.
15. Szirth BC, Matsumoto E, Wright KW, Murphree AL. Attachment for the Bausch & Lomb keratometer in pediatrics. J Pediatr Ophthalmol Strabismus. 1987; 24(4): 186-9.
16. Szirth BC. Light toxicity symposium, ophthalmic photography equipment evaluation. J Ophthal Photography. 1988; 10(1-2): 18-20.
17. Szirth BC, Murphree AL, McNamara L. Infant fundus photography. Japanese J Ophthal Photography. 1988; 6(1): 10-14. (in Japanese)
18. White L, Gomer CJ, Doiron DR, Szirth BC. Ineffective photodynamic therapy (PDT) in a poorly vascularized xenograft model. Br J Cancer. 1988; 57(5): 455-8.
19. Gomer C, Ferrario A, Hayashi N, Rucker N, Szirth BC, Murphree AL. Molecular, cellular and tissue responses following photodynamic therapy. Lasers Surg Med. 1988; 8(5): 450-63.
20. White L, Szirth BC, Benedict WF. Evaluation of the response to chemotherapy in retinoblastoma heterotransplanted to the eyes of nude mice. Cancer Chemother Pharmacol. 1989; 23(2): 63-7.
21. Szirth BC, Matsumoto E, Wright K, Murphree AL. Attachment for the Bausch & Lomb Keratometer in pediatrics. J Ophthalmic Nurs Technol. 1988; 7(1): 26-9.
22. Szirth BC, Wong GD, Bate R, Bartlett D. Legal ramifications of intravenous administration of sodium fluorescein. J Ophthal Photography. 1989; 11(2): 66-78.
23. Wong GD, Szirth BC. Reflex Plus-database management to the rescue of the ophthalmic photographer. J Ophthal Photography. 1989; 11(11): 253-7.
24. Szirth B. New developments in ophthalmic imaging. Japanese J Ophthal Photography. 1991; 9(1): 9-11.
25. Szirth B, Murphree AL. The modified Equator-Plus fundus camera. J Ophthal Photography. 1991; 13(2): 58-64.
26. Szirth B, Wong GD, McNamara LW, Murphree AL. Use of ocular reflex photography for documentation of retinoblastoma tumors. J Ophthal Photography. 1991; 13(2): 65-70.
27. Szirth B. History of the Photographic Department of Childrens Hospital Los Angeles. Japanese J Biomed Photography. 1992; 30(1): 25-32. (in Japanese)
28. Szirth B, Good W, Zarbin M. A 35-year journey of the hand held retinal camera. J Ophthal Photography. 2000; 22(2);64-8.
29. Cavallerano J, Lawrence MG, Zimmer-Galler I, et al. American Telemedicine Association, Ocular Telehealth Special Interest Group; National Institute of Standards and Technology Working Group. Telehealth practice recommendations for diabetic retinopathy. Telemed J E Health. 2004; 10(4): 469-82. doi: 10.1089/tmj.2004.10.469.
30. Khouri AS, Szirth BC, Fechtner RD. Detecting age-related macular degeneration: technologies are best compared when standardized [letter]. Arch Ophthalmology. 2005; 123(8): 1157; author reply 1157-8. doi: 10.1001/archopht.1929.00810010004001.
31. Szirth B, Fechtner R, Khouri A, Malpica B, Forofonova T, Zarbin M. Simultaneous stereo retinal imaging in glaucoma: Color 35 mm film vs 6.1 megapixel digital imaging. Telemed J E Health. 2005; 11(2): 262.
32. Choice CV, Grant GP, Turbin RE, et al. Feasibility and accuracy of Tonopen XL and Medtronic Pneumotonometer for measuring intraocular pressure in the prone position using a modified Prone View™ Helmet System. J Neurosurg Anesthesiol. 2005; 17(4): 249-50.
33. Khouri AS, Szirth BC, Realini T, Fechtner RD. Comparison of digital and film stereo photography of the optic nerve in evaluation of patients with glaucoma. Telemed J E Health. 2006; 12(6): 632-8. doi: 10.1089/tmj.2006.12.632.
34. Grant GP, Turbin RE, Bennett HL, Szirth BC, Heary RF. Use of the ProneViewtm Helmet System with a modified table platform for open access to the eyes during prone spine surgery. Anesth Analg. 2006 Aug; 103(2): 499-500. doi: 10.1213/01.ANE.0000227202.01074.F5
35. Osei-Tutu LP, Grant GP, Turbin RE, et al. Effect of head elevation on intraocular pressure and retinal imaging in the prone position. J Neurosurg Anesthesiol. 2006: 18(4): 278.
36. Szirth B, Shahid K, Zarbin M, Khouri A, Bhagat N. Digital retinal imaging for vision-threatening diseases – An integrated approach to diagnostic screening with a non-mydriatic camera. Business Briefing: Future Directions in Imaging. 2006; 53-5.
37. Grant, GP, Bennett HL, Turbin RE, Szirth BC. A method for measuring ocular physiology in the prone position using a modified ProneView™ helmet system. Anesth Analg. 2006; 102: S-186.
38. Turbin RE, Ahukanna I, Szirth BC, Grant G, Bennett HL, Fechtner RD. Intra-ocular pressure during lumbar disc surgery. Anaesthesia. 2007; 62(1): 91-2; author reply 92. doi: 10.1111/j.1365-2044.2006.04917_1.x
39. Khouri AS, Szirth BC, Bhagat N, Fechtner RD. Screening and diabetes mellitus. Ophthalmol. 2007; 114(2): 398-399; author reply 399-400.
40. Zarbin M, Szirth B. Current treatment of age-related macular degeneration. Optom Vis Sci. 2007; 84: 559-72.
41. Khouri AS, Szirth BC, Salti HI. DICOM transmission of simultaneous stereoscopic images of the optic nerve in patients with glaucoma. J Telemed Telecare. 2007; 13(7): 337-40. doi: 10.1258/135763307782215389
42. Khouri AS, Szirth BC, Shahid KS, Fechtner RD. Software-assisted optic nerve assessment for glaucoma tele-screening. Telemed J E Health. 2008 Apr; 14(3): 261-5. doi: 10.1089/tmj.2007.0049.
43. Grant GP, Szirth BC, Bennett HL, Heary RF, Turbin RE. Effects of Prone and Reverse Trendelenburg Positioning on Ocular Parameters. J Neurosurg Anesthesiol. 2009; 21(4): 419-20. doi: 10.1097/ALN.0b013e3181c294e1.
44. Grant GP, Szirth BC, Bennett HL, et al. Effects of prone and reverse Trendelenburg positioning on ocular parameters. Anesthesiology. 2010; 112(1): 57-65. doi: 10.1097/ALN.0b013e3181c294e1.
45. Shahid K, Kolomeyer AM, Nayak NV, et al. Ocular telehealth screenings in an urban community. Telemed J E Health. 2012 Mar; 18(2): 95-100. doi: 10.1089/tmj.2011.0067.
46. Kolomeyer AM, Szirth BC, Shahid K, Pelaez G, Nayak NV, Khouri AS. Software-assisted analysis during ocular health screening. Telemed J E Health. 2013; 19(1): 2-6. doi: 10.1089/tmj.2012.0070.
47. Kolomeyer AM, Nayak NV, Szirth BC, Khouri AS. Fundus autofluorscence imaging in an ocular screening program. Intl J Telemed & Applications. 2012; doi: 10.1155/2012/806464. doi: 10.1155/2012/806464
48. Shah A. Szirth B, Sheng I, Xia T, Khouri AS. Optic disc drusen in a child: Diagnosis using noninvasive imaging tools. Optom Vis Sci. 2013; 90(1): e269-73. doi: 10.1097/OPX.0000000000000021.
49. Kolomeyer AM, Nayak NV, Khouri AS, Szirth BC. Complimentary imaging technologies in blunt ocular trauma. Oman J Ophthalmol. 2013; 6(2): 108-11. doi: 10.4103/0974-620X.116644.
50. Kolomeyer AM, Baumrind BR, Szirth BC, Shahid K, Khouri AS. Fundus autofluorescence and colour fundus imaging compared during telemedicine screening in patients with diabetes. J Telemed Telecare. 2013 Jun; 19(4): 209-12. doi: 10.1177/1357633X13492292.

Shi Fang Yan, MD

Associate Professor
Department of Medicine and Pharmacology
New York University School of Medicine
550 1st Ave
New York, NY 10016, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Yan has completed her postdoctoral training at Physicians and Surgeons College of Columbia University. She was an Assistant Professor and then an Associate Professor at Physicians and Surgeons College of Columbia University. Now she is an Associate Professor at the Department of Medicine, Biochemistry and Molecular Pharmacology, New York University School of Medicine. She is a leading investigator of the molecular and cellular mechanisms of diabetic complications, including ischemic disorders and vascular disorders. Her major focuses are on the dissection of the interplay between the three key molecules linked to vascular stress, including Egr-1, PKCβ, and RAGE. She has published more than 100 research/review articles in medical journals, including Nature Medicine, Journal of Clinical Investigation, PNAS, Circulation Research, FASEB, JBC, ATVB, Atherosclerosis, Diabetes and etc. She was the Winners of the Council’s 2000 Cournand and Comroe Young Investigator Award and a best poster award (2005) at the American Heart Association. She has been serving as an editorial board member, a grant reviewer at American Heart Association Cardiac Bio BCT 1 study section.

Her research interests includes: cellular and molecular mechanisms of diabetic complications (such as atherosclerosis and limb ischemia) and aging. she concentrate on the dissection of the interplay between key molecules linked to ischemic disorders, vascular stress and heart disease-related vascular injury, including Egr-1 (early growth response-1), PKC-beta (protein kinase C-beta) and RAGE (receptor for advanced glycation end products).

1. Grant reviewer, American Heart Association Cardiac Bio BCT 1 study section.
2. Editorial board Member for Journal of Diabetes Research.
3. Editorial Board Member for Journal of Pharmacogenomics & Pharmacoproteomics.
4. Invited Reviewer: FASEB Journal.
5. Diabetologia.
6. Metabolism.
7. Free Radical Research.
8. Clinical and Experiemntal Medicine.
9. European Journal of Heart Failure.
10. Expert Review of Endocrinology and Metabolism.
11. Clinical Lipidology.
12. Journal of Biological Chemistry.
13. Future Medicine.
14. The American Journal of Physiology-Cell Physiology.
15. Biochemical journal.
16. Molecular and Cellular Biology.
17. Anatomical Record.
18. Neuroscience letter.
19. Journal of Pathology.

PEER-REVIEWED ARTICLES

1. Kong L, Shen X, Lin L, Rosario R, Zou YS, Yan SF. PKC Beta Promotes Vascular Inflammation and Acceleration of Atherosclerosis in Diabetic ApoE Null Mice. Arterioscler Thromb Vasc Biol. 2013; 33(8): 1779-1787. doi: 10.1161/ATVBAHA.112.301113.
2. Song F, Hurtado Del Pozo C, et al. RAGE regulates the metabolic and inflammatory response to high fat feeding in mice. Diabetes. 2014. doi: 10.2337/db13-1636
3. Vedantham S, Thiagarajan D, Ananthakrishnan R, et al. Aldose Reductase drives hyperacetylation of egr-1 in hyperglycemia and consequent upregulation of proinflammatory and prothrombotic signals. Diabetes. 2014; 63: 761-774. doi: 10.2337/db13-0032.
4. Juranek JK, Geddis MS, Song F, et al. RAGE Deficiency Improves Postinjury Sciatic Nerve Regeneration in Type 1 Diabetic Mice. Diabetes. 2012. doi: 10.2337/db12-0632.
5. Ramasamy R, Yan SF, Schmidt AM. The diverse ligand repertoire of the receptor for advanced glycationendproducts and pathways to the complications of diabetes. Vascul Pharmacol. 2012; 57(5-6): 160-167. doi: 10.1016/j.vph.2012.06.004.
6. Toure F, Fritz G, Li Q, et al. Formin mDia1 mediates vascular remodeling via integration of oxidative and signal transduction pathways. Circ Res. 2012; 110(10): 1279-1293. doi: 10.1161/CIRCRESAHA.111.262519.
7. Dinorcia J, Lee MK, Moroziewicz DN, et al. RAGE Gene Deletion Inhibits the Development and Progression of Ductal Neoplasia and Prolongs Survival in a Murine Model of Pancreatic Cancer. Journal of Gastrointestinal Surgery. 2012; 16(1): 104-112. doi: 10.1007/s11605-011-1754-9.
8. Rai V, Maldonado AY, Burz DS, et al. Signal transduction in receptor for advanced glycation end products (RAGE). SOLUTION STRUCTURE OF C-TERMINAL RAGE (ctRAGE) AND ITS BINDING TO mDia1 (vol 287, pg 5133, 2012). Journal of Biological Chemistry. 2012; 287(14): 11283-11283. doi: 10.1074/jbc.M111.277731
9. Ramasamy R, Yan SF, Schmidt AM. Advanced glycationendproducts: from precursors to RAGE: round and round we go. Amino acids. 2012; 42(4): 1151-1161. doi: 10.1007/s00726-010-0773-2.
10. Zeng S, Zhang QY, Huang J, et al. Opposing roles of RAGE and Myd88 signaling in extensive liver resection. FASEB journal . 2012; 26(2): 882-893. doi: 10.1096/fj.11-192997.
11. Ramasamy R, Yan SF, Ann Marie S. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Annals of the New York Academy of Sciences. 2011; 1243(1): 88-102. doi: 10.1111/j.1749-6632.2011.06320.x.
12. Dinorcia J, Lee MK, Moroziewicz DN, et al. RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer. J Gastrointest Surg. 2011. doi: 10.1007/s11605-011-1754-9
13. Tekabe Y, Shen X, Luma J, et al. Imaging the effect of receptor for advanced glycationendproducts on angiogenic response to hindlimb ischemia in diabetes. EJNMMI Res. 2011; 1(1): 3. doi: 10.1186/2191-219X-1-3
14. DiNorcia J, Moroziewicz, DN, Ippagunta, N, et al. RAGE signaling significantly impacts tumorigenesis and hepatic tumor growth in murine models of colorectal carcinoma. Journal of gastrointestinal surgery. 2010; 14(11): 1680-1690. doi: 10.1007/s11605-010-1347-z.
15. Ramasamy R, Yan SF, Schmidt AM. Advanced glycation end products: From precursors to RAGE: round and round we go. Amino Acids .2012; 42(4): 1151-1161. doi: 10.1007/s00726-010-0773-2.
16. Hallam KM, Li Q, Ananthakrishnan R, et al. Aldose reductase and AGE-RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats. Aging Cell. 2010; 9(5): 776-784. doi: 10.1111/j.1474-9726.2010.00606.x
17. Huang C; Chang JS, Xu Y, et al. Reduction of PKCbetaII activity in smooth muscle cells attenuates acute arterial injury. Atherosclerosis . 2010; 212(1): 123-130. doi: 10.1016/j.atherosclerosis.2010.05.039.
18. Xu Y, Toure F, Qu W, et al. Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. Journal of Biological Chemistry. 2010; 285(30): 23233-23240. doi: 10.1074/jbc.M110.117457.
19. Yan SF, Ramasamy R, Schmidt AM. Soluble RAGE: Therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol. 2010; 79: 1379-1386. doi: 10.1016/j.bcp.2010.01.013.
20. Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: A fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res. 2010; 106: 842-85. doi: 10.1161/CIRCRESAHA.109.212217.
21. Shang L, Ananthakrishnan R, Li Q, et al. RAGE modulates hypoxia/reoxygenation injury in adult murine cardiomyocytes via JNK and GSK- 3beta signaling pathways. PLoS ONE. 2010; 5(4): e10092-e10092. doi: 10.1371/journal.pone.0010092.
22. Yan SF, Ramasamy R, Schmidt AM. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochemical pharmacology. 2010; 79(10): 1379-1386. doi: 10.1016/j.bcp.2010.01.013
23. Fang F,Lue LF, Yan S, et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimers disease. FASEB Journal. 2010; 24(4): 1043-1055. doi: 10.1096/fj.09-139634
24. Bu DX, Rai V, Shen XP, et al. Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice. Circulation Research. 2010; 106(6): 1040-1051. doi: 10.1161/CIRCRESAHA.109.201103
25. Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circulation Research. 2010; 106(5): 842-853. doi: 10.1161/CIRCRESAHA.109.212217
26. DAgati, V, Yan SF, Ramasamy R, Schmidt AM. RAGE, glomerulosclerosis and proteinuria: roles in podocytes and endothelial cells. Trends in Endocrinology and Metabolism. 2010; 21(1): 50-56. doi: 10.1016/j.tem.2009.07.003
27. Bucciarelli LG, Pollreisz A, Kebschull M, et al. Inflammatory stress in primary venous and aortic endothelial cells of type 1 diabetic mice. Diabetes and vascular disease research. 2009; 6(4): 249-261. doi: 10.1177/1479164109338775
28. Harja E, Chang JS, Lu Y, et al. Mice deficient in PKCbeta and apolipoprotein E display decreased atherosclerosis. FASEB Journal. 2009; 23(4): 1081-1091. doi: 10.1096/fj.08-120345.
29. Hassid BG, Nair MN, Ducruet AF, et al. Neuronal RAGE expression modulates severity of injury following transient focal cerebral ischemia. Journal of Clinical Neuroscience. 2009; 16(2): 302-306. doi: 10.1016/j.jocn.2007.12.011.
30. Ramasamy R,Yan SF, Schmidt AM. RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts. Journal of Leukocyte Biology. 2009; 86(3): 505-512. doi: 10.1189/jlb.0409230.
31. Yan SF, Ramasamy R, Schmidt AM. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. Journal of Molecular Medicine (Berlin). 2009; 87(3): 235-247. doi: 10.1189/jlb.0409230.
32. Yan SF, Ramasamy R, Schmidt AM. The receptor for advanced glycationendproducts (RAGE) and cardiovascular disease. Expert Reviews in Molecular Medicine. 2009; 11: e9-e9. doi: 10.1017/S146239940900101X.
33. Yan SF, Yan SD, Ramasamy R, Schmidt AM. Tempering the wrath of RAGE: An emerging therapeutic strategy against diabetic complications, neurodegeneration and inflammation. Annals of medicine (Helsinki). 2009; 41(6): 408-422. doi: 10.1080/07853890902806576.
34. Zeng S, Dun H, Ippagunta N, Rosario R, et al. Receptor for advanced glycation end product (RAGE)-dependent modulation of early growth response-1 in hepatic ischemia/reperfusion injury. Journal of Hepatology. 2009; 50(5) : 929-936. doi: 10.1016/j.jhep.2008.11.022
35. Bucciarelli LG, Ananthakrishnan R, Hwang YC, et al. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes. 2008; 57(7): 1941-1951. doi: 10.2337/db07-0326
36. Guo J, Ananthakrishnan R,Qu W, et al. RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. Journal of the American Society of Nephrology. 2008; 19(5): 961-972. doi: 10.1681/ASN.2007101109
37. Aleshin A, Ananthakrishnan R, Li Q, et al. RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model. American journal of physiology. Heart and circulatory physiology. 2008; 294(4): H1823-H1832. doi: 10.1152/ajpheart.01210.2007
38. Kong L, Andrassy M, Chang JS, et al. PKCbeta modulates ischemia-reperfusion injury in the heart. American Journal of Physiology, Heart and Circulatory Physiology. 2008; 294(4): H1862-H1870. doi: 10.1152/ajpheart.01346.2007
39. Chang JS, Wendt T, Qu W, et al. Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circulation Research. 2008 ; 102(8): 905-913. doi: 10.1161/CIRCRESAHA.107.165308
40. Harja E, Bu DX, Hudson BI, et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. Journal of Clinical Investigation. 2008; 118(1): 183-194. doi: 10.1172/JCI32703
41. Ramasamy R, Yan SF,Herold K, Clynes, Schmidt AM. Receptor for advanced glycation end products: fundamental roles in the inflammatory response: Winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Annals of the New York Academy of Sciences. 2008; 1126: 7-13. doi: 10.1196/annals.1433.056.
42. Ramasamy R,Yan SF, Schmidt AM. Stopping the primal RAGE reaction in myocardial infarction: capturing adaptive responses to heal the heart [Editorial]. Circulation. 2008; 117(25): 3165-3167. doi: 10.1161/CIRCULATIONAHA.108.784397
43. Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nature Clinical Practice Endocrinology and Metabolism. 2008; 4(5): 285-293. doi: 10.1038/ncpendmet0786.
44. Clynes R, Moser B, Yan SF, Ramasamy R, Herold K, Schmidt AM. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Current Molecular Medicine. 2007; 7(8): 743-751. doi: 10.2174/156652407783220714
45. Herold K, Moser B, Chen Y, et al. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. Journal of Leukocyte Biology. 2007; 82(2): 204-212. doi: 10.1189/jlb.1206751
46. Moser B, Desai DD, Downie MP, et al. Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo. Journal of Immunology. 2007; 179(12): 8051-8058.
47. Ramasamy R,Yan SF, Schmidt AM. Arguing for the motion: yes, RAGE is a receptor for advanced glycation end products[Comment]. Molecular Nutrition and Food Research. 2007; 51(9): 1111-1115. doi: 10.1002/mnfr.200700008
48. Yan SF, Barile GR, DAgati V, Yan SD, Ramasamy R, Schmidt AM. The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications. Current diabetes reports . 2007; 7(2): 146-153.
49. Yan SF,DAgati V, Schmidt AM, Ramasamy R. Receptor for Advanced Glycation End products (RAGE): A formidable force in the pathogenesis of the cardiovascular complications of diabetes and aging. Current Molecular Medicine. 2007; 7(8): 699-710. doi: 10.2174/156652407783220732
50. Bucciarelli LG, Kaneko M, Ananthakrishnan R, et al. Receptor for advanced-glycation end products: Key modulator of myocardial ischemic injury. Circulation. 2006; 113(9): 1226-1234. doi: 10.1161/CIRCULATIONAHA.105.575993
51. Masek KS, Fiore J,Leitges M,Yan SF, Freedman BD, Hunter CA. Host cell Ca2+ and protein kinase C regulate innate recognition of Toxoplasma gondii. Journal of Cell Science. 2006; 119(Pt 21): 4565-4573. doi: 10.1242/jcs.03206
52. Ramasamy R,Yan SF, Schmidt AM. Methylglyoxal comes of AGE. Cell. 2006; 124(2): 258-260. doi: http://dx.doi.org/10.1016/j.cell.2006.01.002
53. Ramasamy R, Yan SF, Schmidt AM. Sphingosine-1-phosphate: waging a battle in the diabetic blood vessel [Editorial]. Circulation Research. 2006; 99(7): 669-671. doi: 10.1161/01.RES.0000245453.09893.7f
54. Toth C, Schmidt AM,Tuor UI, et al. Diabetes, leukoencephalopathy and rage. Neurobiology of Disease. 2006; 23(2): 445-461. doi: 10.1016/j.nbd.2006.03.015
55. Wendt T, Harja E, Bucciarelli LG, et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis. 2006; 185(1): 70-77. doi: http://dx.doi.org/10.1016/j.atherosclerosis.2005.06.013
56. Yan SF, Naka Y, Hudson BI, et al. The ligand/RAGE axis: lighting the fuse and igniting vascular stress. Current atherosclerosis reports. 2006; 8(3): 232-239.
57. Yan SF, Yan SD, Herold K, Ramsamy R, Schmidt AM. Receptor for advanced glycation end products and the cardiovascular complications of diabetes and beyond: lessons from AGEing. Endocrinology and Metabolism Clinics of North America . 2006; 35(3): 4565-4573. doi: 10.1016/j.ecl.2006.06.003
58. Yan SF, Harja E, Andrassy M, Fujita T, Schmidt AM. Protein kinase C beta/early growth response-1 pathway: a key player in ischemia, atherosclerosis, and restenosis. Journal of the American College of Cardiology. 2006; 48(9 Suppl 1): A47-A55. doi: 10.1016/j.jacc.2006.05.063
59. Andrassy M, Belov D, Harja et al. Central role of PKCbeta in neointimal expansion triggered by acute arterial injury. Circulation research. 2005; 96(4): 476-483. doi: 10.1161/01.RES.0000156903.37007.d1
60. Barile GR, Pachydaki SI, Tari SR, et al. The RAGE axis in early diabetic retinopathy. Investigative Ophthalmology and Visual Science, IOVS. 2005; 46(8): 2916-2924. doi: 10.1167/iovs.04-1409
61. Cataldegirmen G, Zeng S, Feirt N, et al. RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. Journal of Experimental Medicine. 2005; 201(3): 473-484. doi: 10.1084/jem.20040934
62. Hudson BI, Wendt T,Bucciarelli LG, et al. Diabetic vascular disease: its all the RAGE. Antioxidants and Redox Signaling. 2005; 7(11-12): 1588-1600. doi: 10.1089/ars.2005.7.1588
63. Kaneko M,Bucciarelli LG, Hwang YC, et al. Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury. Annals of the New York Academy of Sciences. 2005; 1043: 702-709. doi: 10.1196/annals.1333.081
64. Kim W, Hudson BI, Moser B, et al. Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis. Annals of the New York Academy of Sciences. 2005; 1043: 553-561. doi: 10.1196/annals.1338.063
65. Ramasamy R,Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology. 2005; 15(7): 16R-28R. doi: 10.1093/glycob/cwi053
66. Ramasamy R, Yan SF, Schmidt AM. The RAGE axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond. Trends in Cardiovascular Medicine. 2005; 15(7): 237-243. doi: http://dx.doi.org/10.1016/j.tcm.2005.08.003
67. Rong LL, Gooch C, Szabolcs M, et al. RAGE: A journey from the complications of diabetes to disorders of the nervous system - striking a fine balance between injury and repair. Restorative Neurology and Neuroscience. 2005; 23(5-6): 355-365.
68. Arancio O, Zhang HP, Chen X, et al. RAGE potentiates a beta-induced perturbation of neuronal function in transgenic mice. EMBO journal. 2004; 23(20): 4096-4105. doi: 10.1038/sj.emboj.7600415
69. Fujita T, Asai T, Andrassy M, et al. PKC beta regulates ischemia/reperfusion injury in the lung. Journal of clinical investigation. 2004; 113(11): 1615-1623. doi: 10.1172/JCI19225.
70. Harja E, Bucciarelli LG, Lu Y, et al. Early growth response-1 promotes atherogenesis: Mice deficient in early growth response-1 and apolipo protein E display decreased atherosclerosis and vascular inflammation. Circulation Research. 2004; 94(3): 333-339. doi: 10.1161/01.RES.0000112405.61577.95
71. Naka Y, Bucciarelli LG, Wendt T, et al. RAGE axis: Animal models and novel insights into the vascular complications of diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology. 2004; 24(8): 1342-1349. doi: 10.1161/01.ATV.0000133191.71196.90
72. Rong LL, Yan SF, Wendt T, et al. RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB journal. 2004; 18(15): 1818-1825. doi: 10.1096/fj.04-1900com
73. Schmidt AM, Hudson BI, Yan SF, Stern DM. Receptor-dependent vascular stress in diabetes. Diabetes and cardiovascular disease: Integrating science and clinical medicine. Philadelphia, USA: Lippincott Williams and Wilkins; 2004.
74. Yan SF, Ramasamy R, Bucciarelli LG, et al. RAGE and its ligands: A lasting memory in diabetic complications. Diabetes and vascular disease research. 2004; 1(1): 10-20. doi: 10.3132/dvdr.2004.001
75. Hudson BI, Bucciarelli LG, Wendt T, et al. Blockade of receptor for advanced glycationendproducts: A new target for therapeutic intervention in diabetic complications and inflammatory disorders. Archives of biochemistry and biophysics(ABB). 2003; 419(1): 80-88. doi: 10.1016/j.abb.2003.08.030
76. Sakaguchi T, Yan SF, Yan SD, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. Journal of clinical investigation. 2003; 111(7): 959-972. doi: 10.1172/JCI17115
77. Wendt T, Tanji N, Guo J, et al. Glucose, glycation, and RAGE: Implications for amplification of cellular dysfunction in diabetic nephropathy. Journal of the American Society of Nephrology. 2003; 14(5): 1383-1395. doi: 10.1097/01.ASN.0000065100.17349.CA
78. Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: A scaffold for the macrovascular complications of diabetes and beyond. Circulation Research. 2003; 93(12): 1159-1169. doi: 10.1161/01.RES.0000103862.26506.3D
79. Yan SS, Wu ZY, Zhang HP, et al. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nature Medicine. 2003; 9(3): 287-293. doi: 10.1038/nm831
80. Bucciarelli LG, Wendt T, Rong L, et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cellular and Molecular Life Sciences, (CMLS). 2002; 59(7): 1117-1128.
81. Hudson BI, Hofmann MA, BucciarelliL, et al. Glycation and diabetes: The RAGE connection. Current Science. 2002; 83: 1515-1521.
82. Okada M, Wang CY, Hwang DW, et al. Transcriptional control of cardiac allograft vasculopathy by early growth response gene-1 (Egr-1). Circulation Research. 2002; 91(2): 135-142. doi: 10.1161/01.RES.0000027815.75000.33
83. Okada M,Yan SF,Pinsky DJ. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. FASEB journal. 2002; 16(14): 1861-1868. doi:
84. Stern DM, Yan SD,Yan SF, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing research reviews. 2002; 1(1): 1-15. doi: 10.2174/156652407783220732
85. Stern D, Yan SD,Yan SF, Schmidt AM. Receptor for advanced glycation endproducts: A multiligand receptor magnifying cell stress in diverse pathologic settings. Advanced drug delivery reviews. 2002; 54(12): 1615-1625. doi: 10.1016/S0169-409X(02)00160-6
86. Wendt T, Bucciarelli L, Qu W, et al. Receptor for advanced glycationendproducts (RAGE) and vascular inflammation: Insights into the pathogenesis of macrovascular complications in diabetes. Current atherosclerosis reports. 2002; 4(3): 228-237 .
87. Yan SF, Pinsky DJ, Stern DM. Hypoxia-induced activation of early growth response (Egr)-1: A novel pathway mediating the vascular response to oxygen deprivation. Interactions of Blood and the Pulmonary Circulation. Armonk, NY, USA: Futura; 2002.
88. Fujita T, Toda K, Karimova A, et al. Paradoxical rescue from ischemic lung injury by inhaled carbon monoxide driven by derepression of fibrinolysis. Nature Medicine. 2001; 7(5): 598. doi: 10.1038/87929
89. Goova MT, Li J, Kislinger T, et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. American Journal of Pathology. 2001; 159(2): 513-525. doi: http://dx.doi.org/10.1016/S0002-9440(10)61723-3
90. Guha M, OConnell MA, Pawlinski R, et al. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood. 2001; 98(5): 1429-1439. doi: http://dx.doi.org/10.1182/blood.V98.5.1429
91. Okada M, Fujita T, Sakaguchi T, et al. Extinguishing Egr-1-dependent inflammatory and thrombotic cascades after lung transplantation. FASEB Journal. 2001; 15(14): 2757-2759. doi: 10.1096/fj.01-0490fje
92. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. Journal of clinical investigation. 2001; 108(7): 949-955. doi: 10.1172/JCI14002.
93. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochimica and biophysica acta. 2000; 1498(2-3): 99-111. doi: 10.1016/S0167-4889(00)00087-2
94. Yan SF, Fujita T, Lu J, et al. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nature Medicine. 2000; 6(12): 1355-1361. doi: 10.1038/82168
95. Yan SF, Lu J, Xu L, et al. Pulmonary expression of early growth response-1: Biphasic time course and effect of oxygen concentration. Journal of applied physiology (Bethesda). 2000; 88(6): 2303-2309.
96. Yan SF, Lu J, Zou YS, et al. Protein kinase C-beta and oxygen deprivation. A novel Egr-1-dependent pathway for fibrin deposition in hypoxemic vasculature. Journal of biological chemistry. 2000; 275(16): 11921-11928. doi: 10.1074/jbc.275.16.11921
97. Yan SF, Pinsky DJ, Mackman N, Stern DM. Egr-1: Is it always immediate and early. Journal of clinical investigation. 2000; 105(5): 553-554. doi: 10.1172/JCI9513.
98. Yan SF, Pinsky DJ, Stern DM. A pathway leading to hypoxia-induced vascular fibrin deposition. Seminars in thrombosis and hemostasis. 2000; 26(5): 479-483. doi: 10.1055/s-2000-13203
99. Zhang W, Yan SD, Zhu A, et al. Expression of Egr-1 in late stage emphysema. American Journal of Pathology. 2000; 157(4): 1311-1320. doi: http://dx.doi.org/10.1016/S0002-9440(10)64646-9
100. Kislinger T, Fu C, Huber B, et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. Journal of biological chemistry. 1999; 274(44): 31740-31749. doi: 10.1074/jbc.274.44.31740
101. Prestigiacomo CJ, Kim SC, Connolly ES Jr, Liao H, Yan SF, Pinsky DJ. CD18-mediated neutrophil recruitment contributes to the pathogenesis of reperfused but not nonreperfused stroke. Stroke. 1999; 30(5): 1110-1117. doi: 10.1161/01.STR.30.5.1110
102. Yan SF, Lu J, Zou YS, Soh-Won J, et al. Hypoxia-associated induction of early growth response-1 gene expression. Journal of biological chemistry. 1999; 274(21): 15030-15040. doi: 10.1074/jbc.274.21.15030
103. Yan SF, Mackman N, Kisiel W, Stern DM, Pinsky DJ. Hypoxia/Hypoxemia-Induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. Arteriosclerosis, thrombosis, and vascular biology. 1999; 19(9): 2029-2035. doi: 10.1161/01.ATV.19.9.2029
104. Jiang XC, DArmiento J, Mallampalli RK, Mar J, Yan SF, Lin M. Expression of plasma phospholipid transfer protein mRNA in normal and emphysematous lungs and regulation by hypoxia. Journal of biological chemistry. 1998; 273(25): 15714-15718. doi: 10.1074/jbc.273.25.15714
105. Pinsky DJ, Liao H, Lawson CA, et al. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. Journal of clinical investigation. 1998; 102(5): 919-928. doi:
106. Yan SF, Pinsky D, Mackman N, Lee S, Milbrandt J, Stern D. Hypoxia triggers activation of coagulation and vascular fibrin deposition. Keystone Symposia on Molecular and Cellular Biology. 1998; P88: 013-013
107. Yan SF, Lawson CA, Stern DM, Pinsky DJ. Hypoxia-mediated modulation of vascular function--implications for organ preservation and thrombogenesis: Roger S. Mitchell lecture. Chest. 1998; 114(1 Suppl): 46S-50S. doi: 10.1378/chest.114.1_Supplement.46S
108. Yan SF, Zou YS, Gao Y, et al. Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95(14): 8298-8303.
109. Yan SD, Zhu H, Fu J, et al. Amyloid-beta peptide-receptor for advanced glycationendproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America. 1997; 94(10): 5296-5301.
110. Lawson CA, Yan SD, Yan SF, et al. Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. Journal of Clinical Investigation. 1997; 99(7): 1729-1738. doi: 10.1172/JCI119337.
111. Yan SF, Ogawa S, Stern DM, Pinsky DJ. Hypoxia-induced modulation of endothelial cell properties: Regulation of barrier function and expression of interleukin-6. Kidney international. 1997; 51(2): 419-425.
112. Yan SF, Zou YS, Mendelsohn M, et al. Nuclear factor interleukin 6 motifs mediate tissue-specific gene transcription in hypoxia. Journal of Biological Chemistry. 1997; 272(7): 4287-4294. doi: 10.1074/jbc.272.7.4287
113. Pinsky DJ, Yan SF, Lawson C, Naka et al. Hypoxia and modification of the endothelium: Implications for regulation of vascular homeostatic properties. Seminars in cell biology. 1995; 6(5): 283-294.
114. Yan SD, Yan SF, Chen X, et al. Non-enzymatically glycated tau in Alzheimers disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nature Medicine. 1995; 1(7): 693-699.
115. Yan SF, Tritto I, Pinsky D, et al. Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6. Journal of Biological Chemistry. 1995; 270(19): 11463-11471. doi: 10.1074/jbc.270.19.11463
116. Yan SF, Bao Y. Two biotin-labeled probes of gentamicin resistance genes. Actamicro Biologica Sinica. 1991; 31(2): 128-132.
117. Yan SF, Bao YD. Molecular cloning of gentamicin reistant gene. Chinese journal of antibiotics. 1990; 5: 333-.
118. Yan SF, Bao YD. [Investigation into the horizontal spread of gentamicin resistance gene. Guowaiyixue. Liu xingbingxue. Foreign medicine. Epidemiology and infection diseases section. 1989; 5: 216-219.
119. Dai GS, Zhan LQ, Yan SF, et al. [Studies on enterotoxin plasmids.III. Analysis of plasmids in resistant and enterotoxigenic Escherichia coli by gel electrophoresis]. Actamicrobiologica Sinica. 1985; 25(3): 245-249.
120. Bao YD, Dai GS, Zhan LQ, Chen JZ, Yan SF. Experiment of transposition directly of Transposon 5 (Tn5) into Ent plasmid in the enterotoxingenic. Chinese Journal of Microbiology and Immunology. 1984; 4: 104.

Jing Chen, PhD

Assistant Scientist
Department of Pathology, Immunology and Laboratory Medicine
University of Florida
Gainesville, FL 32610, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Chen joined the faculty of Department of Pathology, Immunology and Laboratory Medicine at University of Florida in October 2007. She has been working on genetics and pathogenesis of diabetes for more than 10 years. She studied mitochondrial gene mutations and their functional consequences in human diabetes. Using mouse models, Dr. Chen and her colleagues mapped genetic linkages conferring protection/resistance to Type 1 Diabetes (T1D) in both nuclear and mitochondrial genomes, and identified a SNP in the mitochondrially encoded gene mt-Nd2 that is associated with beta cell susceptibility to immune attack. Functional studies revealed that the protective allele of the SNP is associated with lower oxidative stress. A corresponding SNP exists in the human mt-ND2 gene, and is also associated with T1D as well as a series of human physiological status and pathologies that are closely related with oxidative stress. Dr. Chen and her colleagues are also studying the mechanism of the protective allele on human beta cells. Combine her expertise in immunology and mitochondrial biology, Dr. Chen started an unprecedented area in T1D study, and is currently looking at the metabolic control of T cell autoimmunity in human T1D. The goal is to identify metabolic abnormalities that cause T cell autoreactivity and develop new methods for disease prediction, prevention and target for new therapy.

Her research interests includes Genetics of Type 1 Diabetes, Interaction between genomic and mitochondrial genomes in the pathogenesis of Type 1 Diabetes , Role of mitochondrial function in pancreatic beta cells and Role of T-cell mitochondrial function and metabolism during development of autoimmune Type 1 Diabetes.

PROFESSIONAL MEMBERSHIP


• Japan Diabetes Society, professional member (1999-2003)
• American Diabetes Association, professional member (2006-present)
• American Association of Immunologists, regular member (2006-present)
• Immunology of Diabetes Society, member (2010-present)

1. Chen J, Mathews CE. Use of Chemical Probes to Detect Mitochondrial ROS by Flow Cytometry and Spectrofluorometry. Methods Enzymol. 2014; 542: 223-41. doi: 10.1016/B978-0-12-416618-9.00012-1..
2. Lightfoot YL, Chen J, Mathews CE. Oxidative Stress and Beta Cell Dysfunction. Methods Mol. Med. 2012; 900: 347-62. doi: 10.1007/978-1-60761-720-4_17..
3. Lightfoot YL, Chen J, Mathews CE. Immune-mediated B-cell death in type 1 diabetes. Eur J Clin Invest. 2012; 42(11): 1244-51.
4. Chen J, Grieshaber S, Mathews CE. Methods to assess beta cell death mediated by cytotoxic T lymphocytes. J Vis Exp. 2011; 16 (52): Pii2724. doi: 10.3791/2724.
5. Lightfoot YL, Chen J, Mathews CE. Role of the mitochondria in immune-mediated apoptotic death of the human pancreatic B cell line BLox5. PLoS One. 2011; 6(6): e20617. doi: 10.1371/journal.pone.0020617.
6. Chen J, Gusdon AM, Mathews CE. Role of genetics in resistance to type 1 diabetes. Diabetes Metab Res Rev. 2011; 27(8): 495-53. doi: 10.1002/dmrr.1260.
7. Thayer TC, Delano M, Liu C, et al. Superoxide production by macrophages and T cells is critical for the induction of autoreactivity and type 1 diabetes. Diabetes. 2011; 60(8): 2144-51. doi: 10.2337/db10-1222.
8. Chen J, Gusdon AM, Piganelli J, Leiter EH, Mathews CE. mt-Nd2(a) Modifies resistance against autoimmune type 1 diabetes in NOD mice at the level of the pancreatic B-cell. Diabetes. 2011; 60(1): 355-9. doi: 10.2337/db10-1241.
9. Li J, Liu X, Ran X, et al. Sterol regulatory element-binding protein-1c knockdown protected INS-1E cells from lipotoxicity. Diabetes Obes Metab. 2010; 12(1): 35-46. doi: 10.1111/j.1463-1326.2009.01093.x.
10. Gusdon AM, Chen J, Votyakova TV, Mathews CE. Quantification, localization, and tissue specificities of mouse mitochondrial reactive oxygen species production. Methods Enzymol. 2009; 456: 439-57. doi: 10.1016/S0076-6879(08)04424-8.
11. Zhang M, Chen J, Guo Z, Li L, Zhang Y, Li J. Rosiglitazone inhibits RANTES expression by human epidermal keratinocytes. Eur J Dermatol. 2009; 19(2): 176-7. doi: 10.1684/ejd.2008.0591
12. Chen J, Gusdon AM, Thayer TC, Mathews CE. Role of increased ROS dissipation in prevention of T1D: Lessons from the ALR mouse. Ann N Y Acad Sci. 2008; 1150: 157-66. doi: 10.1196/annals.1447.045.
13. Chen J, Lu Y, Lee C-H, Li RH, Leiter EH, Mathews CE. Commonalities of genetic resistance to spontaneous autoimmune and free radical-mediated diabetes. Free Radic Biol Med. 2008; 45(9): 1263-70. doi: 10.1016/j.freeradbiomed.2008.07.020.
14. Chen J, Hatori, Y, Nakajima K, et al. Mitochondrial complex I activity is significantly decreased in a patient with maternally inherited type 2 diabetes mellitus and hypertrophic cardiomyopathy associated with mitochondrial DNA C3310T mutation: a cybrid study. Diabetes Res Clin Pract. 2006; 74(2): 148-53. doi: http://dx.doi.org/10.1016/j.diabres.2006.03.024
15. Chen J, Chen YG, Reifsnyder PC, et al. Targeted disruption of CD38 accelerates autoimmune diabetes in NOD/Lt mice by enhancing autoimmunity in an ADP-ribosyltransferase 2-dependent fashion. J Immunol. 2006; 176(8): 4590-9.
16. Lee CH, Chen YG, Chen J, et al. Novel leptin receptor mutation in NOD/LtJ mice suppresses type 1 diabetes progression: II. Immunologic analysis. Diabetes. 2006; 55(1): 171-8. doi: 10.2337/diabetes.55.01.06.db05-1129
17. Chen Y-G, Chen J, Osborne MA, et al. CD38 is required for the peripheral survival of immunotolerogenic CD4+ iNKT-cellsin NOD mice. J Immunol. 2006; 177(5): 2939-47.
18. Chen J, Reifsnyder PC, Scheuplein F, et al. Agouti NOD": Identification of a CBA-derived Idd locus on Chromosome 7 and its use for chimera production with NOD embryonic stem cells". Mammalian Genome. 2005; 16(10): 775-83. doi: 10.1007/s00335-005-0007-1
19. Lee C-H, Reifsnyder PC, Naggert JK, Chen J, Leiter EH . Novel Leptin Receptor Mutation in NOD/LtJ Mice Suppresses Type 1 Diabetes Progression. I. Pathophysiologic analysis. Diabetes. 2005; 54(9): 2525-32. doi: 10.2337/diabetes.54.9.2525
20. Ohkubo E, Aida K, Chen J, et al. A patient with type 2 diabetes mellitus associated with mutations in calcium sensing receptor gene and mitochondrial DNA. Biochem Biophys Res Commun. 2000; 278(3): 808-13. doi: 10.1006/bbrc.2000.3867
21. Aida K, Ikegishi Y, Chen J, et al. Disruption of aldose reductase gene (Akr1b1) causes defect in urinary concentrating ability and divalent cation homeostasis. Biochem Biophys Res Commun. 2000; 277(2): 281. doi: 10.1006/bbrc.2000.3648
22. Tawata M, Hayashi JI, Isobe K, et al. A new mitochondrial DNA mutation at 14577 T/C is probably a major pathogenic mutation for maternally inherited type 2 diabetes. Diabetes. 2000; 49(7): 1269-7. doi: 10.2337/diabetes.49.7.1269
23. Fu M, Li XJ, Xian Y, Yu YR, Chen J, Zhang M. Distribution and content of nueropeptide Y in the pancreas of STZ-induced diabetic rats. Natl Med J China. 2000; 80: 715-716. .
24. Yu YR, Pan HR, Wang DF, et al. Clinical study on treatment of growth hormone deficiency with domestically produced recombinant human growth hormone. Chinese Journal of Endocrinology and Metabolism. 1999 (2) .
25. Hu GH, Chen J. Clinical analysis of 41 cases of geriatric primary hypothyroidism. Journal of Luzhou Medical College. 1999; 22(6) 533-534 .
26. Chen J, Tian HM, Liang JZ. Current research on malnutrition associated diabetes mellitus. Foreign Medical Science, Endocrinology. 1996; 16(4): 178-181 .
27. Chen J, Tian HM. The effect of Ginkgo Biloba extract on lipid and lipid peroxidation of diabetic patients. West China Medial Journal. 1995; 10(4): 400-401 .

David Simmons, MD

CMO at Bayer Diabetes Care
36 Columbia Road P.O. Box 1910
Morristown, New Jersey 07962, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Simmons have spent the last 35 years working to improve the quality of diabetes prevention, diagnosis and management. He have twenty years of experience in academic medicine in the field of Diabetes. He have thirteen years experience in industry, eight in pharma and the last five in the world of devices. I am currently responsibile for the Department of Medical and Clnical Affairs at Bayer HealthCare Diabetes Care.

His research interests include Diabetes, Internal Medicine, Management of medical assets in healthcare Industry, Medical Affairs, Late Stage Development.

Godwin K. Simon, MD, FRCP

Consultant Physician of Acute Medicine, Diabetes and Endocrinology
Basildon and Thurrock University Hospital NHS Trust
Nethermayne, SS165NL, UK

BiographyResearch InterestScientific ActivitiesPublications
QUALIFICATIONS

• (2013) FRCP, Royal College of Physicians and Surgeons, Glasgow
• (2009) CCT, Joint Royal College of Physicians Training Board, UK
• (2004) MRCP, Royal College of Physicians, UK
• (1998) MD General Medicine, PGIMER, Chandigarh, India
• (1994) MBBS, Medical College Thrissur, University of Calicut, India


EMPLOYMENT HISTORY

Consultant Posts

• (1/10/2013-Present) Consultant Physician, Acute Medicine, Diabetes and Endocrinology Basildon and Thurrock University Hospital, Basildon,UK
• (24/02/2010-30/9/2013) Consultant Physician, Acute Medicine, Diabetes and Endocrinology Southend University Hospital, Westcliff-on-sea, UK
• (29/8/2009-23/2/2010) Consultant Physician, Diabetes Endocrinology (Locum), Royal Blackburn Hospital, Blackburn

His research interests include: Diabetes New Therapies; Obesity Metabolic Surgery in Type 2 Diabetes; Medical Education, Simulation Training; Ambulatory Care in Acute Medicine; Portfolio and Commercial Research Trials

ORAL PESENTATIONS

• British Endocrine Society, Clinical Cases Meeting, Manchester 2010, Pheochromocytoma, papillary carcinoma, hyperparathyroidism; MEN variant or a coincidence?
• International Diabetes Federation Conference, Cape Town, 2006, Symptomatic neuropathy seems irreversible despite early metabolic and glycaemic improvements - A case control study
• Wessex Endocrine Diabetes Association Meeting, Isle of Wight, 2007, When benign is not benign A dopamine secreting paraganglioneuroma
• Wessex Endocrine Diabetes Association Meeting, Salisbury, 2006, When malignant is not malignant - Bilateral testicular rest tumours in a case of congenital adrenal hyperplasia


COURSES & CONFERENCES

I have been attending local and national courses and conferences regularly. Included below is a representative selection.
• British Endocrine Society, Conference 2006,2007,2008,2009,2013,2014
• University College London and Harvard Business School Management Training Programme-Basildon Transformational Programme-2014
• Castle Simulation Course for Faculty Development Addenbrooks Simulation Centre, Cambridge 2013
• Educational Supervisors Course, London Deanery 2012,2013
• Clinical Supervisors Course Anglia Ruskin University, Chelmsford 2012
• European Association for Study of Diabetes Conference, Amsterdam, 2007, Berlin 2012
• Diabetes UK Annual Professional Conference 2006, 2008
• Insulin Pump Course, Bournemouth, 2006, 2008
• Second International Conference of Society of Acute Medicine, London, 2008
• King’s Fund Management Course,Oxford, 2008
• American Diabetes Association Conference, SanDiego,2005 & Washington, 2006
• Educational Supervisor Development Course, Wessex Deanery 2006
• International Diabetes Federation Conference, Cape Town, 2006

ARTICLES

1. Kemp O, Lockwood AM, Lockwood GL, Simon GK, Kemp J. The impact of education on the knowledge and documentation of Driving and Vehicle Licensing Agency (DVLA) driving restrictions by doctors. Acute Medicine. 2011; 10(1): 13-17.
2. Tapley P, Cranfield T, Simon GK. Cerebral nocardiosis in a case of Waldenstroms macroglobulinaemia. Acute Medicine. 2008; 7(3): 128-130.
3. Bhandari S, Walker M, Simon GK, Cranfield T. Cerebral nocardiosis in a patient with lymphaplasmacytic lymphoma treated with fludarabine. British Journal of Haematology. 2008; 143(4): 454.
4. Coppini DV, Jones C, Spruce M, Simon GK. Neuropathic symptoms in newly diagnosed type 2 diabetics persist at six months, despite early glycaemic improvements. Practical Diabetes International. 2007; 24(7): 334-335. doi: 10.1111/j.1365-2141.2008.07304.x.

Peng Wang, PhD

Assistant Professor Medicine, Endocrinology, Diabetes and Bone Disease
Mount Sinai School of Medicine
One Gustave L. Levy Place, Box 1152
New York, NY 10029, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Wang is an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai in New York City. He received his PhD in Genetics from the Institute of Genetics and Developmental Biology at the Chinese Academy of Science in Beijing, China. He was a postdoctoral fellow and instructor in diabetes and beta cell biology at the University of Pittsburgh. Since 2012, he has been at Mount Sinai as an Assistant Professor.
Dr. Wang works on understanding and developing novel means for inducing the replication and regeneration of human pancreatic beta cells. He has developed a high throughput screening system to identify small molecules which can drive human beta cell replication. He has found some compounds that can drive human beta cell proliferation. He is working on these compound modifications and understanding molecular to drive beta cell proliferation.

His current research interests include: 1) Developing cell-based strategies for small molecular screens aimed at inducing human beta cell expansion and survival. 2) Use shRNA RNA and related approaches to silence cell cycle inhibitors in human beta cells with the goal of generating sustained proliferation in human beta cells.

GRANTS, CONTRACTS, FOUNDATION SUPPORT

1) Exploiting Normal cMyc Biology for Human Beta Cell Expansion

Role: Co-Investigator
Principal Investigator : Stewart
Agency: Juvenile Diabetes Research Foundation, 17-2011-598
Period: 9/01/11 - 8/31/13


Active:

2) Pancreatic Islet Growth Factors: Transgenic and Viral Modeling

Role: Co-Investigator
Principal Investigator: Stewart
Agency: NIH/NIDDK R-01 55023
Period: 5/1/12 - 4/30/16

SELECTED PEER-REVIEWED PUBLICATIONS

1. Ming LH, Wang P, Bank A, Yu J, Zhang L. PUMA dissociates Bax and BCL-XL to induce apoptosis in colon cancer cells. Journal of Biological Chemistry. 2006; 281: 16034-16042.
2. Wu B, Qiu W, Wang P, Yu H, Cheng T, Zambetti GP, Zhang L, Yu J. p53-independent induction of PUMA mediates intestinal apoptosis in response to ischaemia-reperfusion. Gut. 2007; 56: 645-654.
3. Yu J, Wang P, Ming LH, Wood M, Zhang L. SMAC/Diablo mediates the pro-apoptotic function of PUMA by regulating PUMA-induced mitochondrial events. Oncogene. 2007; 26: 4189-4198.
4. Wang P, Yu J, Zhang L. The nuclear function of p53 is required for PUMA-mediated apoptosis induced by DNA damage. Proc Natl Acad Sci USA. 2007; 104: 4054-4059.
5. Bank A, Wang P, Du CY, Yu J, Zhang L. SMAC mimetics sensitize NSAID-induced apoptosis by promoting caspase-3-mediated cytochrome-c release. Cancer Research. 2008; 68: 276-284.
6. Wang P, Qiu W, Dudgeon C, et al. PUMA is directly activated by NF-kB and contributes to TNF-alpha-induced apoptosis. Cell Death & Differentiation. 2009; 16: 1192-1202. doi: 10.1038/cdd.2009.51
7. Wang P, Zou F, Zhang X, et al. MicroRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Research. 2009; 69: 8157-8165. doi: 10.1158/0008-5472.CAN-09-1996.
8. Dudgeon C, Wang, P, Sun, X, et al. PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor, UCN-01. Molecular Cancer Therapeutics. 2010; 9: 2893-2902. doi: 10.1158/1535-7163.MCT-10-0635.
9. Li H, Wang P, Sun Q, et al. Following cytochrome c release, autophagy is inhibited during chemotherapy-induced apoptosis by caspase 8-mediated cleavage of Beclin 1. Cancer Research. 2011; 71: 36 25-34. doi: 10.1158/0008-5472.CAN-10-4475.
10. Dudgeon C, Peng R, Wang P, Sebastiani A, Yu J, Zhang L. Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3ß and NF-kB to suppress tumor cell growth. Oncogene. 2012; 31: 4848-4858. doi: 10.1038/onc.2011.644.
11. Li H, Wang P, Yu J, and Zhang L. Cleaving Beclin 1 to suppress autophagy in chemotherapy-induced apoptosis. Autophagy. 2011; 7: 1239-1241. doi: 10.4161/auto.7.10.16490.

Rajakrishnan Veluthakal, PhD

Scientist
Department of Opthalmology
Kresge Eye Institute
162,Dorchester drive, Apartment 187
Rochester Hills, Michigan 48307, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Veluthakal is a Seasoned and remarkably astute scientist with extensive knowledge and background in biochemistry, molecular and cell biology, and pathology honed from more than 12 years ofexperience in the field of diabetes. Display the capability to identify various technical issues in the system flow and recommend sound and efficient resolutions to problems. Possess solid interpersonal skills as exemplified by the ability to work well with professionals of diverse backgrounds and levels and adeptness in liaising between an organization and various academic laboratories.

Diabetes mellitus describes several diseases of abnormal carbohydrate metabolism that are characterized by hyperglycemia resulting from insulin deficiency or defect in insulin action on tissues or even both. These can lead to complications and even death. Both Type 1 [also knows as Insulin dependent diabetes mellitus; IDDM] [autoimmune disorder] and Type 2 [improper utilization of insulin] are equally disastrous. Dr.Rajakrishnan Veluthakal current research focuses on signaling mechanisms underlying the cytokine [e.g., IL-1beta] mediated loss of beta-cell viability, a well accepted model for IDDM, as well as the normal physiological function of pancreatic islet beta-cells [e.g. Glucose-stimulated insulin secretion]. His general research interest in the area of islet biology will enable him to understand the complexities involved in diabetes both type 1 and type 2. Below he will summarize his current research and also outline his future research plan.


Glucose-stimulated insulin secretion, a role for GTP-binding proteins:

Glucose, the most important and most studied secretogue for insulin secretion from pancreatic islets beta cells, uses different signaling pathways to facilitate insulin secretion. The challenge for the cells is to traffic the insulin-laden secretory granules across the cytoskeletal barriers, to the plasma membrane for fusion and release of insulin. The task of trafficking the secretory granules is undertaken by small GTP-binding proteins including Rac1, Cdc42, ARF6, and Rap1. The functional activation of GTP-binding proteins requires the exchange of the bound GDP inactive statefor GTP active statewhich is, carried out by the GDP/GTP exchange factors.
This exchange then facilitates the active GTP-binding proteins to interact with their effector proteins. For inactivation, the GTP-bound form is converted, by the action of the intrinsic GTPase activity, to the GDP-bound form, which then releases the bound effectors. Thus, the activation/inactivation cycle is achieved, and small G proteins serve as molecular switches that transduce an upstream signal to downstream effectors.
The activation of small GTP-binding protein e.g., Rac1, translocation, and effector interaction of these proteins with its upstream regulatory protein Tiam1, an exchange factor for Rac1, in insulin secretion were studied by using different pharmacological, biochemical, and molecular tools [published articles are appended, Diabetes, 56: 204-210, 2007; Diabetes, 54: 3523-3529, 2005 and Am J Physiol Cell Physiol, 292: C1216-1220, 2007]. We were further able to demonstrate the importance of post-translational modifications of these proteins, which is an essential step for the membrane association of these proteins.


Cytokines, the major culprits in islet beta-cell death:

Autoimmune aggression of pancreatic islet beta cells by T cells, macrophages, and dendritic cells leads to secretion of cytokines, IL-1beta, TNFalpha and INFgama, by these cells into the islet micro environment, destroying beta cells, inducing the onset of type 1 diabetes. Although all the three above mentioned cytokines destruct islet beta-cells, the signaling events that they evoke culminating in cell death are diverse. Hence, we mainly focused our attention on IL-1beta-induced beta-cell death. The activation of IL-1beta signaling events leads to functional activation of a transcription factor NF-κB, which induces theexpression of nitric oxide synthase, an enzyme which produces enormous amounts of nitric oxide, leading to cell death.

Our contribution to this signaling pathway was to examine the initial and the distal nuclear events that lead to beta-cell death. We were able to implicate that membrane-associated, cholesterol-enriched caveolae [small flask shaped membrane invaginations] and their key constituent proteins [i.e., caveolin-1] play significant regulatory roles in the IL-1beta signaling pathway in isolated beta-cells. We were able to demonstrate by using mutants of caveolin-1as well as RNAi approaches that tyrosine phosphorylation of caveolin-1 is essential for the early signaling events leading to nitric oxide synthase gene expression and subsequent nitric oxide production publication appended, Diabetes 54: 2576-2585, 2005]. Further we investigated the roles for nuclear lamin-B a structural protein of the nuclear envelope, which has diverse cellular functions including DNA replication, chromatin organization, differentiation, nuclear structural support, and nuclear envelope assembly] in nuclear envelope disassembly, one of the hallmark features of IL-1beta-induced apoptosis of the islet beta- cell



Am J Physiol Cell Physiol, 287: C1152-C1162, 2004.

In this study we were able to demonstrate that nuclear protein lamin-B undergoes phosphorylation and further, is vulnerable to degradation by caspases. The possible mechanism may be due to an increase in the activation of protein kinases that keep the lamin-B in the phosphorylated state or by suppression of lamin phosphatase. We demonstrated recently a unique member of the protein phosphatase 2Ac family; PP4c associated with lamin-B is functionally suppressed by IL-1β which may result in the retention of lamin-B in its phosphorylated state, which a requisite for its degradation byexpression of nitric oxide synthase, an enzyme which produces enormous amounts of nitric oxide, leading to cell death. Our contribution to this signaling pathway was to examine the initial and the distal nuclear events that lead to β-cell death. We were able to implicate that membrane-associated, cholesterol-enriched caveolae [small flask shaped membrane invaginations] and their key constituent proteins [i.e., caveolin-1] play significant regulatory roles in the IL-1β signaling pathway in isolated β-cells. We were able to demonstrate by using mutants of caveolin-1as well as RNAi approaches that tyrosine phosphorylation of caveolin-1 is essential for the early signaling events leading to nitric oxide synthase gene expression and subsequent nitric oxide production [publication appended, Diabetes 54: 2576-2585, 2005]. Further we investigated the roles for nuclear lamin-B a structural protein of the nuclear envelope, which has diverse cellular functions including DNA replication, chromatin organization, differentiation, nuclear structural support, and nuclear envelope assembly] in nuclear envelope disassembly, one of the hallmark features of IL-1beta-induced apoptosis of the islet beta- cell

Am J Physiol Cell Physiol, 287: C1152-C1162, 2004.

In this study we were able to demonstrate that nuclear protein lamin-B undergoes phosphorylation and further, is vulnerable to degradation by caspases. The possible mechanism may be due to an increase in the activation of protein kinases that keep the lamin-B in the phosphorylated state or by suppression of lamin phosphatase. We demonstrated recently a unique member of the protein phosphatase 2Ac family; PP4c associated with lamin-B is functionally suppressed by IL-1β which may result in the retention of lamin-B in its phosphorylated state, which a requisite for its degradation bycaspases, leading to the apoptotic demise of the beta-cell Apoptosis, 11: 1401-1411, 2006.

Fatty acid-induced pancreatic beta cell dysfunction is mediated by ceramide:

Abnormal lipid metabolism is a hallmark feature of Type 2 diabetes mellitus. The abnormalities in lipid metabolism, excessive circulating lipid levels, and hyperglycemia contribute to the progressive deterioration of beta cell function. Chronic exposure of isolated β-cells to fatty acids [e.g., palmitate] impairs insulin gene expression, affects expression of the transcription factor pancreatic and duodenal homeobox-1 [PDX-1], and impairs pre-proinsulin mRNA stability and insulin promoter activity. Most of the palmitate effects are mediated by an increase in cellular production of ceramide.We recently demonstrated that ceramide markedly reduced mitochondrial membrane ceramide.We recently demonstrated that ceramide markedly reduced mitochondrial membrane potential in insulin-secreting INS cells, which was followed by a significant accumulation of cytochrome c in the cytosolic compartment. In these studies we were able to demonstrate that ceramide-induced mitochondrial changes are due to activation of a ceramide sensitive protein phosphatase in islet beta-cells


Apoptosis, 10: 841-850, 2005 and Biochem Biophys Res Commun, 348: 649-652, 2006.

These above mentioned studies helped him in understanding the complex signaling cascade associated with 1 pancreatic islet beta-cell death evoked by IL-1beta, 2 helped him to gain an insight into the mechanistic details of the physiological function i.e., insulin secretion of pancreatic islet beta-cells, and 3 added to his knowledge about the complex signaling events associated with pancreatic islet β-cell death due to type 2 diabetes and associated complications.


PET Imaging

The National Cancer Institute defines a biomarker as "A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. In the context of diabetes, blood glucose, HbA1c and insulin levels all qualify as biomarkers reflecting endocrine pancreas function, but their shortfall in being truly useful predictors or surrogate endpoints of "abnormal processes or disease" lies in that alteration in their levels are dependent on a variety comorbidities and occur too late in the disease process to be useful sentinels. Because diabetic disease is projected to represent a significant world health care burden there is currently a significant international research effort directed at finding better biomarkers of diabetic disease. Over the past couple of years I have undertaken the challenge of identifying and validating novel biomarkers of diabetic disease suitable for non invasive imaging of beta cell mass (BCM) by evaluating compounds Potential PET ligands that can be of potential use in measuring pancreatic BCM by PET imaging.

Scientific Liaison/Collaborations:

Established external Liaison and internal collaborations with academic laboratories to pursue research projects and their fulfillment in a timely fashion. [Wayne State University; 2005-2009, Columbia University; 2009-2011.


Coordinator

Recruited and managed a team of over 35 field staff who collected epidemiological data and biological samples from children enrolled in the study of zinc supplementation strategy and zinc status on preschool children [a collaborative project between Annamalai University, India and The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD] , and coordinated between field staff, clinicians and research lab personals to efficiently run the program and reported to the Director, Center for Micronutrient Research, Annamalai University, India .1998-2001


Lab Manager:

Independent project design, development and accomplishment of projects, coordinated activities throughout the laboratory, delegate work amongst the various technicians, monitor outputs and keep records of workflow and usage of supplies, supervised the ordering and delivery of new supplies, promote the continuing professional development of staff and oversee the training of trainees, make risk assessments for the laboratory and ensure that the health & safety policy is observed Wayne State University; 2005-2009, Columbia University; 2009-2011.


Reviewer:

Reviewed grant proposals and original manuscripts for Journal of Transplantation.


Presenter:

Prepared and presented the research findings at various National and International meetings/seminars and prepared and defended the novel project proposals for funding.


1. Amin R, Chen H, Veluthakal, R ,et al. Mastoparan-induced insulin secretion from insulin-secreting betaTC3 and INS-1 cells: Evidence for its regulation by rho subfamily of G-proteins. Endocrinolog. 2003; 144: 405-418. doi: http://dx.doi.org/10.1210/en.2003-0106
2. Chen, H, Tannous M, Veluthakal R, Amin R, Kowluru A. Novel roles for palmitoylation of Ras in IL-1beta-induced nitric oxide release and caspases-3 activation in insulin secreting beta-cells. Biochemical Pharmacology. 2003; 66: 1681-1694. doi: 10.1016/S0006-2952(03)00549-5
3. Chen H, VeluthakalR, Rengasamy P, Kowluru A. GTP-Binding protein-independent potentiation by mastoparan of IL-1beta-induced nitric oxide release from insulin-secreting HIT-T15 cells. Apoptosis. 2004; 9: 145-148.
4. Jangati, G.R., Veluthakal R, Kowluru A. siRNA-mediated depletion of endogenous protein phosphatase 2Acα markedly attenuates ceramide-activated protein phosphatase activity in insulin-secreting INS-832/13 cells. Biochemical and Biophysical Research Communications. 2006; 348: 649-652. doi: 10.1016/j.bbrc.2006.07.100
5. Jangati GR, Veluthakal R, Susick L, Gruber SA, Kowluru A. Depletion of the catalytic subunit of protein phosphatase- 2A (PP2Ac) markedly attenuates glucose-stimulated insulin secretion in pancreatic beta-cells. Endocrine. 2007; 31: 248-253.
6. Kowluru A, Veluthakal R. Rho GDP-Dissociation Inhibitor GDI plays a negative modulatory role in glucose- stimulated insulin secretion. Diabetes. 2005; 54: 3523-3529. doi: 10.2337/diabetes.54.12.3523
7. Kowluru R, Kowluru A, Veluthakal R, et al. Tiam1-Rac1 signaling axis mediated activation of NADPH oxidase-2 initiates mitochondrial damage in the development of diabetic retinopathy. Diabetologia. doi: 10.1007/s00125-014-3194-z.
8. Kowluru A, Veluthakal R, Kaetzel D. Regulatory roles for nm23/nucleoside diphosphate kinase-like enzymes in insulin secretion from the pancreatic islet beta-cell. Journal of Bioengineering and Biomembranes. 2006; 38: 227-232. doi: 10.1007/s10863-006-9038-x
9. Kowluru A, Veluthakal R, RhodesC, Kamath V, Syed I, Koch B. Protein farnesylation-dependent Raf/extracellular signal related kinase signaling links to cytoskeletal remodeling to facilitate glucose-induced insulin secretion in pancreatic beta-cell. Diabetes. 2010; 59: 967-977. doi: 10.2337/db09-1334.
10. McDonald, P., Veluthakal R, Kaur, H., and Kowluru, A. Biologically active lipids promote trafficking and membrane association of Rac1 in insulin-secreting INS 832/13 cells. American Journal of Physiology - Cell Physiology. 2007; 292: C1216-1220. doi: 10.1152/ajpcell.00467.2006
11. Palanivel R, Veluthakal R, Kowluru A. Regulation by glucose and calcium of the carboxylmethylation of the catalytic subunit of protein phosphatase 2A in insulin-secreting INS-1 cells. American Journal of Physiology - Endocrinology and Metabolism. 2004; 286: E1032-1041. doi: 10.1152/ajpendo.00587.2003
12. Palanivel R, Veluthakal R, McDonald, KowluruA. Further evidence for the regulation of acetyl-CoA carboxylase activity by a glutamate- and magnesium-activated protein phosphatase in the pancreatic beta-cell: defective regulation in the diabetic GK rat islet. Endocrine. 2005; 26: 71-77. doi: 10.1385/ENDO:26:1:071
13. Susick L, Senanayake T, Veluthakal R, Woster P, Kowluru A. A novel histone deacetylase inhibitor prevents IL-1beta-induced metabolic dysfunction in pancreatic beta-cell. Journal of Cellular and Molecular Medicine. 2009; 13: 1877-1885. doi: 10.1111/j.1582-4934.2009.00672.x.
14. Susick L, Veluthakal R, Suresh M, Hadden T, KowluruA. Regulatory roles for histone deacetylation in IL-1beta- induced nitric oxide release in pancreatic beta-cell. Journal of Cellular and Molecular Medicine. 2007; 12: 1571-1583. doi: 10.1111/j.1582-4934.2007.00171.x
15. Kowluru R, Kowluru A, Veluthakal R, et al. TIAM1-RAC1 signalling axis-mediated activation of NADPH oxidase-2 initiates mitochondrial damage in the development of diabetic retinopathy. Diabetologia. 2014; 57: 1047-1056. doi: 10.1007/s00125-014-3194-z.
16. Tannous M, Veluthakal R, Amin R, Kowluru A. IL-1beta-induced nitric oxide release from insulin secreting beta-cells: Further evidence for the involvement of GTP-binding proteins. Diabetes and Metabolism. 2002; 28: 3S78-3S84.
17. Veluthakal R, Harris P. In vivo beta-cell imaging with VMAT 2 ligands-current state-of-the-art and future perspective. Current Pharmaceutical Design. 2010; 16: 568-1581. doi: 10.2174/138161210791164180
18. Veluthakal, R. Kowluru A. Post translational modifications of nuclear lamin: Possible implication in survival and demise of pancreatic beta-cell. Recent Research Developments in Biophysics and Biochemistry. 2003; 3: 519-529.
19. Veluthakal R, Amin R, Kowluru, A. IL-1beta- induces posttranslational carboxymethylation and alterations in subnuclear distribution of lamin B in insulin-secreting RINm5F cells. American Journal of Physiology -Cell Physiology. 2 004; 287: C1152-1162. doi: 10.1152/ajpcell.00083.2004
20. Veluthakal R, Chvyrkova I. Tannous, M,et al. Essential Role for Membrane Lipid Rafts in Interleukin-1beta-Induced Nitric Oxide Release from insulin-secreting cells: Potential regulation by caveolin-1. Diabetes. 2005; 54: 2576-2585. doi: 10.2337/diabetes.54.9.2576
21. Veluthakal R, Jangati GR, and Kowluru A. IL-1beta-induced iNOS expression, NO release and loss in metabolic cell viability are resistant to inhibitors of ceramide synthase and sphingomyelinase in INS 832/13 cells. Journal of the Pancreas. 2006; 7: 596-601.
22. Veluthakal R, Kaetzel D, Kowluru A. Nm23-H1 Regulates Glucose-Stimulated Insulin Secretion in Pancreatic beta-Cells via Arf6-Rac1 Signaling Axis. Cellular Physiology and Biochemistry. 2013; 32: 533-541. doi: 10.1159/000354457.
23. Veluthakal R, Kaur H, Goalstone M, Kowluru A. Dominant negative alpha-subunit of farnesyl- and geranyl-transferase inhibits glucose-stimulated insulin secretion from insulin-secreting INS-cells. Diabetes. 2007; 56: 204-210.
24. Veluthakal R, Kha I, Tannous M, Kowluru A. Functional inactivation by interleukin-1 of glyceraldehyde-3- phosphate dehydrogenase in insulin-secreting cells. Apoptosis. 2002; 7: 241-246.
25. Veluthakal R, Madathilparambil S, McDonald P, Olson L, Kowluru A. Regulatory roles for Tiam1, a guanine nucleotide exchange factor for Rac1, in glucose-stimulated insulin secretion in pancreatic beta-cell. Biochemical Pharmacology. 2009; 77: 101-113. doi: 10.1016/j.bcp.2008.09.021.
26. Veluthakal R, Palanivel R, Zhao , McDonald P, Gruber S, Kowluru A. Ceramide induces mitochondrial abnormalities in insulin-secreting INS-1 cells: Potential mechanisms underlying ceramide-mediated metabolic dysfunction of the beta-cell. Apoptosis. 2005; 10: 841-850. doi: 10.1007/s10495-005-0431-4
27. Veluthakal R, Suresh MV, Kowluru A. Down-regulation of expression and function of nucleoside diphosphate kinase in insulin-secreting beta-cell under in vitro conditions of glucolipotoxicity. Molecular and Cellular Biochemistry. 2009; 329: 121-129. doi: 10.1007/s11010-009-0113-6.
28. Veluthakal R, Wadzinski B, Kowluru A. Selective inhibition of nuclear protein phosphatase 4 by IL-1beta-in insulin- secreting INS-1 cells. Apoptosis. 2006; 11: 1401-1411.

Lilian De Jonge, PhD

Affiliate Professor
Department of Nutrition and Food Studies
George Mason University
10340 Democracy Ln, Suite 306
Room 333
Fairfax, VA 22030, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Jonge is an Affiliate Professor at the Department of Nutrition and Food Studies. She obtained her Ph.D. degree in nutrition from the Université de Montréal, in Montréal, Canada. After her Ph.D. degree, Dr. de Jonge moved to the Pennington Biomedical Research Center in Baton Rouge, LA where she was a Faculty Member and the Director of the Metabolic Chambers Laboratory, a position she held until 2010. During this time, she developed the Indirect Calorimetry Core Laboratory. As the Director of the core, she was involved in the redesign and reprogramming of the metabolic chambers. These chamber have become a model for several other metabolic chambers in the USA, including the NIH/NIDDK and the University of Colorado. At the Pennington Biomedical Research Center she studied the adaptation of energy expenditure and substrate oxidation to changes in dietary composition and energy balance and the role of physical activity in this adaptation. Dr. de Jonge has collaborated with a large number of investigators on numerous studies, both federally and privately funded, including several long-term multicenter studies such as POUNDS LOST, a 2-year intervention exploring the effect of diet composition on long-term weight loss and patient adherence, and CALERIE, a 2-year intervention studying the effects of 25% caloric restriction on markers of longevity. In September 2010, Dr. de Jonge accepted a Staff Scientist position at the National Institutes of Health in Bethesda, MD where she was involved in the study of the role sleep and circadian rhythm on obesity.

Her research interests include: The adaptation of energy and substrate metabolism to short and long-term changes in diet composition and energy balance, the effects of specific dietary components on energy metabolism and body composition and the role of circadian rhythm on body weight and energy balance.


INVITED PRESENTATIONS

1. US-China Business Training Center. Nutrition Research Methods; From Research to Product. August 12, 2014
2. NUTRIM, Maastricht University. Metabobolic Adaptation; Beyond Energy Balance. November 4, 2013
3. Hogeschool van Amsterdam. Symposium Protein Intake and Body Composition. Van eiwit word je niet dik (protein does not make you fat) February 22, 2012
4. NIDDK-Bethesda. Metabolic adaptation to long term energy imbalance. December 2009. 5. NIDDK-Phoenix Branch: Protein intake and overfeeding; The PROOF study. Methods and pitfalls. August 2009.
6. University of Texas at Brownsville Border Health Series. Protein intake and overfeeding; The PROOF study. April 2008
7. RACMEM 2008, Denver CO. Best clinical practices for the measurement of RMR. Feb 5 2008 8. LSU Department of Kinesiology. Adaptation to a high fat diet: Effects of environment and physiology, February 17, 2007.
9. University of Montreal. Department of Nutrition seminar series. Adaptation to a high fat diet: Effects of environment and physiology, May 16, 2006.
10. University of Texas at Brownsville Border Health Series: Adaptation to a high fat diet: Effects of environment and physiology, March 3, 2006.
11. NIDDK-Phoenix Branch. Role of the autonomic nervous system in the Thermic Effect of Food in lean and obese individuals. May 1997
12. Club de Recherche Clinique du Quebec. Thermogenese facultative chez des personnes obeses (Facultative thermogenesis in obese individuals). Sept 1994


PROFESSIONAL SERVICE

• Nederlandse Obesitas Vereniging (Dutch Obesity Patients Organization Quarterly Magazine): summarize scientific research papers into lay language for the magazine, 1999-2010.
• Member, Research Advisory Committee - Put Active Play in Every Childs Day: Louisianas Report Card on Physical Activity and Health for Children and Youth (first annual report card for Louisiana), 2008.



PROFESSIONAL CONFERENCES


• Co-Organizer Obesity and the Brain Scientific Symposium. NIDDK/NIH. March 22-23, 2012.
• Session Chair – Recent Advances in Calorimetry and Measurement of Energy Metabolism (RACMEM), Maastricht, The Netherlands, Nov. 2011
• Organizing Committee member –Louisianas report card for childrens physical activity and health conference. Pennington Biomedical Research Center, Baton Rouge LA. 2008-2009.
• Co-Organizer – Recent Advances in Calorimetry and Measurement of Energy Metabolism (RACMEM) 2008, Denver CO, Feb 2008.
• Session Chair – Recent Advances in Calorimetry and Measurement of Energy Metabolism (RACMEM) 2008, Denver CO, Feb 2008.
• Session Chair – Experimental Biology, San Diego, April, 2003.
• Local Organizing Committee member – International Congress on Nutrition, Montreal, PQ, July 1997.


AD HOC MANUSCRIPT REVIEWER


• American Journal of Clinical Nutrition • Diabetes • European Journal of Clinical Nutrition • International Journal of Obesity • JAMA • Journal of Applied Physiology • Journal of Nutrition • Medicine and Science in Sports and Exercise. • Metabolism • Nutrition and Dietetics • Obesity • Obesity Reviews


EDITORIAL BOARD


• The Scientific World Journal


PROFESSIONAL ORGANIZATION MEMBERSHIPS


1996 – present: The Obesity Society (regular member) 2010 – present: American Nutrition Society 2012 – present: Academy of Nutrition and Dietetics


CONSULTING ACTIVITIES


• Cosmed Inc.: data reviewing and advising to adapt a metabolic cart for pediatric use, 2013 • National Institute for Standards and Technology. Advising on calculations for air quality in office buildings. (Investigator: Dr. Andrew Persily). 2013-present. • Self Magazine: invited article on the role of calcium in fat metabolism, 2002 • General Mills: protocol design for a study of the role of breakfast consumption on energy balance, 2001



RESEARCHAND SCIENCE OUTREACH


• Member of Employee Wellness Committee. Pennington Biomedical Research Center. 2008-2010 • Womens Wellness Day – Metabolism measurements, demonsdemonstrations and information. Pennington Biomedical Research Center. 1999-2006, 2008 • Mens Wellness Day – Metabolism measurements, demonstrations and information. Pennington Biomedical Research Center. 2006-2008 • National Youth Leadership Forum – Introduction to biomedical research. 2004, 2005, 2006 • Capital Area YMCA Womens Fitness Day - Metabolism measurements and information. 2003, 2005 • Womens Wellness Day. Pennington Biomedical Research Center. Seminar: Gender differences in weight control. 2003 • Womens Health Seminar Series. Pennington Biomedical Research Center. Seminar: Gender differences in weight control. 2002 • Womens Wellness Seminar. Gender differences in energy and substrate metabolism. Pennington Biomedical Research Center. 2001 • Womens Health Series Seminar. Gender differences in energy metabolism. Pennington Biomedical Research Center. 2000


UNIVERSITY SERVICE


• Lexington Network for the Study of America, Faculty of Law and Political Sciences, University of Liege, Belgium. Board member. 2005-2011 • LSU Academic Convocation, 2004, 2006-2009. • LSU Study Abroad Program Placement Committee, 2005-2008 • Pennington Biomedical Research Center Office for International Employees – developed handbook for international employees 1997-1998


COMMUNITY SERVICE


• PTA board member. Rosemont Elementary School. Gaithersburg MD. Sept 2014 • Teach Calories to second graders. Rosemont Elementary School. Gaithersburg MD. November 2013. • Rosemont Elementary School Science Fair Judge. 2013, 2014. • Community Health Fair organizer. Epworth United Methodist Church. Gaithersburg MD. October 26, 2013. • American Heart Association. Company Leader for the Capital City Area Heart Walk, 2007-2010. • Louisiana Regional and State Science Fair Judge, 1999, 2000, 2001, 2003, 2007, 2008. • Rape Crisis Center of Baton Rouge. Phone and Support Volunteer. 2000-2007 • American Red Cross - Member, Disaster Action Team, 2001-2003 - Captain, Disaster Action Team, 2003-2009 - Hurricane Response – Baton Rouge Emergency Operating Center Liaison, Shelter Operations and Staffing, Damage Assessment, 2002 (Hurricane Lili), 2004 (Hurricane Ivan), 2005 (Hurricanes Dennis and Katrina)



RECOGNITION


• NIDDK Directors Award, National Institute of Diabetes and Digestive and Kidney Diseases, NIH. 2012. • President, Foreign Student Association. School of Medicine. University of Montreal. Academic year 1994-1995. • Foreign Student Award. Academic year 1993-1994. University of Montreal • Prize of Excellence for Graduate Students. Academic year 1993-1994. Medical faculty of the University of Montreal • President, Graduate Student Association, Department of Nutrition, University of Montreal. Academic year 1993-1994. • Prize of Excellence for Graduate Students. Academic year 1992-1993. Medical faculty of the University of Montreal. • Foreign Student Award. Academic year 1992-1993. University of Montreal.


REFEREED PUBLICATIONS - Original Manuscripts


1. Jonge L, Persily A. Update on Carbon Dioxide Generation Rates for Building Occupants Standards. Indoor Air in progress. 2014.
2. Apolzan J, Bray G, Smith S, Jonge L,et al. Effects of weight gain induced by controlled overfeeding on physical activity. Am J Physiol. 2014. doi: 10.1152/ajpendo.00386.2014.
3. Apolzan J, Bray G, Smith S, et al. Effects of Dietary Protein Content during Overeating on Physical Activity. Am J Clin Nutr in press. 2014.
4. Bray G, Redman L, Jonge L, et al. Effect of Protein Overfeeding on Energy Expenditure Measured in a Metabolic Chamber. Am JClin Nutr in press. 2014.
5. Cizza G, Piaggi P, Rother K, Csako G. Hawthorne Effect with Transient Behavioral and Biochemical Changes in a Randomized Controlled Sleep Extension Trial of Chronically Short-Sleeping Obese Adults: Implications for the Design and Interpretation of Clinical Studies. PLoS One. 2014; 98: e104176. doi: 10.1371/journal.pone.0104176.
6. Frost E, Redman L, Jonge L, et al. Post-Exercise induced increase in energy expenditure is dependent on dietary fat. Am J Physiol Endocrinol Metab. 2014.
7. Cizza G, Jonge L, Piaggi P, et al. Neck circumference is a predictor of metabolic syndrome and obstructive sleep apnea in short sleeping obese men and women. Metab Syndr Relat Disord. 2014; 12: 231-241.. doi: 10.1089/met.2013.0093.
8. Lucassen E, Piaggi P, Jonge L, et al. Sleep extension without medications improves neurocognitive functions in chronically short-sleeping obese individuals. PLoS One. 2014; 9: E84832. doi: 10.1371/journal.pone.0084832.
9. Mirzaei K, Xu M, Qi Q, et al. Glucose and circadian related genetic variants affect response of energy expenditure to weight-loss diets: the POUNDS LOST Trial. American Journal of Clinical Nutrition. 2014;99: 392-399. doi: 10.3945/ajcn.113.072066.
10. Redman L, Kraus W, Bhapkar M, et al. CALERIE Study Group. Energy requirements in nonobese men and women: results from CALERIE. Am J Clin Nutr. 2014; 99: 71-78. doi: 10.3945/ajcn.113.065631.
11. Cizza G, Piaggi P, Lucassen E, et al. Glucose Metabolism In Obese Individuals With Short Sleep Duration. PLoS One. 2013; 29(8): e65400.
12. Galli G, Piaggi P, Mattingly M, et al. Food And Alcohol Intake In Obese Subjects Are Inversely Related To Sleep Duration And Sleep Quality. Nutr Diabetes. 2013; 3: e58.
13. Whiting D, Tomycz N, Jonge L, et al. Lateral hypothalamic area deep brain stimulation accelerates human metabolism. J Neuro Surg. 2013; 19: 56-63.
14. Lucassen E, Zhao X, Mattingly M, et al. Correlations between Chronotype, Food Intake Behavior And Endocrine Parameters In Obese Participants Reporting Sleeping Less Than Six And Half Hours Per Night. PLOS One. 2013; 83: e56519.
15. Jonge L, Mattingly M, Zuber S, Zhao X, Cizza G. Associations between Sleep with Resting Energy Expenditure in Chronic Sleep Deprived Obese Men and Pre-Menopausal Women. J Clin Endocrinol Metab. 2012; 97: 2881-2889.
16. Jonge L, Bray G, Smith S, Ryan D, et al. Effect of weight loss and diet composition on resting energy expenditure in the POUNDS LOST study. Obesity. 2012; 20: 2384–2389. doi: 10.1038/oby.2012.127.
17. Bray G, Smith S, Jonge L, et al. Effect of Dietary Protein on Nutrient Partitioning and Thermogenesis during Overfeeding. JAMA. 2012; 307: 47-55.
18. Bray G, Smith S, Jonge L, et al. Changes in energy expenditure with weight loss in the POUNDS LOST Study. Int J Obes. 2012; 36: 448-55.
19. Cizza G, Requena M, Galli G, Jonge L. Chronic sleep deprivation and seasonality: Implications for the obesity epidemic. J Endocrinol Invest. 2011; 34: 793-800.. doi: 10.3275/7808.
20. Martin C, Das S, Lindblad L, et al. CALERIE Study Team. Effect of calorie restriction on the free-living physical activity levels of nonobese humans: results of three randomized trials. J Appl Physiol. 2011; 110: 956-63. doi: 10.1152/japplphysiol.00846.2009.
21. Pieper C, Redman L, Racette S, et al. CALERIE Team. Development of adherence metrics for caloric restriction interventions. Clin Trials. 2011; 8(2): 155-64. doi: 10.1177/1740774511398369
22. Rochon J, Bales CW, Ravussin E, et al. WE CALERIE Study Group. Design and conduct of the CALERIE study: comprehensive assessment of the long-term effects of reducing intake of energy. J Gerontol A Biol Sci Med Sci. 2011; 66(1): 97-108. doi: 10.1093/gerona/glq168.
23. Galgani J, Jonge L, Rood J, Smith S, Young A, Ravussin E. Urinary C-peptide excretion: a novel alternate measure of insulin sensitivity in physiological conditions. Obesity. 2010; 18: 1852-7.. doi: 10.1038/oby.2010.70.
24. Galgani J, Jonge L, Most M, Bray G, Smith S. Whole-body carbohydrate oxidation predicts lower ad-libitum energy intake in humans. Int J Obes. 2010; 34: 886-91.
25. Cefalu W, Rood J, Jonge L, et al. Characterization of the Metabolic and Physiologic Response from Chromium Supplementation in Subjects with Type 2 Diabetes. Metabolism. 2010; 59: 755-62. doi: 10.1016/j.metabol.2009.09.023.
26. Meyer D, Ravussin E, Heilbronn L, Jonge L. Ghrelin peptide Y in postpartum lactating and nonlactating women. Am J Clin Nutr. 2010; 91: 366-72. doi: 10.3945/ajcn.2009.28616
27. Redman L, Veldhuis J, Rood J, Smith S, Williamson D, Ravussin E. Pennington CALERIE Team. The effect of caloric restriction interventions on growth hormone secretion in nonobese men and women. Aging Cell. 2010; 32-39. doi: 10.1111/j.1474-9726.2009.00530.x.
28. Jonge L, Moreira E, Martin C, Ravussin E. Impact of Six-Month Caloric Restriction on Autonomic Nervous System Activity in Healthy, Overweight, Individuals. Obesity. 2010; 18: 414-416. doi: 10.1038/oby.2009.408.
29. Sparks L, Pasarica M, Sereda O, et al. Effect of adipose tissue on the sexual dimorphism in metabolic flexibility. Metabolism. 2009; 58: 1564-1571. doi: 10.1016/j.metabol.2009.05.008.
30. Sparks L, Pasarica M, Jonge L, et al. Relation of adipose tissue to metabolic flexibility. JCEM Diabetes Res Clin Pract. 2009; 831: 32-43. doi: 10.1016/j.diabres.2008.09.052.
31. Redman L, Heilbronn L, Jonge L, et al. Caloric restriction, weight loss and metabolic adaptation in non-obese humans. PLoS ONE. 2009; e4377. doi: 10.1038/oby.2007.354.
32. Lefevre M, Redman L, Heilbronn L, et al. Caloric restriction alone and with exercise improves CVD risk in healthy non-obese individuals. Atherosclerosis. 2009; 203: 206-13. doi: 10.1016/j.atherosclerosis.2008.05.036.
33. Wang S, Xie H, Jonge L, Greenway F, Sparks L, Smith S. Subtyping Obesity With Microarrays. implications for the diagnosis and treatment of obesity. Int J Obes. 2009; 33: 481-489. doi: 10.1038/ijo.2008.277.
. 34. Sacks F, Bray G, Carey V, et al. Randomized trial comparing fat, protein, and carbohydrate composition of diets for weight loss. NEJM. 2009; 360: 859-873.
35. Meyer D, Newcomer B, Heilbronn L, et al. Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity. 2008; 16: 1355-1362. doi: 10.1038/oby.2008.201.
36. Redman L, Rood J, Anton S, Champagne C, Smith S, Ravussin E. Pennington Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy (CALERIE) Research Team. Calorie restriction and bone health in young, overweight individuals. Arch Intern Med. 2008; 168: 1859-1866. doi: 10.1001/archinte.168.17.1859.
37. Lovejoy J, Jonge L, Champagne C, Xie H, Smith S. Decreased physical activity and increased visceral fat during the Menopausal Transition. Int J Obes. 2008; 32: 949-958. doi: 10.1038/ijo.2008.25.
38. Jonge L, Smith S. Macronutrients and exercise. Obesity Management. 2008; 4: 11-13.
39. Williamson D, Martin CK, Anton S, et al. Is caloric restriction associated with development of eating-disorder symptoms Results from the CALERIE trial. Health Psychol. 2008; 27: S32-42. doi: 10.1037/0278-6133.27.1.S32.
40. Martin C, Anton S, Crowe E, et al. Pennington CALERIE Team. Empirical evaluation of the ability to learn a calorie counting system and estimate portion size and food intake. Br J Nutr. 2007; 98: 439-444. doi: http: //dx.doi.org/10.1017/S0007114507708802
41. Frisard M, Broussard A, Davies S, et al. Aging, Resting Metabolic Rate and Oxidative Damage: Results from the Louisiana Healthy Aging Study. J Gerontol Med Sci. 2007; 62: 752-9..
42. Martin C, Jonge L, Heilbronn L, et al. Effect of calorie restriction on the metabolic adaptation of resting metabolic rate and spontaneous physical activity. Obesity. 2007; 15: 2964-2973.. doi: 10.1038/oby.2007.354.
43. Pasarica M, Zachwieja J, Jonge L, Redmann S, Smith S. Effect of growth hormone on body composition and visceral adiposity in middle aged men with central obesity. J Clin Endocrinol Metab. 2007; 92: 4265-42670. doi: http: //dx.doi.org/10.1210/jc.2007-0786
44. Bogacka I, Jonge L, Gettys T, et al. Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation upregulates lipid metabolism in human subcutaneous adipose tissue. Diabetes Care. 2007; 30: 1179-1186.
45. Ukropcova B, Sereda O, Jonge L, et al. Family history of diabetes links impaired substrate switching and reduced mitochondrial content in skeletal muscle. Diabetes. 2007; 56: 720-727. doi: 10.2337/db06-0521
46. Redman L, Jonge L, Fang X, et al. Lack of an effect of a novel beta-adrenoceptor agonist, TAK-677 on energy metabolism in obese individuals: A double-blind, placebo-controlled randomized study. JCEM. 2007; 92: 527-531. doi: http: //dx.doi.org/10.1210/jc.2006-1740
47. Sözen M, Jonge L,Greenway F, Ravussin E, Smith S, Argyropoulos G. A rare mutation in AgRP, plus79G greaterA, affects promoter activity. Eur J Clin Nutr. 2007; 61: 809-812. doi: 10.1038/sj.ejcn.1602585
48. Civitarese A, Carling S, Heilbronn L, et al. CALERIE Pennington Team. Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med. 2007 ; 43: e76. doi: 10.1371/journal.pmed.0040076
49. Jonge L, Redman L, Nguyen T, Ravussin E. Assessment of Adherence to Caloric Restriction using Doubly Labeled Water and Changes in Body Composition author reply. AJCN. 2007; 86: 1252-1253..
50. Jonge L, DeLany J, Nguyen T, Howard J, Redman L, Ravussin E. Assessment of Adherence to Caloric Restriction using Doubly Labeled Water and Changes Body Composition.
51. Lefevre M, Lovejoy J, Smith S, et al. Comparison of the acute response to cis- and trans-oleic acid containing fats on glucose and lipids in overweight individuals with differing FABP-2 genotypes. Metabolism. 2005; 54: 1652-1658. doi: http: //dx.doi.org/10.1016/j.metabol.2005.06.015
52. Greenway F, Jonge L, Martin C, Roberts A, Grundy I, Parker C. Dietary herbal supplements with phenylephrine for weight loss. J Med Food. 2006; 9: 572-578. doi: 10.1089/jmf.2006.9.572.
53. Roberts A, Jonge L, Parker C, Grundy I, Yu Y, Greenway F. Globin digest: no evidence for a weight loss mechanism. J Med Foods. 2006; 9: 579-581. doi: 10.1089/jmf.2006.9.579.
54. Heilbronn L, Jonge L, Delany J, et al. Metabolic adaptation and low body temperature in response to caloric restriction in man. JAMA. 2006; 295: 1539-1548.
55. Roberts A, Jonge L, Parker C, Greenway F. The effect of black tea extract and caffeine TeaLean on oxygen consumption in man. Alternative Medicine Review. 2005; 10: 321-325.
56. Sparks L, Mynatt R, Koza R, Jonge L, Bray G, Smith S. High Fat Diet Coordinately Downregulates Genes Required for Mitochondrial Oxidative Phosphorylation In Skeletal Muscle. Diabetes. 2005; 54: 1926-1933. doi: 10.2337/diabetes.54.7.1926
57. Ukropcova B, McNeil M, Sereda O, et al. Dynamic changes in fat oxidation in human primary myocytes mirror metabolic characteristics of the donor. J Clin Invest. 2005; 115: 1934-1941. doi: 10.1172/JCI24332.
58. Smith S, Bray G, Jonge L, Volaufova J. Effect of pioglitazone on body composition and energy expenditure: A randomized controlled trial. Metabolism. 2005; 5224-5232. doi: http: //dx.doi.org/10.1016/j.metabol.2004.07.008
59. Greenway F, Jonge L, Frisard M. Effect of a dietary herbal supplement containing caffeine and ephedrine on weight, metabolic rate and body composition. Obesity Research. 2004; 121152-121157.
60. Nguyen T, Jonge L, Smith S, Bray G. Implementation of a fast-response algorithm for the pull-calorimeters at the Pennington Biomedical Research Center. Med Biol. Eng. Comp 2003; 41572-41586.
61. BrayG,Lovejoy J, Jonge L, et al. A nine-month randomized clinical trial comparing a fat-substituted and fat-reduced diet in healthy obese men: The Ole Study. Am J Clin Nutr. 2002; 76 :29-34.
62. Jonge L, Bray G. The thermic effect of food is reduced in obesity. Nutr Rev. 2002; 29(2-3): 426-430. doi: 10.1301/002966402320387233
63. Lovejoy J,Champagne C, Smith S, Jonge L, Xie H. Ethnic differences in dietary intakes, physical activity, and energy expenditure in middle-aged, premenopausal women: The Healthy Transitions Study. Am J Clin Nutr. 2001; 74905.
64. Jonge L, Smith S, Zachwieja J, Roy H, Bray G. Prediction of energy expenditure in a whole body indirect calorimeter at both low and high levels of physical activity. Int J Obes. 2001; 25: 929-934.
65. Smith S, Jonge L, Zachwieja J, et al. Fat and carbohydrate balances during the adaptation to a high fat diet. Am J Clin Nutr. 2000; 71: 450-457.
66. Smith S, Jonge L, Pellymounter M, et al. Peripheral Administration of human CRH, but not ovine CRH, Increases Energy Expenditure and Fat Oxidation in-vivo in humans. J Clin Endocrinol Metab. 2001; 8619918.
67. Smith S, Lovejoy J, Greenway F, Ryan D, Jonge L, et al. Deep abdominal subcutaneous adipose tissue. sexual dimorphism and relationship to fasting insulin levels. Metabolism. 2001; 50: 425-435.
68. Smith S, Jonge L, Zachwieja J, et al. Physical fitness is associated with improved fat oxidation during the adaptation to a high fat diet. Am J Clin Nutr. 2007; 2131-2138.
69. Jonge L, Bray G. The thermic effect of food in obesity: A critical review. Obesity Research. 1997; 562231.
70. Jonge L, Garrel D. Role of the autonomic nervous system in the thermogenic response to food in lean individuals. Am J Physiol. 1997; 272: E775-780.
71. Jobin N, Jonge L, Garrel D. Effects of RU486 on energy expenditure and meal tolerance in normal men. J Am Coll Nutr. 1996; 15: 283-238.
72. Garrel D, Jonge L. Should we still use the Harris and Benedict equations. Nutrition in Clinical Practice. 1996; 11: 99-103.
73. Garrel D, Jonge L. Intragastric feeding does not decrease the thermogenic response to food in obesity. Am J Clin Nutr. 1994; 59971-59974.
74. Nadeau M, Jonge L, Garrel D. Thermogenic Response to Food Intra-individual variability and measurement reliability. J Am Coll Nutr. 1993;12511-12516.
75. Garrel D, Jonge L. Thermogenic response to feeding in severely burned patients Relationship with resting metabolic rate. Burns. 1993;19467-19474.
76. Jonge L, Agoues I, Garrel D. Decreased thermogenic response to food with intragastric vs oral feeding. Am J Physiol. 1991; 260: E238-E242.

Ines Slim, MD, MSc, PhD

General Secretary of the Tunisian
Endocrine Society (STEDIAM)
Consultant & Assistant Professor in Diabetes & Endocrinology
Farhat Hached University Hospital, Sousse, Tunisia
Ibn Jazzar Faculty of Medicine, University of Sousse, Tunisia

BiographyResearch InterestScientific ActivitiesPublications

• Dr. Slim is Consultant & Assistant Professor in Diabetes & Endocrinology since 2010 in: o Department of Endocrinology in FarhatHached University Hospital, Sousse, Tunisia o IbnJazzar Faculty of Medicine, University of Sousse, Tunisia
• She has been awarded with distinction by Cardiff University (UK) for Post-graduate diploma in diabetes in 2010
• She has been awarded with distinction by University of South Wales (UK) for MSc in Diabetes (supported by IDF) in 2014
• She obtained many other Postgraduate Diplomas in Pituitary diseases (University of Paris XI, France, 2008), in Reproduction (University of Paris VI, 2009), in anti-infectious chimiotherapy (University of Sousse, Tunisia, 2010), in Medical Computing (University of Sousse, Tunisia, 2010), and in nutrition (University of Sfax, Tunisia, 2014)
• She is following PhD studies in Pharmaceutic Sciences since 2013 (research field :Pharmacogenetics in diabetes), Faculty of Pharmacy, University of Monastir, Tunisia
• She is Honorary Tutor in the Postgraduate Diploma/ Certificate in Diabetes (supported by BMJ group) since 2011, Department of Health Sciences, University of Leicester, UK

Her research interests includes Diabetes, Diabetes complications, Cardiovascular diseases, Endocrinology, Genetics, Therapeutic education and Motivational interviewing and she gave many national and international conferences in those fields.

• She has published more than 20 scientific articles and book chapters in the field of Diabetes and Endocrinology
• She has directed more than 10 medical thesis in the field of Diabetes and Endocrinology
• She is General Secretory of Tunisian Endocrine Society (2014 – 2017)
• She is member of the board of Tunisian Network for the Promotion of Research and Publication in Health Sciences since 2012
• She is member of “Global Health of International Advisors” (GHIA, Washington, supported by WHO), and project manager in the Tunisian –GHIA board since 2014
• She is member of French Endocrine Society since 2007 and the Endocrine Society since 2014

She selected pee-reviewed publications for many national and international indexed journals BMJ case reports, Obesity,Diabetes and Metabolism, Indian journal of Endocrinology, TunisieMédicale, and co-editor of Internet J geriatrics and gerontology

Dimiter Dimitrov, MD, PhD

Consultant Endocrinologist
Diavita Ltd
Varna, Bulgaria

BiographyResearch InterestScientific ActivitiesPublications
EDUCATION

• 2003 – 12.2005 Endocrinology Specialty, University Hospital Varna, Bulgaria
• 2002 – 09.2002 PostDoc Human Nutrition, University of Copenhagen, Denmark
• 06. 1999 – 11. 2002 Ph.D. in Endocrinology and Metabolic diseases, Medical University Varna, Bulgaria
• 01.1998 – 12. 2003 Internal Diseases Specialty, University Hospital Varna, Bulgaria
• 09. 1991 – 09.1997 Medical Doctor (MD), Medical University Varna, Bulgaria


EMPLOYMENTS


• 2012 – present Consultant Endocrinologist Diavita Ltd
• 2000–2006 Department of Endocrinology, University Hospital Varna, Bulgaria
• 2007 – 2010 AstraZeneca R&D Sweden

His research interests include: metabolic syndrome, gut microbiome, systems biology, systems medicine, medical informatics

MEMBERSHIPS

Editorial Board

• Current Pharmacogenomics and Personalized Medicine
• Predictive, Preventive and Personalized Medicine (EPMA) Journa


Expert - Panel Biomarkers

European Society for Translational Medicine


CaSYM

The Coordinating Action for Systems Medicine across Europe


EPMA

The European Association for Predictive, Preventive & Personalised Medicine

PUBLICATIONS IN INTERNATIONAL SCIENTIFIC JOURNALS

1. Dimitrov D. Systems approaches to computational modeling of the oral. Publications in International Scientific Journals Microbiome. Front Physiol. 2013; 4: 172. doi: 10.3389/fphys.2013.00172.
2. Mikkelsen I, Sloth B, Dimitrov D, et al. A low glycemic index diet does not affect postprandial energy metabolism but decreases postprandial insulinemia and increases fullness ratings in healthy women. The Journal of Nutrition. 2011; 141(9): 1679-1684. doi: 10.3945/jn.110.134627.
3. Dimitrov DV. Personalized Medicine and Molecular Diagnostics for Obesity Metabolic Systems Reconstruction and Gut Microbiome Biomarkers. Current Pharmacogenomics and Personalized Medicine. 2011.
4. Dimitrov D. The Human Gutome Nutrigenomics of Host –Microbiome Interactions. OMICS: Journal of Integrative Biology. 2011; vol. 15. doi: 10.1089/omi.2010.0109.
5. Dimitrov D. Current healthcare in Bulgaria time for predictive diagnostics and preventive medicine. EPMA Journal. 2010; 1: 607-610. doi: 10.1007/s13167-010-0051-0.
6. Bohchelian H, Dimitrov D, Koeva L. Screening for diabetic foot and osteoporosis in Bulgari . The Diabetic Foot Journal. 2007; Vol 10: 1.
7. Dimitrov D. et al. Nutrigenomics DNA -based diet plan. Biomedical Reviews. 2007.
8. Dimitrov D. et al. Homo Obesus -A metabotrophin deficient species. pharmacology and nutrition insight. Curr Pharm Des. 2007. doi: 10.2174/138161207781039616
9. Dimitrov D. Stress, dietary habits and Metabolic syndrome. Biological Psychiatry and Psychopharmacology. 2006; vol.2.
10. Dimitrov D, Bohchelian H Koeva L. Effect of Orlistat on plasma leptin levels and risk factors for the metabolic syndrome. Metabolic Syndrome and Related Disorders Journal. 2003; 2 pp:149-156. doi: 10.1089/met.2005.3.122.
11. Dimitrov D. Role of oxidative stress in the pathogenesis of diabetes mellitus and complications review. Endocrine Diseases.1998; 4: 3-12. doi: 10.2174/157339911797415585
12. Dimitrov D, et al. Leptin and cardiovascular risk factors among overweight diabetics. Bulgarian Endocrinology. 2000; 1: 6-11.
13. Dimitrov D, Koeva L. Leptin- the voice of adipose tissue –review. Bulgarian Endocrinology. 2000; 1: 3-8.
14. Dimitrov D, Koeva L, Bochchelian H. Effect of alpha-lipoic acid on EMG in diabetic Patients. Modern Medicine. 2001; 1: 3-11.
15. Dimitrov D. Do we need new therapies for diabetes?. Diabetes Res Open J. 2015; 1(3): 75-76. doi: 10.17140/DROJ-1-112

Maria Zannikou, PhD

Psychologist
Researcher and Clinical associate of Evangelismos Hospital
Pandrosou 43, 17564
Paleo Faliro, Athens
Greece

BiographyResearch InterestScientific ActivitiesPublications

Dr. Zannikou is a Medical Neuropsychologist at Evangelismos Hospital in Athens, Greece. She received her BSc of Honours in Psychology 2009 and MSc in Health Psychology 2011 from University of Hertfordshire Hatfield-London-UK and nowadays, she is in the final year of PhD in Neuroscience expected by December to 2015.
Until now, she had worked as a researcher at Aigintio, ErrikosDinan, and Gennimatas Neurological Department Research on Quality of Life in Multiple Sclerosis patients, the effect of neuropsychological state on memory and locus of control and Ippokratio Hospital A research on Diabetes type I and II The effect of illness perception, eating experience nutrition and the usage of Nutritionists in the patients well being and The effect of Counselling on Patients with Diabetes type I and II in Athens Greece. The mentioned researches were presented in European 25th Conference of Health Psychology and Greek Conferences 4th Conference of Health Psychology and 4thConference of Counselling.
She has also worked as Health Psychologist Counselling Cancer- patients in Oncological Day Clinic of Metropolitan Hospital and she run a research concerning the cooling cup usage during chemotherapy research on issues such as body image, trait and state theory and the use of cooling cup. After that, she worked at Onassis Cardiac Clinic OCC as Health Psychologist and she was using Eclectic Psychotherapy in mothers that their children had diagnosed with Contigenal Heart Disease CHD. She was, also offering preoperative preparation and postoperative support to both children diagnosed with CHD and their siblings. Nowadays she is running researches on Vad and CHD at OCC pilot survey, qualitative and quantitative research.
During the time she was working at OCC she started her PhD Jenuary 2012 in Neuroscience and eventually got a position at Evaggelismos Hospital.
Dr. Maria Zannikou is a Clinical Associate in the department of Controlling Pain in Patients and a researcher of Neurological Department inEvangelismos Hospital. She is working on projects concerning Multiple Sclerosis, the cerebral topography of the demyelinating foci and the effect of new types of medications in brain-atrophy.

Her current research interests include the analysis and understanding of biopsychosocial and Neuropsychological aspects of Illness and how barriers in adherence to treatment and Nutrition Self-Efficacy could be controlled by psychotherapy or by the development of psychological frameworks. Further to this,she is interested in cross- cultural studies that include the analysis of personalitysociety interaction in concern of illness perception Locus of Control and Quality of Life.

Dr. Maria Zannikou had worked voluntarily in Therapeutic Riding Association of Greece. This association is mainly helping children with syndromes to get socialized and exercised through horseriding. Moreover she have done her placement in ODC- Oncology Day Clinic of Metropolitan Hospital in Greece where she runned a research concerning the effect of chemotherapy and cooling cup usage on Cancer patients Quality of Life traits and states. After this she was working as Health Psychologist in Onasio Cardiac Clinic OCC and nowadays, she runned a series of studies concerning Congenital Heart Disease and Vad expected to be publish by the end of the year. Due to her PhD thesis she started working with Multiple Sclerosis patients in Evangelismos hospital and eventually she got the position of Clinical associate of Evangelismos Hospital and researcher of The Department of Neurology and Neurosurgery at Evangelismos Hospital.

1.Zannikou M. The effect of using Cooling Cup during Chemotherapy on Body Image in Cancer Patients. Metropolitan Public Conference. 2010.
2.Zannikou M.Stavropoulou K. Multiple Sclerosis: The Effect of Locus of Control, Depression, and Neuropsychological State of patients on Quality of life. 4th Greek Conference of Health Psychology. 2010.
3.Zannikou M. Manara E. Diabetis type I and II: Illness Percection, Eating Experience, and Nutrition Self- Efficacy. 25th European Conference of Heath Psychology. 2011.
4.Zannikou M. Counseling in Diabetis Patients. 4th Greek Conference of Counseling . 2012.

Andrew C. Shin, PhD

Assistant Professor
Department of Nutritional Science
College of Human Science
Texas Tech University
2500 Broadway, Lubbock, TX 79409
USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Shin received his PhD in Neuroscience at Michigan State University in 2008. His doctoral dissertation was on leptin insensitivity in the brainstem and dysregulation of the HPA axis in rats. Dr. Shin did his first postdoctoral fellowship with Dr. Hans-Rudolf Berthoud at Pennington Biomedical Research Center until 2011 where he studied the underlying mechanisms of Roux-en-Y gatric bypass (RYGB) surgery in rats. He demonstrated RYGB-induced changes in meal patterns, hormonal responses, and food reward behaviors in rats that are found to be similar to those reported in human patients. He completed his second postdoctoral fellowship with Dr. Christoph Buettner at Icahn School of Medicine at Mount Sinai in 2013 and was promoted to an Instructor of Medicine at Icahn School of Medicine. His current NIH grant examines the role of brain insulin in the control of branched-chain amino acid (BCAA) metabolism.

His research interests include: Role of brain insulin signaling in the control of branched-chain amino acid (BCAA) metabolism, Roux-en-Y gastric bypass (RYGB) surgery and the mechanisms underlying altered food reward behaviors, appetite control, gut peptides, and energy homeostasis, Interplay between reward and homeostatic neural systems, Dysregulation of HPA axis and obesity.

AWARDS AND RECOGNITIONS

• Keystone Symphosia Scholarship, 2010
• Society for Study of Ingestive Behavior (SSIB) New Investigator Travel Award, 2009
• Committee on Institutional Cooperation (CIC) Recognition Award, 2008
• Food, Nutrition, and Chronic Disease Fellowship, MSU, 2007
• American Physiological Society (APS) Mead Johnson Research Award in Endocrinology and Metabolism, 2007
• MSU Summer Retention Fellowship, 2007
• NSF Alliance for Graduate Education and the Professoriate Program (AGEP) Fellowship, 2007
• Biomedical Health Research Initiative Assistantship, MSU, 2005 – 2007
• 1st Prize on Ph.D. Oral Presentation Awards, Phi Zeta Research Day, College of Veterinary Medicine, MSU, 2006
• Neuroscience Program Travel Fellowship, MSU, 2005 – 2007
• Graduate Office Travel Fellowship, MSU, 2005
• The National Academies honorable list, 2005
• National Institute of Health (NIH) NRSA T32 Predoctoral Training Fellowship, 2002 – 2003; 2004 – 2005
• Academic Achievement Graduate Assistantship (AAGA), MSU, 2003 – 2004


MEMBERSHIPS AND HONORS

• Peer Reviewer, Physiology & Behavior, Present
• Peer Reviewer, Neuropsychopharmacology, Present
• Peer Reviewer, Journal of Neuroendocrinology, Present
• Peer Reviewer, International Journal of Obesity, Present
• Member, Society for Study of Ingestive Behavior (SSIB), 2009 – Present
• Member, Society for Neuroscience (SFN), 2005 – Present
• Student Member, Experimental Biology (FASEB), 2007
• Student Member, Endocrinology (ENDO), 2006 – 2007
• Member, The Obesity Society, 2004 – Present

PEER-REVIEWED PUBLICATIONS

1. Shin AC, Fasshauer M, Filatova N, et al. Brain insulin lowers circulating BCAA levels by inducing hepatic BCAA catabolism. Cell Metabolism. 2014. doi: S1550-S4131(14): 00400-00408. 10.1016/j.cmet.2014.09.003.
2. Shin AC, Berthoud HR. Obesity surgery: happy with less or eternally hungry? Trends Endocrinol Metab. 2013; 24(2): 101-108. doi: 10.1016/j.tem.2012.11.009.
3. Shin AC, Zheng H, Berthoud HR. Longitudinal assessment of food intake, fecal energy loss and energy expenditure after Roux-en-Y gastric bypass surgery in high-fat fed obese rats. Obesity Surgery. 2013 April; 23(4): 531-540. doi: 10.1007/s11695-012-0846-2.
4. Kasturi BS, MohanKumar SM, Sirivelu MP, Shin AC, MohanKumar PS. Chronic oestradiol-17β exposure suppresses hypothalamic norepinephrine release and the steroid-induced luteinizing hormone surge: Role of nitration of tyrosine hydroxylase. Brain Research. 2013 Feb 1; 1493: 90-8.
5. Fargali S, Scherer T, Shin AC, Sadahiro M, Buettner C, Salton SR. Germline ablation of VGF increases lipolysis in white adipose tissue. Journal of Endocrinology. 2012 Nov; 215(2): 313-22. doi: 10.1530/JOE-12-0172.
6. Berthoud HR, Zheng H, Shin AC. Food reward in the obese and after weight loss induced by calorie restriction or bariatric surgery. Annals of New York Academy of Sciences. 2012; 1264(1): 36-48 . doi: 10.1111/j.1749-6632.2012.06573.x.
7. Shin AC, Zheng H, Berthoud HR. Vagal innervation of hepatic portal vein and liver is not necessary for Roux-en-Y gastric bypass surgery-induced hypophagia, weight loss, and hypermetabolism. Annals of Surgery. 2012; 255(2): 294-301. doi: 10.1097/SLA.0b013e31823e71b7.
8. Shin AC, Berthoud HR. Food reward functions as affected by obesity and bariatric surgery. International Journal of Obesity. 2011; 35(Suppl 3): S40-S44. doi: 10.1038/ijo.2011.147.
9. Shin AC, Townsend RL, Patterson LM, Berthoud HR. Liking and wanting of sweet and oily food stimuli as affected by high-fat diet-induced obesity, weight loss, leptin, and genetic predisposition. American Journal of Physiology: Reg Integ Comp Physiol. 2011; 301(5): R1267-R1280. doi: 10.1152/ajpregu.00314.2011.
10. Berthoud HR, Lenard NR, Shin AC. Food reward, hyperphagia, and obesity. American Journal of Physiology: Reg Integ Comp Physiol. 2011; 300(6) R1266-1277. doi: 10.1152/ajpregu.00028.2011.
11. Berthoud HR, Shin AC, Zheng H. Obesity surgery and gut-brain communication. Physiology and Behavior. 2011; 105(1): 106-119. doi: 10.1016/j.physbeh.2011.01.023.
12. MohanKumar SM, Kasturi BS, Shin AC,et al. Chronic estradiol exposure induces oxidative stress in the hypothalamus to decrease hypothalamic dopamine and cause hyperprolactinemia. American Journal of Physiology: Reg Integ Comp Physiol. 2011; 300(3): R693-R699. doi: 10.1152/ajpregu.00481.2010.
13. Shin AC, Zheng H, Pistell PJ, Berthoud HR. Roux-en-Y gastric bypass surgery changes food reward in rats. International Journal of Obesity. 2011; 35(5): 642-651. doi: 10.1038/ijo.2010.174.
14. Shin AC, Pistell PJ, Phifer CB, Berthoud HR. Reversible suppression of food reward behavior by chronic μ-opioid receptor antagonism in the nucleus accumbens. Neuroscience. 2010; 170(2): 580-588. doi: 10.1016/j.neuroscience.2010.07.017.
15. Zheng H, Townsend RL, Shin AC, Patterson LM, Phifer CB, Berthoud HR. High-fat intake induced by μ-opioid activation of the nucleus accumbens is inhibited by Y1R-blockade and MC3/4R-stimulation. Brain Research. 2010; 1350: 131-138. doi: 10.1016/j.brainres.2010.03.061.
16. Shin AC, Zheng H, Townsend RL, Sigalet DL, Berthoud HR. Meal-induced hormone responses in a rat model of Roux-en-Y gastric bypass surgery. Endocrinology. 2010; 151(4): 1588-1597. doi: 10.1210/en.2009-1332.
17. Shin AC, MohanKumar SM, Sirivelu MP, et al. Chronic exposure to a high fat diet affects stress axis function differentially in diet-induced obese and diet-resistant rats. International Journal of Obesity. 2010; 34(7): 1218-1226. doi: 10.1038/ijo.2010.34.
18. Zheng H, Shin AC, Lenard NR, et al. Meal patterns, satiety, and food choice in a rat model of Roux-en-Y gastric bypass surgery. American Journal of Physiology: Reg Integ Comp Physiol. 2009; 297(5): R1273-R1282. doi: 10.1152/ajpregu.00343.2009.
19. Shin AC, Zheng H, Berthoud HR. An expanded view of energy homeostasis: neural integration of metabolic, cognitive, and emotional drives to eat. Physiology and Behavior. 2009; 97(5): 572-580. doi: 10.1016/j.physbeh.2009.02.010.
20. Zheng H, Lenard N, Shin AC, Berthoud HR. Appetite control and energy balance regulation in the modern world: external stimuli overwhelm internal repletion signals in a reward-driven brain. International Journal of Obesity.2009; 33 (Suppl 2): S8-S13.
21. Sirivelu MP, Shin AC, Perez G, MohanKumar PS, MohanKumar SM. Effect of L-DOPA on IL-1β-induced suppression of luteinizing hormone secretion in intact female rats. Human Reproduction.2009; 24(3): 718-725. doi: 10.1093/humrep/den434.
22. Sirivelu MP, Burnett B, Shin AC, Kim C, MohanKumar PS, MohanKumar SM. Interaction between GABA and norepinephrine in IL-1Beta-induced suppression of lutenizing hormone surge. Brain Research.2009; 1248: 107-114. doi: 10.1016/j.brainres.2008.10.057.
23. Clark KA, Shin AC, Sirivelu MP, MohanKumar SM, MohanKumar PS. Systemic administration of leptin decreases plasma corticosterone levels: role of hypothalamic norepinephrine. Brain Research.2008; 1195: 89-95. doi: 10.1016/j.brainres.2007.12.009.
24. MohanKumar SM, King A, Shin AC, Sirivelu MP, MohanKumar PS, Fink GD. Developmental programming of cardiovascular disorders: Focus on hypertension. Review of Endocrine and Metabolic Disorders.2007; 8(2):115-125. doi: 10.1155/2011/105076.
25. Pasarica M, Shin AC, Yu M, et al. Human Adenovirus Ad-36 induces adiposity, increases insulin sensitivity, and alters hypothalamic monoamines and stress axis in rat. Obesity.2006; 14(11):1905-1913.

Xinfu Guan, PhD

Assistant Professor
USDA/ARS Childrens Nutrition Research Center
Division of Diabetes, Endocrinology & Metabolism
Departments of Pediatrics & Medicine
Baylor College of Medicine
1100 Bates St. Houston, Texas 77030, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Guan is an Assistant Professor of Nutrition and Endocrinology in Departments of Pediatrics and Medicine, Baylor College of Medicine. After he obtained his Ph.D. degree from Michigan State University, Dr. Guan completed his post-doctoral fellowship at the USDA Children’s Nutrition Research Center, Baylor College of Medicine.After his fellowship training, Dr. Guan has been appointed a tenure-track faculty at Baylor College of Medicine and a nutrition scientist (principal investigator) at the USDA Children’s Nutrition Research Center. His research interests are to understand the molecular control of glucose homeostasis & energy balance; define metabolic actions & signaling networks of gut hormones on gut growth and function; and to ameliorate glucose intolerance & insulin resistance in obesity and diabetes and improve intestinal absorption deficiency in short bowel syndrome. Specifically, his research objectives are to elucidate the gut-brain-liver axis in the control of energy balance (feeding behavior, food intake, and gastrointestinal motility) and glycemic control (glucose homeostasis and insulin sensitivity). His recent work is focused on intestinal epithelialgrowth (adaptation & regeneration) and metabolic function; and hypothalamic-brainstem neuroendocrine control of peripheral glucose metabolism. His research work has been funded by the NIH, the USDA, and private foundations. His laboratory has made significant progress in establishing the functional relevance of gut hormones (namely glucagon-like peptide-2) and receptors in the control of energy balance and glucose homeostasis. Over the years, Dr. Guan’s work has identified that GLP-2 enhances intestinal circulation, glycolysis & protein synthesis (Gastro 2003); GLP-2R is localized to distinct types of cells in the gut (Gastro 2006); GLP-2R interacts with p85α (the PI3K regulatory subunit)(Cell Metab 2013). Using his newly generated Glp2r-specific KO mice, Dr. Guan’s laboratory has defined that Glp2r in the hypothalamus controls feeding behavior, gastrointestinal motility, and glucose homeostasis (AJP Endo 2012; Cell Metab 2013). Dr. Guan has been selected for the 2006 Peter Reeds Outstanding Young Investigator Award by the American Society for Nutrition; the 2007 Outstanding Young Investigator Award by the National Natural Science Foundation of China; and the 2012New Investigator Awardin the Neural Control & Autonomic Regulation by the American Physiological Society. Dr. Guan is reviewer for prestigious journals such as the Journal of Clinical Investigation,Gastroenterology, Endocrinology, American Journal of Physiology, and Journal of Nutrition etc. In addition, Dr. Guan has served on editorial boards of multiple international journals and as a scientific reviewer for the ADA grants.

His research interests are to elucidate the gut-brain-liver axis in the control of energy balance (feeding behavior, food intake, and gastrointestinal motility) and glycemic control (glucose homeostasis and insulin sensitivity); and to ameliorate glucose intolerance and insulin resistance in obesity and diabetes. Dr. Guan’s recent work is focused on intestinal epithelial growth (adaptation & regeneration) and metabolic reprogramming; and hypothalamic-brainstem neural control of peripheral glucose/amino acid metabolism. Dr. Guan’s specific aims are to [1] define the physiological function and signaling network of intestinal glucagon-like peptide-2 receptor (GLP-2R) that controls intestinal epithelial growth, absorption and microcirculation; and regulates energy balance and glucose homeostasis; [2] determine the physiological significance of CNS GLP-1/2 receptors’ activation in the control of glucose homeostasis and energy balance (including feeding behavior, food intake and gastric emptying); and [3] elucidate GLP-1/2-mediated neuroendocrine roles in glucose homeostasis and insulin sensitivity following metabolic surgery.
To address these specific aims, Dr. Guan’s laboratory has developed/established innovative tools and state-of-the-art approaches. Dr. Guan’s laboratory has 1) Generated Glp2rflox/flox mice that have provided an innovative genetic tool for the Cre-LoxP system to dissect cell-specific Glp2r actions and signaling pathways, i.e., the functional significance of GLP-2R in the target tissues as the brain and the gut on glucose metabolism and insulin sensitivity; 2) Developed state-of-the-art stable isotopic tracer dilution techniques (in conjunction with elementary meal-based oral glucose challenge or hyperinsulinemic euglycemic clamp) to quantify dynamic glucose fluxes at postprandial and postabsorptive states; and assess tissue-specific insulin sensitivity in conscious mice; 3) Employed LC-MS/MS-based metabolomics to identify intracellular 13C-D-glucose metabolites responsible for intestinal stem cells’ metabolic reprograming & cell homeostasis; 4) Established an ex vivo culture model of the human/mouse intestinal organoids (i.e., mini-guts formed as the 3-D crypt-villus-like epithelium) to assess intestinal stem cells’ function and metabolism; 5) Utilized electrophysiological approaches (such as the whole-cell patch clamp and Ca2+ imaging) to assess endocrine secretory activities in the mini-guts and neuronal electric activities in brains slices; and 6) Utilized the rodent vertical sleeve gastrectomy (VSG) model to define genetic/physiological components and endocrine mechanisms responsible for improving glucose homeostasis and restoring metabolic outcomes (such as insulin sensitivity) in obesity and diabetes. Dr. Guan is a recognized expert in stable isotopic tracer techniques (to assess metabolic reprograming of glucose & glutamine), hyperinsulinemic euglycemic clamp (to quantify insulin sensitivity and glucose homeostasis during), LC-MS/MS-based metabolomics, and electrophysiological whole-cell patch clamps to determine activities of ion channels in neurons and endocrine cells.

OTHER EXPERIENCE AND PROFESSIONAL MEMBERSHIPS

• Editorial Board of the Journal of Endocrinology and Metabolic Syndrome; the Journal of Endocrinology, Diabetes and Obesity; Journal of Nutritional Disorders and Therapy; Journal of Obesity and Weight Loss Therapy; Austin Journal of Endocrinology and Diabetes; Austin Journal of Pediatrics.
• Reviewer: American Journal of Physiology-Endocrinology and Metabolism; Journal of Nutrition; British Journal of Nutrition, European Journal of nutrition, Journal of Cellular Physiology; Journal of Clinical Investigation; American Journal of Physiology-Cell Physiology; Journal of Nutritional Biochemistry; Endocrinology; International Journal of Obesity; Gastroenterology; Molecular Neurobiology; Molecules, Neurogastroenterology and Motility; Neuropeptides; Regulatory Peptides.
• Reviewer: American Diabetes Association Research Grants.
• Member: American Gastroenterological Association; American Society for Nutrition; American Physiological Society; the Endocrine Society; Society for Experimental Biology and Medicine; Sigma Xi.


HONORS (PARTIAL LIST)

• 1995 British-Sino Friendship Scholarship Award, British Council and China Ministry of Education
• 1998 Nutrition Research Achievement Award, BASF Corp.
• 1998 Annual Biomedicine Research Award (the 1st Place), Michigan State University
• 2006 The ASN Peter Reeds Outstanding Young Investigator Award, the American Society for Nutrition
• 2006 Honorary Professorship of Nutrition, China Agricultural University, Beijing
• 2006 NIH NIDDK KO1 Award
• 2007 Outstanding Young Investigator Award, the National Natural Science Foundation of China
• 2008 Bristol-Myers Squibb/Mead Johnson Nutrition Award
• 2009 NIH NIDDK RO3 Award
• 2011 The Mead Johnson Research Award in Endocrinology and Metabolism Section (Postdoc Mentor), the American Physiological Society
• 2012 The New Investigator Award in the Neural Control and Autonomic Regulation Section, the American Physiological Society
• 2012 The ENDO 2012 Research Summaries Book, the Endocrine Society
• 2012 The Research Recognition Award in Endocrinology and Metabolism Section (Postdoc Mentor), the American Physiological Society
• 2013 The Takeda Travel Award in the Gastrointestinal and Liver (GIandL) Physiology Section (Postdoc Mentor), the American Physiological Society
• 2014 The Research Recognition Award in the Gastrointestinal and Liver (GIandL) Physiology Section (Postdoc Mentor), the American Physiological Society

SELECTED PAPERS:

1. Guan X. The CNS glucagon-like peptide-2 receptor in the control of energy balance and glucose homeostasis. Am J Physiol Regul Integr Comp Physiol. 2014; 307(6):R585-R596. doi: 10.1152/ajpregu.00096.2014.
2. Shi X, Li Y, Wang F, et al. Central GLP-2 enhances hepatic insulin sensitivity via activating PI3K signaling in POMC neurons. Cell Metab. 2013; 18: 86-98. doi: 10.1016/j.cmet.2013.06.014.
3. Guan XX, Shi X, Li B, et al. GLP-2 receptor in POMC neurons suppresses feeding behavior and gastric motility. Am J Physiol Endocrinol Metab. 2012; 303: E853-64. doi: 10.1152/ajpendo.00245.2012.
4. Wang YX, Shi J, Qi X, Li K, Uray, Guan X. SIRT1 inhibits the mouse intestinal motility and epithelial proliferation. Am J Physiol - Gastrointest Liver Physiol. 2012; 302(2):G207-17. doi: 10.1152/ajpgi.00302.2011.
5. Shi X, Li X, Wang Y, et al. Glucagon-like peptide-2 (GLP-2) stimulated protein synthesis through the PI3-kinase-dependent Akt-mTOR signaling pathway. Am J Physiol Endocrinol Metab. 2011; 300: E554-63. doi: 10.1152/ajpendo.00620.2010.
6. Wang Y, Li X, Guo Y, Chan L, Guan X. Alpha-lipoic acid increases energy expenditure by enhancing AMPK-PGC-1α signalling in the skeletal muscle of aged mice. Metabolism. 2010; 59: 967-976. doi: 10.1016/j.metabol.2009.10.018.
7. Wang Y, Guan X. GLP-2 potentiates L-type Ca2+ channel activity associated with stimulated glucose uptake in hippocampal neurons. Am J Physiol Endocrinol Metab. 2010; 298: E156–166. doi: 10.1152/ajpendo.00585.2009.
8. Guan X, Wang Y, Qi J, et al. Sirt1 regulates the mouse gastric emptying and intestinal growth. Gastroenterology. 2010; 138: S402.
9. Burrin DG, Stoll B, Guan X, et al. GLP-2 rapidly activates divergent intracellular signaling pathways involved in intestinal cell survival and proliferation in neonatal piglets. Am J Physiol Endocrinol Metab. 2007; 292(1):E281-91.
10. Guan X, Karpen HE, Stephens J, et al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology. 2006; 130: 150-164.
11. Burrin DG, Stoll G, Guan X, Cui L, Chang X, Holst JJ. GLP-2 dose-dependently activates intestinal cell survival and proliferation in neonatal piglets. Endocrinology. 2005; 146: 22-32.
12. Bos C, Stoll B, Fouillet H, et al. Postprandial intestinal and whole-body nitrogen kinetics and distribution in piglets fed a single. Am J Physiol Endocrinol Metab. 2005; 288: E436-46.
13. Guan X, Bequette BJ, Ku PK, Tempelman RJ, Trottier NL. The amino acid need for milk synthesis is defined by the maximal uptake of plasma amino acids by porcine mammary glands. J. Nutr. 2004; 134: 2182-2190.
14. Guan X, Stoll B, Lu X, et al. GLP-2-mediated upregulation of intestinal blood flow and glucose uptake is nitric-oxide-dependent in TPN-fed piglets. Gastroenterology. 2003; 125: 136-147.
15. Guan XF, Bequette BJ, Calder B, Ku PK, Ames KN, Trottier NL. Amino acid. availability affects amino acid flux and protein metabolism in the porcine mammary gland. J Nutr. 2002; 132: 1224-1234.

Mohammad Alhadj Ali, MD,PgDip, MSc, PhD

Clinical Research Fellow in Diabetes and Endocrinology
University School of Medicine Heath Park Cardiff
Institute of Molecular & Experimental Medicine Cardiff
CF14 4XN, UK

BiographyResearch InterestScientific ActivitiesPublications

Dr. Ali began his academic life in 1994 at the Faculty of Medicine in the University of Aleppo and graduated in 2000 with MD degree. He started his post-graduate training at Aleppo University Hospital and finished his training in the speciality of Internal Medicine in 2004. In 2005, He was selected to be a member of the teaching staff in the specialty of Diabetes and Endocrinology at the University of Aleppo. In 2006, he completed Diploma degree in the History and Philosophy of Medicine from the University of Aleppo. He was awarded fellowship to do PhD degree in the speciality of Diabetes and Endocrinology and he did his research project at the University of Bristol and Cardiff University in the United Kingdom. He obtained his Doctorate of Philosophy in the field of immunotherapy for type 1 diabetes from the University of Bristol. Dr. Alhadj Ali currently works as Clinical Research Fellow in Diabetes and Endocrinology at Cardiff University and University Hospital of Wales.

His research interests include: Immunotherapy for Type 1 Diabetes and how to improve and optimise the effectiveness of such therapy when administered via dermal route. He presented his research data in different peer-reviewed diabetes and endocrine conferences. He also has special clinical interest in the newer agents for the treatment of Type 2 Diabetes.

HONORS AND AWARDS


1. Donald D. Etzwiler Scholar 2015: International Diabetes Center (IDC) / Mayo Clinic/WHO Collaborating Centre - September 2014
2. Rising Star in Diabetes: International Diabetes Centre (IDC) - June 2013
3. EASD 2012 Travel Grant Award: European Association for the Study of Diabetes - August 2012
4. Pioneers in Diabetes: Merck Sharp & Dohme - October 2011
5. EASD 2011 Travel Grant Award: European Association for the Study of Diabetes - September 2011
6. IDS Travel Grant Award for Young Researchers: Immunology of Diabetes Society - October 2010
7. IPSEN Fund Training Award 2010: IPSEN Fund - September 2010
8. Best oral presentations in the ABCD SpR meeting: Association of British Clinical Diabetologists - November 2009
Abstract selected as one of the best four for oral presentations in the ABCD SpR meeting in London between 20-21 November 2009
9. Appreciation Certificate from the Syrian Diabetes Association - October 2009
10. Appreciation Certificate from the Arab Medical Union in Europe: The Arab Medical Union in Europe - November 2006
11. Appreciation Certificate from the Syrian Orthopaedic Association: Syrian Orthopaedic Association - April 2004

1. Alhadj Ali et al. Functional modulation of epidermal dendritic cells by topical steroid treatment to optimise the tolerogenic potential of immunotherapy for type 1 diabetes. Diabetologia. 2012; (Poster presentation) The 48th EASD Annual Meeting in Berlin. 2012; 55 (supp.1): S 192 (456-PS).
2. Alhadj Ali et al. Optimizing the tolerogenic potential of a Vaccine for type 1 diabetes by topical Betamethasone therapy. Diabetologia. 2011; (Oral presentation) The 47th EASD Annual Meeting in Lisbon. 2011; 54 (supp.1): S 88 (195-OP) .
3. Alhadj Ali et al. Effects of Topical Betamethasone and Calcipotriol Therapy in Improving the Tolerogenic Potential of a Vaccine for Type 1 Diabetes. Endocrine Abstracts. 2011; 25: (P 310). ISSN 1470-3947.
4. Alhadj Ali et al Effects of Topical Steroid and Vitamin D Therapy in Optimizing the Tolerogenic Potential of a Vaccine for Type 1 Diabetes. Diabetic Medicine. 2011; 28 (supp.1): S 80 (P 155).
5. Mohammad Alhadj Ali,Colin M Dayan. The importance of residual endogenous beta-cell preservation in type 1 diabetes. British Journal of Diabetes & Vascular Disease. 2009; 9; No. 6, 248-253.
6. Ali M, Hamdoun S,Khoury A.Bone mineral density in patients with chronic obstructive pulmonary diseases. Medical Research Journal of the University of Aleppo. 2004.

Manoj K. Gupta, PhD

Research Scientist
Harvard Medical School
Joslin Diabetes Center
Boston, MA 02215, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Gupta obtained his PhD from University of Cologne, Germany and presently, he is working as a Research Scientist at Joslin Diabetes Center, Harvard Medical School, Boston. His research focuses on exploring the stem cells in the field of diabetes, obesity and metabolism.

His research interest includes: Growth hormone signaling in development, Diabetes and its related complications, Obesity and metabolism.

AWARDS AND HONORS


• (1990-1994) State level scholarships from 6th to 10th Class
• (2001-2003) Scholarship for pursuing Master’s Degree in Biotechnology by the Department of Biotechnology (DBT), Govt. of India
• (2002) Research fellowship from the Council of Industrial and Scientific Research-University Grant Commision (National Eligibility Test for Lectureship), (CSIR-UGC NET/JRF)
• (2003) Qualified for Graduate Aptitude Test in Engineering (GATE-2003) in Life Sciences with 97.87% percentile
• (2009) Best Poster presentation award in 5th International NRW meeting on Stem cell research in Aachen , Germany
• (2010) ISSCR travel grant award
• (2010) 1st Best Poster award in 5th Annual meeting of German Society for Stem Cell Research in Lübeck , Germany
• (2014) Seahorse travel Grant Award


MEMBERSHIPS


• Member, International Society for Stem Cell Research, ISSCR
• Member, German Society for Stem Cell Research, GSZ

1. Das A, Gupta MK, Saxena RK. Enhanced activation of mouse NK cells by IL-2 in the presence of circulating immune complexes. Curr. Sci. 2004; 87(6): 780-783.
2. Pfannkuche K, Fatima A, Gupta MK, Dieterich R, Hescheler J. Initial colony morphology-based selection for iPS cells derived from adult fibroblasts is substantially improved by temporary UTF1-based selection. PLOS One. 2010; 5(3): e9580. doi: 10.1371/journal.pone.0009580
3. Gupta MK, Illich DJ, Gaarz A, et al. Global transcriptional profiles of beating clusters derived from human induced pluripotent stem cells and embryonic stem cells are highly similar. BMC Dev Biology. 2010; 10: 98. doi: 10.1186/1471-213X-10-98
4. Shao K, Koch C, Gupta MK, et al. Induced pluripotent mesenchymal stromal cell clones retain donor-derived differences in DNA methylation profiles. Mol Therapy. 2013; 21(1): 240-250. doi: 10.1038/mt.2012.207
5. Nguemo F, Fleischmann BK, Gupta MK, et al. The L-type Ca2+ channels blocker nifedipine represses mesodermal fate determination in murine embryonic stem cells. PLOS One. 2013; 8(1): e53407. doi: 10.1371/journal.pone.0053407
6. Fatima A, Kaifeng S, Dittmann S, et al. The disease-specific phenotype in cardiomyocytes derived from induced pluripotent stem cells of two long QT syndrome type 3 patients. PLOS One. 2013; 8(12): e83005. doi: 10.1371/journal.pone.0083005
7. Gupta MK, Rao TN. Hearty miR-363 controls HAND1 in cardiac cell specification. Stem Cell Res Ther. 2014; 5(4): 89. doi: 10.1186/scrt478
8. Rao TN, Marks-Bluth J, Sullivan J, et al. High-level Gpr56 expression is dispensable for the maintenance and function of hematopoietic stem and progenitor cells in mice. Stem Cell Research. 2015; 14(3): 307-322. doi: 10.1016/j.scr.2015.02.001
9. Gupta MK, Teo AK, Rao TN et al. Excessive Cellular proliferation negatively impacts reprogramming efficiency of human fibroblasts. Stem Cell Trans Med. 2015. doi: 10.5966/sctm.2014-0217
10. Bhatt S, Gupta MK, Martinez R, et al. Preserved DNA repair pathway protects from complications in long standing type 1 diabetes. Cell Metabolism. 2015; 22(2): 239-252. doi: 10.1016/j.cmet.2015.07.015.


BOOK CHAPTER


1. Šarić T, Frenzel LP, Fatima A, Gupta MK, Hescheler J. Embryonic stem cells, cardiomyoplasty and the risk of teratoma formation. In: Bharavand H, ed. Trends in Stem cell. Biology and Technology. 2009; 229-260.

Hiroshi Bando, MD, PhD, FACP

Instructor
Tokushima University
President
Medical Research
Nakashowa 1-61
Tokushima City 770-0943, Japan

BiographyResearch InterestScientific ActivitiesPublications

Dr. Bando had graduated from Tokushima University, School of Medicine in 1981. After obtaining the ECFMG certificate, he participated the family practice residency training in United States. He got the degree of Doctors of Medicine in 1989, and engaged in the research of endocrine and metabolic medicine in Tokushima University as an instructor and associate professor. He has been board member and specialist in several medical societies, such as diabetes, primary care, anti-aging medicine, integrated medicine (IM), complementary and alternative medicine (CAM), music therapy and sport medicine. Besides medicine, he has been a pianist with the award of silver medal in the European International Piano Concours (EIPIC) in Japan (2013), and an athlete with award of gold medal in in-line skate and athletic games in Japan.

His research interests include: Diabetes, Metabolic syndrome, Primary care medicine, Complementary and alternative medicine (CAM), Integrated medicine (IM), music therapy (MT).


• Medical Doctor License (1981)
• ECFMG Certificate (1983)
• Fellow of American College of Physicians (FACP) (1987)
• Doctors of Medicine (PhD) (1990)
• Chairman of International Committee, Japanese Primary Care Physicians (1996)
• Chairman of Annual Meeting, 20th Japanese Biomusic Association (1999)
• Chairman of Annual Congress, 9th Japanese Association of Music Therapy (2009)
• Volunteerism & Community Service Award of American College of Physicians (2011)
• Chairman of Annual Meeting, 7th Japan Society of Music and Medicine (2014)
• Chairman of Annual Congress, 8th Japan Primary Care Association (2017)

1. Muneta T, Kawaguchi E, Nagai Y, et al. Ketone body elevation in placenta, umbilical cord, newborn and mother in normal delivery. Glycative Stress Research. 2016; 3(3): 133-140.
2. Bando H, Kan M, Takenaka Y, Yokoyama H, Nakamura T, Konoike K. Effective training of squat exercise-HiSquat trial for patients with diabetes. Glycative Stress Research. 2016; 3(2): 65-73.
3. Bando H, Takenaka Y, Nakamura T, Konoike K, Yonei Y. Investigation for Quality of Life (QOL) and self-esteem for health in masters athletes. Glycative Stress Research. 2015; 2(4): 174-181.
4. Bando H, Nakamura T, Yonei Y, Takenaka Y, Seki K. Lipid profile of masters athletes in ice-skating, a model of anti-aging research. Glycative Stress Research. 2(2): 52-57.
5. Hiyama K, Ozaki M, Hayano K, et al. Positive action is required to achieve the 2020.30 goal of gender equality in Japanese medical societies. Surgery Today. 2013; 44(1): 204-205. doi: 10.1007/s00595-013-0582-9
6. Yonei Y, Takahashi Y, Takahashi H, Watanabe M, Mochizuki T, Bando H. A double-blind clinical study of Rokkaku Reishi essence in women. Anti-Aging Medicine. 2007; 4(1): 28-37. doi: 10.3793/jaam.4.28
7. Bando H, Yoshioka T, Yonei Y, Nakamura T. Investigation of quality life in athletes from an anti-aging perspective. Primary Care Japan. 2006; 4(1): 47-51.
8. Bando H. Music therapy and internal medicine. Progress in Clinical Medicine. Asian Med J. 2001; 44(1): 30-35.
9. Inoue T, Okauchi Y, Matsuzaki Y, et al. Identification of a single cytosine base insertion mutation at Arg-597 of the beta subunit of the human epithelial sodium channel in a family with Liddles disease. European Journal of Endocrinology. 1998; 138(6): 691-697. doi: 10.1530/eje.0.1380691
10. Ishikawa M, Mizobuchi M, Takahashi H, Bando H, Saito S. Somatostatin release as measured by in vivo microdialysis: Circadian variation and effect of prolonged food deprivation. Brain Research. 1997; 749(2): 226-231.
11. Okauchi Y, Takahashi H, Mizobuchi M, Bando H, Saito S. Thyrotropin-releasing hormone release in normal and hyperthyroid rats as measured by microdialysis. The Tokushima Journal of Experimental Medicine. 1997; 43(3-4): 93-100.
12. Wada M, Azuma H, Bando H, et al. A case report of an elderly patient with acromegaly. Endocrine Journal. 1997; 43(6): 715-718. doi: 10.1507/endocrj.43.715
13. Mizobuchi M, Ishikawa M, Okauchi Y, Bando H, Saito S. Effects of Thyroidectomy on Thyrotropin-Releasing Hormone (TRH) and Somatotropin Release-lnhibiting Factor (SRIF) Patterns in Intrahypophysial Microdialysates in Rats. Endocrine Journal. 1996; 43(6): 679-687. doi: 10.1507/endocrj.43.679
14. Kannuki S, Matsumoto K, Sano T, Shintani Y, Bando H, Saito S. Double pituitary adenoma-two case reports. Neurologia Medico-Chirurgica. 1996; 36(11): 818-821. doi: 10.2176/nmc.36.818
15. Bando H, Abe T, Ohkura T, Shintani Y, Saito S. Correlation among serum levels of procollagen type 1 carboxy terminal propeptide and type 1 collagen carboxy terminal telopeptide and urinary excretion of growth hormone and pyridinoline in normal children. Clinical Pediatric Endocrinology. 1996; 5(Suppl 8): 95-97. doi: 10.1297/cpe.5.Supple8_95
16. Bando H, Mizobuchi M, Shintani Y, Saito S. Correlation between urinary growth hormone, pyridinoline, parathyroid hormone-related protein and calcium/phosphate excretion in normal children. Clinical Pediatric Endocrinology. 1996; 5(Suppl 7): 28-29. doi: 10.1297/cpe.5.Supple7_28
17. Rikimaru K, Matsumoto F, Hayashi E, Bando H, Nagayama M. Evaluation of serum concentration of parathyroid hormone-related protein and its implication in hypercalcemia in squamous cell carcinoma of the head and neck. International Journal of Oral and Maxillofacial Surgery. 1995; 24(5): 365-368. doi: 10.1016/S0901-5027(05)80494-1
18. Shintani Y, Yoshimoto K, Horie H, et al. Two different pituitary adenomas in a patient with multiple endocrine neoplasia type 1 associated with growth hormone-releasing hormone-producing pancreatic tumor: Clinical and genetic features. Endocrine Journal. 1995; 42(3): 331-340. doi: 10.1507/endocrj.42.331
19. Mizobuchi M, Kunishige M, Kubo K, Komatsu M, Bando H, Saito S. Syndrome of inappropriate secretion of ADH (SIADH) due to small cell lung cancer with extremely high plasma vasopressin level. Internal Medicine. 1994; 33(8): 501-504. doi: 10.2169/internalmedicine.33.501
20. Takahashi H, Shintani Y, Okauchi T, et al. Measurement of somatostatin release in rat brain by microdialysis. Journal of Neuroscience Methods. 1994; 52(1): 33-38.
21. Nakamura Y, Bando H, Sahintani Y, Yokogoshi Y, Saito S. Serum parathyroid hormone-related protein concentrations in patients with hematologic malignancies or solid tumors. Acta Endocrinologica. 1992; 127(4): 324-330. doi: 10.1530/acta.0.1270324
22. Bando H, Sano T, Ohshima T, et al. Differences in pathological findings and growth hormone responses in patients with growth hormone-producing pituitary adenoma. Endocrinologia Japonica. 1992; 39(4): 355-363. doi: 10.1507/endocrj1954.39.355
23. Takahashi H, Bando H, Zhang CY, Yamasaki R, Saito S. Mechanism of impaired growth hormone secretion in patients with Cushings disease. Acta Endocrinologica. 1992; 127(1): 13-17. doi: 10.1530/acta.0.1270013
24. Bando H, Zhang CY, Takada Y, Takahashi H, Yamasaki R, Saito S. Correlation between plasma levels of ACTH and cortisol in basal states and during the CRH test in normal subjects and patients with hypothalamo-pituitary disorders. The Tokushima Journal of Experimental Medicine. 1992; 38(3-4): 61-69.
25. Zhang CY, Yamasaki R, Mitsuhashi S, Takahashi H, Bando H, Saito S. Radioimmunoassay of growth hormone-releasing hormone (GHRH) with a polyclonal antibody against synthetic GHRH(1-29)-Gly4-Cys-NH2: method and clinical studies. Clinica Chimica Acta. 1991; 202(3): 243-254. doi: 10.1016/0009-8981(91)90055-H
26. Kawano H, Tsuruo Y, Bando H, Daikoku S. Hypophysiotrophic TRH-producing neurons identified by combining immunohistochemistry for pro-TRH and retrograde tracing. The Journal of Comparative Neurology. 1991; 307(4): 531-538. doi: 10.1002/cne.903070402
27. Bando H, Zhang CY, Takada Y, Yamasaki R, Saito S. Impaired secretion of growth hormone-releasing hormone, growth hormone and IGF-I in elderly men. Acta Endocrinologica. 1991; 124(1): 31-36. doi: 10.1530/acta.0.1240031
28. Bando H, Yamasaki R, Saito S. Evaluation of hypothalamic-pituitary function in a combination of tests with four hypothalamic releasing hormones and L-dopa in normal subjects and in patients with hypothalamic and/or pituitary disorders. Endocrinologia Japonica. 1989; 36(5): 705-720. doi: 10.1507/endocrj1954.36.705

Kevin Peter Shotliff, FRCP (UK), MD, DCH

Consultant Physician
Department of Diabetes and Endocrinology
Chelsea and Westminster Hospital;
Honorary Senior Lecturer
Imperial College London
Chelsea, London, UK

BiographyResearch InterestScientific ActivitiesPublications
EDUCATIONAL QUALIFICATIONS


• (1982-1987) St. Georges Hospital Medical School, London
• (July 1987) MBBS, University of London
• (November 1989) Diploma of Child Health (DCH)
• (July 1991) Membership of the Royall College of Physicians MRCP (UK)
• (May 2002) Fellow of the Royal College of Physicians (London)
• (May 1996) Degree of Doctor of Medicine (MD)
• (May 1997) Certificate of Completion of Specialist Training
• (September 2001) Certificate of Teaching (South West Thames Deanery)


PROFESSIONAL EXPERIENCES


• (31 March 2003-Present) Consultant Physician (General Internal Medicine, Diabetes and Endocrinology) Chelsea and Westminster Hospital 369 Fulham Road, London, SW10 9NH, UK
• (February 2004-Present) Honorary Consultant Endocrinologist, Royal Brampton Hospital, Sydney Street, London SW3 6NP, UK
• (August 2009-Present) Honorary Consultant Endocrinologist, Royal Marsden Hospital, Fulham Road, London, UK
• (June 2008-Present) Honorary Senior Lecturer, Imperial College, London, UK

His research interests include: Diabetic retinopathy, Cystic fibrosis related diabetes and obesity, and helped set up the Specialist weight management service/community obesity service for Central London Community Healthcare.

MEMBERSHIP


• Council member for BARS from (2006-2010)

1. Bowness P, Shotliff K, Middlemass A, Myles AB. Prevalence of hypothyroidism in patients with polymyalgia rheumatica and giant cell arteritis. British Journal of Rheumatology. 1991; 30: 349-351. doi: 10.1093/rheumatology/30.5.349
2. Shotliff K, Prasad A. Random blood glucose estimations on admission as a screening test for diabetes in an elderly population. Practical Diabetes. 1993; 10(5): 186-187. doi: 10.1002/pdi.1960100509
3. Smith EM, Ames DE, Liddle BJ, et al. Decisions on resuscitation status of the elderly. British Journal of Clinical Practice. 1993; 47(6): 287-288.
4. Shotliff K, Mukherjee D. The use of thyroid function tests in the screening of acute geriatric admissions. Care of the Elderly. 1994; 6(9): 344-345.
5. Shotliff K, Blight A, Mukherjee D. Incorrect diagnosis of thyroid disease by junior doctors. British Journal of Clinical Practice. 1996; 50(2): 76-78.
6. Shotliff K, Blight A, Patel S. Diabetes mellitus: An underdiagnosed condition? Practical Diabetes. 1996; 13(5): 148-149. doi: 10.1002/pdi.1960130505
7. Shotliff K, Ferrar M. Screening for hypercholesterolaemia after myocardial infarction. The British Journal of Cardiology. 1998; 5(3): 166-167.
8. Shotliff K, Kaushall R, Dove D, Nussey SS. Withholding thrombolysis in patients with diabetes mellitus and acute myocardial infarction. Diabetic Medicine. 1998; 15(12): 1028-1030. doi: 10.1002/(SICI)1096-9136(1998120)15:12<1028::AID-DIA713>3.0.CO;2-S
9. Haq M, Day A, Shotliff K. Screening for diabetes in the elderly. Diabetes Today. 2003; 6(3): 66-67.
10. Pauli R, Huber JW, Duncan G, Shotliff KP. Training evaluation of a course in diabetic retinopathy screening. European Diabetes Nursing. 2005; 2(2). doi: 10.1002/edn.21
11. Martineau M, Campbell R, Williamson P, Shotliff K. Mistaken beliefs about withholding thrombolysis for patients with diabetes mellitus and an acute myocardial infarction. Practical Diabetes International. 2007; 24(5): 236-238. doi: 10.1002/pdi.1107
12. Shotliff K, Lodge F, Zalin B, Meridith E. In patient Diabetes Management: Education of junior doctors and nurses. Practical Diabetes International. 2008; 25(8): 311.
13. Shotliff K, Duncan G, Dewhirst R, et al. British Association of Retinal Screener (BARS) survey of workload in UK diabetic retinal screening programmes. Practical Diabetes International. 2010; 27(4): 152-154.
14. Vaughan L, Shotliff M, Zalin B, Duncan G, Shotliff K. Recognition of diabetic retinopathy in retinal photographs can be improved with a basic education programme. Practical Diabetes International. 2010; 27(5): 189-192. doi: 10.1002/pdi.1479
15. Balasanthiran A, Zalin B, Shotliff K, Baker EH. Hyperglycaemia in the acute setting. Clinical Medicine (Journal of the Royal College of Physicians). 2012; 12(3): 272-275. doi: 10.7861/clinmedicine.12-3-272
16. Webster S, Shotliff K, Burton L. The Graduate as Scientist and Scholar: Building a Curriculum Suitable for all. The Journal of the International Association of Medical Science Educators. 2012; 22(35): 185-189.
17. Webster S, Shotliff K, Sharma U, Bell D. Doctors on Television: Analysis of Doctors working experiences during filming of a documentary in the work place. British Medical Journal. 2012; 345: e8320. doi: 10.1136/bmj.e8220
18. Balasanthiran A, Papoutis C, Shotliff K, et al. The power of information for diabetes research and self care patient views in North West London. Diabetic Medicine. 2013; 30: 126.
19. Zalin A, Papoutsi C, Shotliff K, Majeed A, Marston C, Reed J. The use of information for diabetes research and care: Patient views in West London. Practical Diabetes International. 2016; 33(3): 81-86. doi: 10.1002/pdi.2008

Amit K. Surve, MD

Bariatric Research Specialist
Bariatric Medicine Institute
Surgical and Medical Weight Loss Solutions
Salt Lake City, UT 84102, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Surve has been an active researcher in the field of obesity since 2012. Dr. Surve had a major research interest in problems related to obesity, and the various surgical techniques for the surgical treatment of severe obesity and their beneficial effects on obesity comorbidities. Dr. Surve is currently the Editor-in-Chief of Surgery for Journal of Obesity Management. He first began his research work as a Research Associate and Medical Officer at Asian Bariatric and Cosmetics Pvt. LTD, Ahmedabad, India, under Dr. Mahendra Narwaria. Later, he even went to do his externship in Bariatric and Colorectal Cancer Surgery under guidance of Dr. Luc Lemmens in Belgium, Europe.
He has clinical experience of working under reputed doctors like Dr. Kelvin Higa, Dr. Keith Boone, and Dr. Saber Ghiassi at Fresno Heart and Surgical Hospital, Fresno, California. During his externship, he also extended his research work in pulmonary care at Fresno community hospital, where he coordinated Asthma and COPD projects.
Once finished with his externships, he joined Bariatric Medicine Institute, Utah as a Research Coordinator under Dr. Daniel Cottam, a well know bariatric surgeon in the Unites States. He is currently working as Bariatric Research Specialist at Bariatric Medicine Institute, Utah, USA. Dr. Surve’s research focuses on the Stomach intestinal pylorus sparing surgery (SIPS). He has published more on SIPS surgery more than any other author worldwide. Also, he was one of the first group of authors to publish on SIPS surgery in the literature.
Dr. Surve also has various grants for coordinating research in the field of Bariatric. In addition, he is an active member of the American Society of Metabolic and Bariatric Surgery (ASMBS) and International federation for the surgery of Obesity & Metabolic Disorders (IFSO). He has also presented his various research works at well-known annual meetings of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) and ASMBS. Also, he was an invited speaker for numerous national and international surgical meetings.
He has made various surgical videos for patients, surgeons and has also published several video case reports in renowned journals. Dr. Surve has many publications of groundbreaking work. He is also an expert reviewer for journal like Annals of Surgery, British Journal of Surgery, Journal of the American College of Surgeons, Surgery, The American Journal of Medicine, Gastroenterology, British Medical Journal, International Journal of Surgery, and many more. He also serves as a Member of the Editorial Board of Health Economics & Outcome Research, Journal of Diabetes and Obesity, Obesity & Weight Loss Therapy, Journal of Anesthesia and Surgery, and many other journals.

His research focuses on the Stomach intestinal pylorus sparing surgery (SIPS).

PROFESSIONAL MEMBERSHIPS


• American Society for Metabolic and Bariatric Surgery (ASMBS)
• International Federation for the Surgery of Obesity and Metabolic Disorder (IFSO)
• Obesity Action Coalition (OAC)

1. Surve A, Zaveri H, Cottam D, et al. A Video Presentation on Technique of Laparoscopic Redo of Stenotic Gastrojejunostomy with Hiatal Hernioplasty and Right Crural Release in a Patient with Previous Roux-en-Y Gastric Bypass. Surg Endosc. 2016.
2. Surve A, Zaveri H, Cottam D. A step-by-step surgical technique video with two reported cases of common channel lengthening in patients with previous stomach intestinal pylorus sparing surgery to treat chronic diarrhea. Surg Obes Relat Dis. 2016.
3. Surve A, Zaveri H, Cottam D, Richards C, Medlin W, Cottam A. Laparoscopic stomach intestinal pylorus sparing surgery in a patient with morbid obesity and situs inversus: First video case report. Surg Obes Relat Dis. 2016.
4. Cottam A, Cottam D, Portenier D, et al. A matched cohort analysis of Stomach Intestinal Pylorus Saving (SIPS) Surgery versus biliopancreatic diversion with duodenal switch with two year follow up. Obes Surg. 2016; 1-8. doi: 10.1007/s11695-016-2341-7
5. Cottam S, Cottam A, Cottam D, Surve A, Zaveri H, Richards.C. The use of predictive markers for the development of a model to predict lowest quartile weight loss following Roux-en-Y gastric bypass. Journal of Obesity Management. 2016; 1(1).
6. Surve A, Zaveri H, Cottam D, et al. Laparoscopic adjustable gastric banding versus laparoscopic adjustable gastric banding with gastric plication: midterm outcomes in terms of weight loss and short-term complications. Surg Obes Relat Dis. 2016.
7. Zaveri H1, Surve A1, Cottam D, et al. Comparison of outcomes of bariatric surgery in patient greater than 70 with 18 month of follow up. Springerplus. 2016; 5(1): 1740. doi: 10.1186/s40064-016-3392-x
8. Surve A, Zaveri H, Cottam D. A Video Case Report of Stomach Intestinal Pylorus Sparing Surgery (SIPS) with Laparoscopic Fundoplication (LF): A Surgical Procedure to Treat Gastrointestinal Reflux Disease (GERD) in the Setting of Morbid Obesity. Surg Obes Relat Dis. 2016; 12(5): 1133-1135. doi: 10.1016/j.soard.2016.04.001
9. Surve A, Hinali Zaveri MD, Daniel Cottam MD, Austin Cottam, LeGrand Belnap MD, Christina Richards MD, F.A.C.S., Walter Medlin MD, F.A.C.S. Mid term outcomes of gastric bypass weight loss failure to duodenal switch. Surg Obes Relat Dis. 2016.
10. Cottam A, Cottam D, Roslin M, et al. A matched cohort analysis of sleeve gastrectomy with and without 300 cm loop duodenal switch with 18 month follows up. Obes Surg. 2016; 26(10): 2363-2369. doi: 10.1007/s11695-016-2133-0
11. Le Grand B, Zaveri H, Cottam D, Surve A, Rodgers G. Portal mesenteric vein thrombosis after laparoscopic sleeve gastrectomy: Presentation and management. Surg Obes Relat Dis. 2016.
12. Surve A, Zaveri H, Cottam D. A safer and simpler technique of duodenal dissection and transection of the duodenal bulb for duodenal switch. Surg Obes Relat Dis. 2016; 12(4): 923-924. doi: 10.1016/j.soard.2016.02.022
13. Zaveri H, Dallal RM, Cottam D, et al. Indications and operative outcomes of gastric bypass reversal. Obes Surg. 2016; 26(10): 2285-2290. doi: 10.1007/s11695-016-2105-4
14. Mitzman B1, Cottam D2, Goriparthi R, et al. Stomach intestinal pylorus sparing surgery for morbid obesity: Retrospective analysis of our preliminary experiences. Obes Surg. 2016; 26(9): 2098-2104. doi: 10.1007/s11695-016-2077-4
15. Surve A, Zaveri H, Cottam D. Retrograde filling of the afferent limb as a cause of chronic nausea after single anastomosis loop duodenal switch. Surg Obes Relat Dis. 2016; 12(4): e39-e42. doi: 10.1016/j.soard.2016.01.018
16. Cottam A, Cottam D, Medlin W, et al A matched cohort analysis of loop duodenal switch versus Roux-en-Y gastric bypass with 18 month follow up. Surg Endosc. 2015; 30(9): 3958-3964. doi: 10.1007/s00464-015-4707-7
17. Surve A, Zaveri H, Cottam D. Symptomatic gastric diverticulum following gastric imbrication with conversion to sleeve gastrectomy. Surg Obes Relat Dis. 2016; 12(2): 439-440. doi: 10.1016/j.soard.2015.09.012
18. Zaveri H, Surve A, Cottam D, et al. Stomach intestinal pylorus sparing surgery (SIPS) with laparoscopic fundoplication (LF): A new approach to gastroesophageal reflux disease (GERD) in the setting of morbid obesity. Springerplus. 2015; 4(1): 596. doi: 10.1186/s40064-015-1396-6

Hinali Zaveri, MD

Research Specialist
Bariatric Medicine Institute
Salt Lake City, UT 84102, USA

BiographyResearch InterestScientific ActivitiesPublications

Dr. Zaveri has extensive experience in the field of obesity as an active researcher. This first began with her work as a bariatric coordinator at Asian Bariatric and Cosmetics Pvt. Ltd, Ahmadabad, India. She did primary consultation in Mumbai andMaharashtra before joining Dr. Luc Lemmens for her externship at Bariatric Centre of Excellence in Belgium. Her knowledge, experience & enthusiasm were benefitted to her University when her Dean requested her for imparting knowledge to students in General Pathology and Histology. Her confidence & belief in her abilities made her work with Fresno Heart and Surgical Hospital at California with renowned surgeons like Dr. Kelvin Higa. She played a major role in Dr. Vipul Jain’s one of the projects on Asthma at UCSF-Fresno, California
She is currently working as a Bariatric Research Specialist at Bariatric Medicine Institute, Utah,USA where she continues to do research on various surgical treatments for severe obesity and their beneficial effects on obesity co morbidities
She has been one of the first group of authors in publishing an article on SIPS surgery, recently gaining lots of popularity in the bariatric world. She has published highest number of papers on SIPS surgery worldwide. She is also the research coordinator of a 600,000$ grant looking at the outcomes for this new procedure

• Her main research interest focuses on Stomach Intestinal Pylorus Sparing Surgery (SIPS)
• One of Dr. Zaveri’s areas of interest has been creating the model with multivariate analysis that can predict pre-operative weight loss for various bariatric surgeries
• Dr. Zaveri is currently serving as an expert Reviewer for journal like American Journal of Medicine, British Journal of Surgery, International Journal of Surgery and editor for Health Economics and Research Journal, Journal of Obesity management

AWARDS AND MEMBERSHIPS


• She is an active member of the American Society of Metabolic and Bariatric Surgery (ASMBS)
• International federation for the surgery of Obesity and Metabolic Disorder (IFSO)
• Given symposium presentation at well-known annual meetings of ASMBS and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES)
• Won number of awards at these meetings

1. Surve A, Zaveri H, Cottam D, Belnap L, Richards C, Medlin W, Cottam A, cottam S. A video presentation on technique of laparoscopic redo of stenotic gastrojejunostomy with hiatal hernioplasty and right crural release in a patient with previous roux-en-y gastric bypass. Surg Endosc. 2016.
2. Surve A, Zaveri H, Cottam D. A Step-By-Step Surgical Technique Video with Two Reported Cases of Common Channel Lengthening in Patients with Previous Stomach Intestinal Pylorus Sparing Surgery to Treat Chronic Diarrhea. Surg Obes Relat Dis. 2016.
3. Surve A, Zaveri H, Cottam D, Richards C, Medlin W, Cottam A. Laparoscopic stomach intestinal pylorus sparing surgery in a patient with morbid obesity and situs inversus: First video case report. Surg Obes Relat Dis. 2016. doi: 10.1016/j.soard.2016.08.503
4. Cottam A, Cottam D, Portnier D, Zaveri H, Surve A, Cottam S, Belnap L, Medlin W, Richards C. A matched cohort analysis of stomach intestinal pylorus saving (sips) surgery versus biliopancreatic diversion with duodenal switch with two year follow up. Obes Surg. 2016. doi: 10.1007/s11695-016-2341-7
5. Cottam S, Cottam A, Cottam D, Surve A, Zaveri H, Richards C. The use of predictive markers for the development of a model to predict lowest quartile weight loss following Roux en y gastric bypass. J Obes. 2016; 1(1).
6. Surve A, Zaveri H, Cottam D, Richards C, Medlin W, Cottam S. Laparoscopic adjustable gastric banding vs laparoscopic adjustable gastric banding with gastric plication: outcomes in terms of weight loss and complications. Surg Obes Relat Dis. 2016. doi: 10.1016/j.soard.2016.09.015
7. Zaveri H, Surve A, Cottam D, Summerhays C, Cottam A, Richards C, Belnap L, Medlin W. A comparison of outcomes in geriatric bariatric surgery in patient greater than 70 with 18 month of follow up. SpringerPlus. 2016; 5(1): 1740. doi: 10.1186/s40064-016-3392-x
8. Surve A, Zaveri H, Cottam D, Belnap L, Medlin W, Richards C, Cottam A. A video case report of stomach intestinal pyloris sparing surgery (SIPS) with laparoscopic fundoplication (LF): A surgical procedure to treat the gastrointestinal reflux disease (GERD) in the setting of morbid obesity. Surg Obes Relat Dis. 2016;12(5):1133-35. doi: 10.1016/j.soard.2016.04.001
9. Surve A, Zaveri H, Cottam D, Cottam A, Belnap L, Richards C, Medlin W. Mid term outcomes of gastric bypass weight loss failure to duodenal switch. Surg Obes Relat Dis. 2016. doi: 10.1016/j.soard.2016.03.021
10. Cottam A, Cottam D, Roslin L, Cottam S, Medlin W, Richards C, Surve A, Zaveri H. A matched cohort analysis of sleeve gastrectomy with and without 300 cm loop duodenal switch with 18 month follows up. Obes Surg. 2016; 26(10): 2363-2369. doi: 10.1007/s11695-016-2133-0
11. Belnap L, Zaveri H, Cottam D, Surve A, Rodgers G. Portal mesenteric vein thrombosis after laparoscopic sleeve gastrectomy: Presentation and management. Surg Obes Relat Dis. 2016. doi: 10.1016/j.soard.2016.03.005
12. Surve A, Zaveri H, Cottam D. A safer and simpler technique of duodenal dissection and transection of the duodenal bulb for duodenal switch. Surg Obes Relat Dis. 2016; 12(4): 923-924. doi: 10.1016/j.soard.2016.02.022
13. Zaveri H, Dalal R, Cottam D, Surve A, Kartiko S, Bonnani F, Cottam A, Cottam S. Indications and operative outcomes of gastric bypass reversal. Obes Surg. 2016; 26(10): 2285-2290. doi: 10.1007/s11695-016-2105-4
14. Mitzman B, Cottam D, Goriparthi R, Cottam S, Zaveri H, Surve A, Roslin MS. Stomach intestinal pylorus sparing surgery for morbid obesity: Retrospective analysis of our preliminary experiences. Obes Surg. 2016; 26(9): 2098-2104. doi: 10.1007/s11695-016-2077-4
15. Surve A, Zaveri H, Cottam D. Retrograde filling of the afferent limb as a cause of chronic nausea after single anastomosis loop duodenal switch. Surg Obes Relat Dis. 2016; 12(4): e39-e42. doi: 10.1016/j.soard.2016.01.018
16. Cottam A, Cottam D, Medlin W, Richards C, Cottam S, Zaveri H, Surve A. A matched cohort analysis of loop duodenal switch versus roux-en-y gastric bypass with 18 month follow up. Surg Endosc. 2015; 30(9): 3958-3964. doi: 10.1007/s00464-015-4707-7
17. Surve A, Zaveri H, Cottam D. Symptomatic gastric diverticulum following gastric imbrication with conversion to sleeve gastrectomy. Surg Obes Relat Dis. 2016; 12(2): 439-440. doi: 10.1016/j.soard.2015.09.012
18. Zaveri H, Surve A, Cottam D, Richards C, Medlin W, Belnap L, Cottam S, Cottam A. Stomach intestinal pylorus sparing surgery (SIPS) with laparoscopic fundoplication (LF): a new approach to gastroesophageal reflux disease (GERD) in the setting of morbid obesity. Springerplus. 2015; 4(1): 596. doi: 10.1186/s40064-015-1396-6